

CITATION REPORT

List of articles citing

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)

DOI: 10.1086/651706

Infection Control and Hospital Epidemiology, 2010, 31, 431-55

Source: <https://exaly.com/paper-pdf/49320868/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2283	Clostridium Difficile Infection. 201-212		
2282	.		
2281	New Clinical Practice Guidelines for Clostridium difficile Infection. 2010 , 18, 329-331		
2280	Stronger correlation between antibiotic use and the incidence of Clostridium difficile determined by culture results instead of faecal toxin detection only. 2010 , 29, 1575-8		3
2279	Alternative therapies for Clostridium difficile infections. 2010 , 30, 1266-78		29
2278	Bacterial Diseases. 2010 , 109-240		1
2277	Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. 2010 , 10, 363		78
2276	Les diarrhées post-antibiotiques. 2010 , 2010, 93-99		2
2275	Diagnosis, management, and prevention of Clostridium difficile infection in long-term care facilities: a review. 2010 , 58, 1556-64		70
2274	Clostridium difficile: progress and challenges. 2010 , 1213, 62-9		70
2273	An update on Clostridium difficile infection and its management. 2010 , 14, 391-7		0
2272	What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection?. 2010 , 48, 4347-53		88
2271	Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. 2010 , 126, e239-42		91
2270	Evaluation of the Cepheid Xpert Clostridium difficile Epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital. 2010 , 48, 4519-24		83
2269	Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. 2010 , 330, 831-5		583
2268	Pneumatosis Coli Associated with Pseudomembranous Colitis in a Patient following Colonic Surgery. 2010 , 2010, 138369		3
2267	Regulatory oversight and safety of probiotic use. 2010 , 16, 1661-5		133

2266	Was gibt es Neues in den neuen Leitlinien zur Clostridium difficile-Infektion?. 2010 , 5, 213-222		2
2265	Clostridium difficile-associated disease: impact of the updated SHEA/IDSA guidelines. 2010 , 25, 834-6		8
2264	Probiotics for the prevention of ventilator-associated pneumonia. 2010 , 4, 567-71		1
2263	Assessment of Clostridium difficile infections by quantitative detection of tcdB toxin by use of a real-time cell analysis system. 2010 , 48, 4129-34		70
2262	Detection of Clostridium difficile infection. <i>Infection Control and Hospital Epidemiology</i> , 2010 , 31 Suppl 1, S35-7	2	28
2261	Quantifying interhospital patient sharing as a mechanism for infectious disease spread. <i>Infection Control and Hospital Epidemiology</i> , 2010 , 31, 1160-9	2	56
2260	Rifampin plus metronidazole for Clostridium difficile infection. <i>Infection Control and Hospital Epidemiology</i> , 2010 , 31, 1205; author reply 1205-6	2	2
2259	Reply to Drekonja. <i>Infection Control and Hospital Epidemiology</i> , 2010 , 31, 1205-1206	2	
2258	Clostridium difficile. 2010 , 30, 329-42		17
2257	Stanowisko Grupy Ekspertów w sprawie profilaktyki biegunki związanej ze stosowaniem antybiotyków u dzieci. 2010 , 85, 604-608		4
2256	Clostridium difficile-associated disease among patients in Dhahran, Saudi Arabia. 2010 , 8, 373-6		26
2255	Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. 2010 , 8, 1113-9		69
2254	Potential value of repeat stool testing for Clostridium difficile stool toxin using enzyme immunoassay?. 2010 , 26, 2635-41		15
2253	Tigecycline for the treatment of severe Clostridium difficile infection. 2011 , 45, 1005-10		57
2252	Laboratory testing for Clostridium difficile infection: light at the end of the tunnel. 2011 , 136, 372-80		46
2251	Surgical outcome of community-acquired Clostridium difficile colitis presenting as toxic megacolon: case report. <i>Surgical Infections</i> , 2011 , 12, 317-20	2	2
2250	The host immune response to Clostridium difficile. 2011 , 60, 1070-1079		139
2249	Combating antimicrobial resistance: policy recommendations to save lives. 2011 , 52 Suppl 5, S397-428		436

2248	Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty?. 2011 , 13, 573-82		71
2247	Clostridium difficile infection in 2010: advances in pathogenesis, diagnosis and management of CDI. 2011 , 8, 67-8		20
2246	Treatment of refractory and recurrent Clostridium difficile infection. 2011 , 8, 330-9		65
2245	Systemic absorption of oral vancomycin in patients with Clostridium difficile infection. 2011 , 43, 386-8		59
2244	Diagnostic des infections ^ Clostridium difficile. 2011 , 13, 67-73		2
2243	The appendix may protect against Clostridium difficile recurrence. 2011 , 9, 1072-7		52
2242	The vermiform appendix and recurrent Clostridium difficile infection: a curious connection. 2011 , 9, 1017-9		6
2241	The role of the environment in transmission of Clostridium difficile infection in healthcare facilities. <i>Infection Control and Hospital Epidemiology</i> , 2011 , 32, 207-9	2	25
2240	Epidemiological model for Clostridium difficile transmission in healthcare settings. <i>Infection Control and Hospital Epidemiology</i> , 2011 , 32, 553-61	2	74
2239	Using electronic health information to risk-stratify rates of Clostridium difficile infection in US hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2011 , 32, 649-55	2	39
2238	Clostridium difficile infection in a long-term care facility: hospital-associated illness compared with long-term care-associated illness. <i>Infection Control and Hospital Epidemiology</i> , 2011 , 32, 656-60	2	44
2237	Clostridium difficile outbreak strain BI is highly endemic in Chicago area hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2011 , 32, 897-902	2	26
2236	Impact of PCR testing for Clostridium difficile on incident rates and potential on public reporting: is the playing field level?. <i>Infection Control and Hospital Epidemiology</i> , 2011 , 32, 932-3	2	44
2235	Antimicrobial prescribing practices in response to different Clostridium difficile diagnostic methodologies. <i>Infection Control and Hospital Epidemiology</i> , 2011 , 32, 1133-6	2	17
2234	A targeted strategy to wipe out Clostridium difficile. <i>Infection Control and Hospital Epidemiology</i> , 2011 , 32, 1137-9	2	61
2233	Factores de riesgo para la infecci3n por Clostridium difficile. 2011 , 15, 220-226		7
2232	Repeat stool testing to diagnose Clostridium difficile infection using enzyme immunoassay does not increase diagnostic yield. 2011 , 9, 665-669.e1		35
2231	Traitement des infections digestives ^ Clostridium difficile : anciennes et nouvelles approches. 2011 , 13, 74-86		2

2230	Public reporting of Clostridium difficile and improvements in diagnostic tests. <i>Infection Control and Hospital Epidemiology</i> , 2011 , 32, 1231-2; author reply 1233	2	11
2229	Best strategies in recurrent or persistent Clostridium difficile infection. <i>Surgical Infections</i> , 2011 , 12, 235-9	2	35
2228	Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. 2011 , CD004610		55
2227	Fidaxomicin: in Clostridium difficile infection. 2011 , 71, 2445-56		17
2226	Recurrent Clostridium difficile infection: what are the treatment options?. 2011 , 71, 853-68		23
2225	Conventional versus Molecular Methods for the Detection of Clostridium difficile. 2011 , 49, S49-S52		15
2224	Treating Clostridium difficile infection with fecal microbiota transplantation. 2011 , 9, 1044-9		664
2223	Drug Interactions in Infectious Diseases. 2011 ,		10
2222	Clostridium difficile infection: epidemiology, risk factors and management. 2011 , 8, 17-26		273
2221	Clostridium difficile infection: a comprehensive review. 2011 , 37, 178-87		105
2220	Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays. 2011 , 13, 583-604		61
2219	Infection prevention and control practices related to Clostridium difficile infection in Canadian acute and long-term care institutions. 2011 , 39, 177-82		7
2218	Antimicrobial use and risk for recurrent Clostridium difficile infection. 2011 , 124, 1081.e1-7		44
2217	Clinical approach to severe Clostridium difficile infection: update for the hospital practitioner. 2011 , 22, 561-8		18
2216	Infection Probability Score: a predictor of Clostridium difficile-associated disease onset in patients with haematological malignancy. 2011 , 15, 404-9		20
2215	Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. 2011 , 30, 375-84		251
2214	Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. 2011 , 15, e438-48		37
2213	Fidaxomicin. 2011 , 46, 884-890		

2212	Severe infection with Clostridium difficile PCR ribotype 027 acquired in Melbourne, Australia. 2011 , 194, 369-71	43
2211	Clostridium difficile infection: a new threat on our doorstep. 2011 , 194, 331-2	7
2210	Clostridium difficile Infections in Children. 2011 , 34, 3	1
2209	Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of Clostridium difficile infection. 2011 , 194, 353-8	63
2208	Clostridium difficile infection in outpatients, Maryland and Connecticut, USA, 2002-2007. 2011 , 17, 1946-9	22
2207	Risk factors for recurrence of Clostridium difficile infection: effect of vancomycin-resistant enterococci colonization. 2011 , 26, 859-64	35
2206	[Not Available]. 2011 , 153, 45-50	0
2205	Clostridium difficile laboratory testing in Australia and New Zealand: national survey results and Australasian Society for Infectious Diseases recommendations for best practice. 2011 , 43, 482-7	27
2204	Clinical features, management and infection control of Clostridium difficile infection in an Australian tertiary hospital: a prospective observational study. 2011 , 16, 140-145	
2203	Antibiotic Collateral Damage: Resistance and Antibiotic-Associated Diarrhea. 2011 , 46, 758-768	3
2202	Trends in antimicrobial resistance in intensive care units in the United States. 2011 , 17, 472-9	56
2201	Probiotics in clostridium difficile Infection. 2011 , 45 Suppl, S154-8	55
2200	Update on Clostridium difficile infection. 2011 , 27, 38-47	46
2199	Improving surveillance for pediatric Clostridium difficile infection: derivation and validation of an accurate case-finding tool. 2011 , 30, e38-40	31
2198	Epidemiology and risk factors for Clostridium difficile infection in children. 2011 , 30, 580-4	120
2197	An Innovative Severity Score Index for Clostridium difficile Infection. 2011 , 19, 336-339	10
2196	Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. 2011 , 254, 423-7; discussion 427-9	260
2195	Clostridium difficile in the ICU: the struggle continues. 2011 , 140, 1643-1653	52

2194	ASID/AICA position statement – Infection control guidelines for patients with Clostridium difficile infection in healthcare settings. 2011 , 16, 33-39		16
2193	The Most Effective Treatments for Clostridium difficile Diarrhea. 2011 , 19, 171-181		2
2192	Predicting the Severity of Clostridium Difficile Infection. 2011 , 19, 305-306		
2191	Beyond the target pathogen: ecological effects of the hospital formulary. 2011 , 24 Suppl 1, S21-31		37
2190	Antimicrobial stewardship: attempting to preserve a strategic resource. 2011 , 1,		6
2189	Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. 2011 , 25, E82-7		89
2188	Monomicrobial Clostridium difficile bacteraemias and relationship to gut infection. <i>Journal of Hospital Infection</i> , 2011 , 77, 170-1	6.9	13
2187	Optical density cut-off values for Clostridium difficile enzyme immunoassays. <i>Journal of Hospital Infection</i> , 2011 , 77, 169-70	6.9	6
2186	Decline in incidence of Clostridium difficile infection after relocation to a new hospital building with single rooms. <i>Journal of Hospital Infection</i> , 2011 , 79, 93-4	6.9	10
2185	Diagnostic testing for Clostridium difficile: a comprehensive survey of laboratories in England. <i>Journal of Hospital Infection</i> , 2011 , 79, 4-7	6.9	44
2184	The diagnosis of C. difficile infection (CDI) - two steps forwards?. 2011 , 63, 398-9; author reply 400-1		
2183	Clostridium difficile infection in humans and animals, differences and similarities. 2011 , 153, 205-17		77
2182	Incidence of Clostridium difficile infections in patients receiving antimicrobial and acid-suppression therapy. 2011 , 31, 642-8		21
2181	Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection. 2011 , 31, 877-86		28
2180	Rifaximin: new therapeutic indication and future directions. 2011 , 33, 812-27		48
2179	Tests for the diagnosis of Clostridium difficile infection: the next generation. 2011 , 17, 170-4		92
2178	Biology of Clostridium difficile: implications for epidemiology and diagnosis. 2011 , 65, 501-21		176
2177	Infectious diseases in the critically ill patients. 2011 , 24, 35-43		24

2176	Rapid diagnosis of Clostridium difficile infection by multiplex real-time PCR. 2011 , 30, 1279-85	26
2175	Evaluation of a simultaneous detection kit for the glutamate dehydrogenase antigen and toxin A/B in feces for diagnosis of Clostridium difficile infection. 2011 , 17, 807-11	24
2174	Development of quality measures for monitoring and improving care in gastroenterology. 2011 , 25, 387-95	2
2173	Prevalence and clinical course of Clostridium difficile infection in a tertiary-care hospital: a retrospective analysis. 2011 , 30, 89-93	29
2172	Clostridium difficile infection: clinical spectrum and approach to management. 2011 , 30, 245-54	13
2171	Fulminant, non-antibiotic associated Clostridium difficile colitis following Salmonella gastroenteritis. 2011 , 26, 95-7	5
2170	Clostridium difficile infection in non-HIV-immunocompromised patients and in HIV-infected patients. 2011 , 13, 344-50	17
2169	Current Status of Nonantibiotic and Adjunct Therapies for Clostridium difficile Infection. 2011 , 13, 21-7	6
2168	Decline in Clostridium difficile-associated disease rates in Singapore public hospitals, 2006 to 2008. 2011 , 4, 77	12
2167	Antimicrobial stewardship: optimizing antibiotic use in an era of increasing resistance and rising costs. 2011 , 6 Suppl 1, S1-3	8
2166	Intensive care of the patient with cirrhosis. 2011 , 54, 1864-72	186
2165	Mandatory reporting and improvements in diagnosing Clostridium difficile infection: an incompatible dichotomy?. 2011 , 62, 363-70	20
2164	Oral vancomycin may have significant absorption in patients with Clostridium difficile colitis. 2011 , 43, 149-50	14
2163	Fidaxomicin: first-in-class macrocyclic antibiotic. 2011 , 9, 767-77	35
2162	The role of environmental cleaning in health care-associated infections. 2011 , 34, 11-7	6
2161	Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. 2011 , 4, 185-97	118
2160	A call to arms: the imperative for antimicrobial stewardship. 2011 , 53 Suppl 1, S4-7	90
2159	Modifications of commercial toxigenic Clostridium difficile PCR resulting in improved economy and workflow efficiency. 2011 , 49, 2279-82	6

2158	Vancomycin "telephone". 2011 , 53, 211-2	2
2157	Clinical and infection control implications of Clostridium difficile infection with negative enzyme immunoassay for toxin. 2011 , 53, 287-90	44
2156	Prevention and treatment of Clostridium difficile infection. 2011 , 11, 75-9	11
2155	Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection. 2011 , 52, 1451-7	59
2154	Diagnostic accuracy of real-time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile Infection: a meta-analysis. 2011 , 53, e81-90	105
2153	Evaluation of four different diagnostic tests to detect Clostridium difficile in piglets. 2011 , 49, 1816-21	28
2152	Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. 2011 , 53, 42-8	290
2151	Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. 2011 , 49, 4040-6	66
2150	Clostridium difficile Infection and Inflammatory Bowel Disease: A Review. 2011 , 2011, 136064	46
2149	Clostridium difficile disease and vancomycin--questionable clinical superiority. 2011 , 53, 212	2
2148	Emerging therapies for Clostridium difficile infections. 2011 , 16, 425-39	18
2147	Hospital epidemiology and infection control in acute-care settings. 2011 , 24, 141-73	352
2146	Epidemiology and control of Clostridium difficile infections in healthcare settings: an update. 2011 , 24, 370-6	72
2145	HBV infection decreases risk of liver metastasis in patients with colorectal cancer: A cohort study. <i>World Journal of Gastroenterology</i> , 2011 , 17, 804-8	5.6 30
2144	Fecal transplantation for recurrent or refractory Clostridium difficile diarrhea. 2011 ,	1
2143	Beyond mainstream: making the case for fecal bacteriotherapy. 2011 , 41, 50-3	4
2142	Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. 2011 , 53, 440-7	178
2141	Evaluation of a loop-mediated isothermal amplification assay for diagnosis of Clostridium difficile infections. 2011 , 49, 2714-6	73

2140	Impact of clinical symptoms on interpretation of diagnostic assays for <i>Clostridium difficile</i> infections. 2011 , 49, 2887-93		148
2139	Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against <i>Clostridium difficile</i> infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 5194-9	5.9	78
2138	Prevalence, enumeration, and antimicrobial agent resistance of <i>Clostridium difficile</i> in cattle at harvest in the United States. 2011 , 74, 1618-24		24
2137	Significant publications on infectious diseases pharmacotherapy in 2010. 2011 , 68, 2075-85		12
2136	A Retrospective Analysis of Risk Factors and Therapeutic Outcomes for <i>Clostridium difficile</i> Infection. 2011 , 46, 336-340		2
2135	Immunoglobulins: <i>Clostridium difficile</i> Infection (Diarrhea). 2011 , 46, 170-172		
2134	Vancomycin (Rectal): <i>Clostridium difficile</i> Infection (Severe/Complicated). 2011 , 46, 327-328		
2133	Activities of a <i>Clostridium difficile</i> infection reduction team. 2011 , 68, 1298, 1300-1		3
2132	The emergence of <i>Clostridium difficile</i> infection among peripartum women: a case-control study of a <i>C. difficile</i> outbreak on an obstetrical service. 2011 , 2011, 267249		20
2131	Comparison of strain typing results for <i>Clostridium difficile</i> isolates from North America. 2011 , 49, 1831-7		73
2130	Detection of <i>Clostridium difficile</i> as a routine diagnosis: comparison of real-time PCR and enzyme immunoassay. 2012 , 137, 494-5; author reply 495		3
2129	Controlling <i>Clostridium difficile</i> Infection and the Role of Antibiotic Stewardship. 2012 , 53-62		
2128	Comparison of analytical and clinical performance of three methods for detection of <i>Clostridium difficile</i> . 2012 , 136, 527-31		11
2127	Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of <i>Clostridium difficile</i> infection. 2012 , 54, 568-74		93
2126	Fecal microbiota transplantation in relapsing <i>Clostridium difficile</i> infection. 2012 , 5, 403-20		134
2125	Protection against <i>Clostridium difficile</i> infection with broadly neutralizing antitoxin monoclonal antibodies. 2012 , 206, 706-13		59
2124	Management and prevention of recurrent <i>Clostridium difficile</i> infection in patients after total joint arthroplasty: a review. 2012 , 3, 157-63		4
2123	Detection of toxigenic <i>Clostridium difficile</i> : comparison of the cell culture neutralization, Xpert <i>C. difficile</i> , Xpert <i>C. difficile</i> /Epi, and Illumigene <i>C. difficile</i> assays. 2012 , 50, 1331-5		71

2122	Fidaxomicin for the treatment of Clostridium difficile infections. 2012 , 46, 219-28	22
2121	Infections and the compromised immune status in the chronically critically ill patient: prevention strategies. 2012 , 57, 979-90; discussion 990-2	11
2120	In the Literature. 2012 , 54, iii-iv	
2119	Making the case for fecal bacteriotherapy. 2012 , 7, 42-46	
2118	Clostridium difficile: novel insights on an incessantly challenging disease. 2012 , 25, 405-11	11
2117	Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. 2012 , 28, 1-9	146
2116	Clostridium difficile infections. 2012 , 23, 67-75	3
2115	Prebiotics, probiotics and digestive health. 2012 , 15, 580-5	33
2114	Clostridium difficile Infection in Children: Current State and Unanswered Questions. 2012 , 1, 230-43	49
2113	Efficacy of LFF571 in a hamster model of Clostridium difficile infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4459-62	5-9 49
2112	Need for clinicopathologic correlation of Clostridium difficile colitis in view of molecular diagnosis. 2012 , 54, 156	
2111	Seeing a difference in C. diff. 2012 , 36, 625	
2110	Detection of Clostridium difficile toxin A/B genes by multiplex real-time PCR for the diagnosis of C. difficile infection. 2012 , 61, 274-277	20
2109	Predictors of first recurrence of Clostridium difficile infection: implications for initial management. 2012 , 55 Suppl 2, S77-87	147
2108	Current state of Clostridium difficile treatment options. 2012 , 55 Suppl 2, S71-6	48
2107	Editorial commentary: 027, 078, and others: going beyond the numbers (and away from the hypervirulence). 2012 , 55, 1669-72	22
2106	A woman with community-acquired Clostridium difficile infection. 2012 , 184, 1383-5	3
2105	Pathology consultation on detection of Clostridium difficile. 2012 , 137, 10-5	5

2104	Clostridium difficile - state of the art. 2012 , 08, 81-91		6
2103	Clostridium-difficile-assoziierte Diarrh�e (CDAD) â ein z�unehmendes Problem im Krankenhausalltag. 2012 , 25, 190-193		
2102	Surgical Management of Clostridium difficile Colitis. 2012 , 25, 204-9		21
2101	[Intrahospital mortality in patients with Clostridium difficile-associated diarrhea infection]. 2012 , 77, 60-5		6
2100	Is Clostridium difficile infection still a problem for hospitals?. 2012 , 184, 17-8		7
2099	An overview of the diagnosis and management of Clostridium difficile infection. 2012 , 40, 119-29		1
2098	Clostridium difficile colitis: a review. 2012 , 40, 139-48		24
2097	Verification of performance specifications for a US Food and Drug Administration-approved molecular microbiology test: Clostridium difficile cytotoxin B using the Becton, Dickinson and Company GeneOhm Cdiff assay. 2012 , 136, 20-5		3
2096	Antibiotic heterogeneity optimizes antimicrobial prescription and enables resistant pathogen control in the intensive care unit. <i>Surgical Infections</i> , 2012 , 13, 194-202	2	10
2095	Discrepancies in testing recommendations for Clostridium difficile infection: updated review favors amplification test systems. 2012 , 12, 223-6		8
2094	Clostridium difficile: epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen. 2012 , 36, 645-62		48
2093	Chemical trapping of vancomycin: a potential strategy for preventing selection of vancomycin-resistant Enterococci. 2012 , 18, 109-15		2
2092	The epidemiology of community-acquired Clostridium difficile infection: a population-based study. 2012 , 107, 89-95		420
2091	Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies. 2012 , 7, 677-83		3
2090	Multicenter clinical evaluation of the portrait toxigenic C. difficile assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens. 2012 , 50, 3932-6		33
2089	Clinical and laboratory characteristics of Clostridium difficile infection in patients with discordant diagnostic test results. 2012 , 50, 1303-7		52
2088	Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. 2012 , 55 Suppl 2, S154-61		246
2087	Loop-mediated isothermal amplification compared to real-time PCR and enzyme immunoassay for toxigenic Clostridium difficile detection. 2012 , 50, 640-5		45

2086	Prospective observational study comparing three different treatment regimes in patients with <i>Clostridium difficile</i> infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 1974-8	5.9	28
2085	Antibiotic Use in Home Health: A Primer. 2012 , 24, 50-55		1
2084	Evolution of testing algorithms at a university hospital for detection of <i>Clostridium difficile</i> infections. 2012 , 50, 3073-6		44
2083	Repeat stool testing for <i>Clostridium difficile</i> using enzyme immunoassay in patients with inflammatory bowel disease increases diagnostic yield. 2012 , 28, 1553-60		15
2082	Significant publications on infectious diseases pharmacotherapy in 2011. 2012 , 69, 1671-81		10
2081	Reduced acquisition and overgrowth of vancomycin-resistant enterococci and <i>Candida</i> species in patients treated with fidaxomicin versus vancomycin for <i>Clostridium difficile</i> infection. 2012 , 55 Suppl 2, S121-6		87
2080	Metronidazole-induced encephalopathy in a patient with end-stage liver disease. 2012 , 2012, 209258		19
2079	Safety and efficacy of fidaxomicin in the treatment of <i>Clostridium difficile</i> -associated diarrhea. 2012 , 5, 395-402		15
2078	Renal failure and leukocytosis are predictors of a complicated course of <i>Clostridium difficile</i> infection if measured on day of diagnosis. 2012 , 55 Suppl 2, S149-53		54
2077	Nosocomial diarrhea: a review of pathophysiology, etiology, and treatment strategies. 2012 , 40, 130-8		3
2076	Utility of perirectal swab specimens for diagnosis of <i>Clostridium difficile</i> infection. 2012 , 55, 1527-30		44
2075	<i>Clostridium difficile</i> testing algorithms using glutamate dehydrogenase antigen and <i>C. difficile</i> toxin enzyme immunoassays with <i>C. difficile</i> nucleic acid amplification testing increase diagnostic yield in a tertiary pediatric population. 2012 , 50, 1185-8		38
2074	In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of <i>Clostridium difficile</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 5023-30	5.9	69
2073	Sustained clinical response as an endpoint in treatment trials of <i>Clostridium difficile</i> -associated diarrhea. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4043-5	5.9	16
2072	The evolution of <i>Clostridium difficile</i> infection in cancer patients: epidemiology, pathophysiology, and guidelines for prevention and management. 2012 , 7, 157-70		27
2071	Glycopeptides. 2012 , 7, 1-5		
2070	Rifaximin in Combination with Metronidazole and Oral Vancomycin for the Treatment of an Initial Episode of <i>Clostridium difficile</i> -Associated Diarrhea: Case Report and Literature Review. 2012 , 47, 206-213		
2069	Risk factors and outcomes associated with severe <i>clostridium difficile</i> infection in children. 2012 , 31, 134-8		100

2068	An evaluation of repeat stool testing for Clostridium difficile infection by polymerase chain reaction. 2012 , 46, 846-9	28
2067	The role of acute care surgery in the treatment of severe, complicated Clostridium difficile-associated disease. 2012 , 73, 789-800	26
2066	Evaluating contemporary antibiotics as a risk factor for Clostridium difficile infection in surgical trauma patients. 2012 , 72, 691-5	15
2065	Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. 2012 , 46, 145-9	154
2064	Advances in laboratory diagnostic technologies in clinical microbiology and what this means for clinical practice. 2012 , 9, 347-352	8
2063	Fidaxomicin, a new treatment for Clostridium difficile infections. 2012 , 48, 101-8	3
2062	Clostridium difficile: a new look at an old but increasingly deadly infection. 2012 , 25, 32-6	
2061	Repeat Stool Testing to Diagnose Clostridium difficile Infection Using Enzyme Immunoassay Does Not Increase Diagnostic Yield. 2012 , 2012, 404-405	
2060	What would we do without metronidazole?. 2012 , 343, 316-9	9
2059	Infection prevention in solid organ transplantation. 2012 , 30 Suppl 2, 27-33	15
2058	Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. 2012 , 55, 1652-8	127
2057	Clostridium difficile: development of a novel candidate vaccine. 2012 , 30, 4307-9	84
2056	Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. 2012 , 69, 933-43	29
2055	Antimicrobial-resistant strains of Clostridium difficile from North America. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 2929-32	5.9 82
2054	Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing. 2012 , 3,	130
2053	Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. 2012 , 12, 281-9	513
2052	Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price. 2012 , 32, e17-24	16
2051	Clostridium-difficile-assozierte Kolitis. 2012 , 34, 379-390	1

2050 Clostridium-difficile-assozierte Kolitis. **2012**, 34, 447-455

2049 Laboratory Tests for the Diagnosis of Clostridium difficile Infections. **2012**, 34, 151-157

2

2048 Case fatality associated with a hypervirulent strain in patients with culture-positive Clostridium difficile infection: a retrospective population-based study. **2012**, 16, e532-5

13

2047 Is primary prevention of Clostridium difficile infection possible with specific probiotics?. **2012**, 16, e786-92

87

2046 Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. **2012**, 40, 643-8

87

2045 Fidaxomicine, un nouveau traitement pour les infections ^ Clostridium difficile. **2012**, 15, 32-38

2044 Frequent hospital readmissions for Clostridium difficile infection and the impact on estimates of hospital-associated C. difficile burden. *Infection Control and Hospital Epidemiology*, **2012**, 33, 20-8

2

43

2043 Evaluation of stethoscopes as vectors of Clostridium difficile and methicillin-resistant Staphylococcus aureus. *Infection Control and Hospital Epidemiology*, **2012**, 33, 96-8

2

36

2042 Quantitative efficacy of alcohol-based handrub against vancomycin-resistant enterococci on the hands of human volunteers. *Infection Control and Hospital Epidemiology*, **2012**, 33, 98-100

2

8

2041 Completeness of surveillance data reported by the National Healthcare Safety Network: an analysis of healthcare-associated infections ascertained in a tertiary care hospital, 2010. *Infection Control and Hospital Epidemiology*, **2012**, 33, 94-6

2

25

2040 High proportion of false-positive Clostridium difficile enzyme immunoassays for toxin A and B in pediatric patients. *Infection Control and Hospital Epidemiology*, **2012**, 33, 175-9

2

19

2039 Implementation of an antimicrobial stewardship program at a 60-bed long-term acute care hospital. *Infection Control and Hospital Epidemiology*, **2012**, 33, 405-8

2

42

2038 Effective antimicrobial stewardship in a long-term care facility through an infectious disease consultation service: keeping a LID on antibiotic use. *Infection Control and Hospital Epidemiology*, **2012**, 33, 1185-92

2

101

2037 A gastroenterologist's guide to probiotics. **2012**, 10, 960-8

95

2036 Practical considerations in the use of outpatient antimicrobial therapy for musculoskeletal infections. **2012**, 87, 98-105

11

2035 Saccharomyces boulardii w profilaktyce biegunki związanej z antybiotykoterapią i doświadczenia w łsne. **2012**, 87, 14-18

2034 Detecting and treating Clostridium difficile infections in patients with inflammatory bowel disease. **2012**, 41, 339-53

27

2033 Strategies for the care of adults hospitalized for active ulcerative colitis. **2012**, 10, 1315-1325.e4

46

2032	Intra-abdominal and pelvic emergencies. 2012 , 96, 1171-91		8
2031	Evaluating pouch problems. 2012 , 41, 355-78		16
2030	Evaluation of the diagnostic algorithm consisting of enzyme immunoassay for toxins and polymerase chain reaction, for the diagnosis of Clostridium difficile-associated diarrhoea. 2012 , 44, 969-72		4
2029	Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature. 2012 , 44, 228-30		22
2028	Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. 2012 , 5, 111-25		173
2027	Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting. 2012 , 44, 243-9		16
2026	Fidaxomicin: a guide to its use in Clostridium difficile infection. 2012 , 28, 1-5		
2025	Treat Clostridium difficile infection based on its severity and number of previous episodes. 2012 , 28, 10-13		
2024	Clostridium difficile Infection. 2012 , 1, e69-e86		0
2023	Potential for transmission of Clostridium difficile by asymptomatic acute care patients and long-term care facility residents with prior C. difficile infection. <i>Infection Control and Hospital Epidemiology</i> , 2012 , 33, 638-9	2	22
2022	Daily disinfection of high-touch surfaces in isolation rooms to reduce contamination of healthcare workers' hands. <i>Infection Control and Hospital Epidemiology</i> , 2012 , 33, 1039-42	2	71
2021	Empirical antimicrobial prescriptions in patients with Clostridium difficile infection at hospital admission and impact on clinical outcome. <i>Infection Control and Hospital Epidemiology</i> , 2012 , 33, 1101-6	2	10
2020	Burden of Clostridium difficile infection in long-term care facilities in Monroe County, New York. <i>Infection Control and Hospital Epidemiology</i> , 2012 , 33, 1107-12	2	50
2019	Efficacy of different cleaning and disinfection methods against Clostridium difficile spores: importance of physical removal versus sporicidal inactivation. <i>Infection Control and Hospital Epidemiology</i> , 2012 , 33, 1255-8	2	47
2018	[Current data and trends on the development of antibiotic resistance of Clostridium difficile]. 2012 , 55, 1410-7		12
2017	Clinical and laboratory evaluation of a real-time PCR for Clostridium difficile toxin A and B genes. 2012 , 31, 2219-25		43
2016	The potential economic value of screening hospital admissions for Clostridium difficile. 2012 , 31, 3163-71		27
2015	Role of fecal Clostridium difficile load in discrepancies between toxin tests and PCR: is quantitation the next step in C. difficile testing?. 2012 , 31, 3295-9		41

2014	Nosocomial diarrhea: evaluation and treatment of causes other than Clostridium difficile. 2012 , 55, 982-9	117
2013	Clostridium difficile infection in the community: a zoonotic disease?. 2012 , 18, 635-45	218
2012	A Clostridium difficile infection "intervention": change in toxin assay results in fewer C difficile infection cases without changes in patient outcomes. 2012 , 40, 349-53	6
2011	Introducing a population-based outcome measure to evaluate the effect of interventions to reduce catheter-associated urinary tract infection. 2012 , 40, 359-64	43
2010	Clostridium difficile infection in older adults: a review and update on its management. 2012 , 10, 14-24	42
2009	Clostridium difficile infection in the pediatric surgery population. 2012 , 47, 1385-9	7
2008	Synthesis and antibacterial activity against Clostridium difficile of novel demethylvancomycin derivatives. 2012 , 22, 4942-5	11
2007	[Epidemiology of Clostridium difficile infection in Spain]. 2012 , 30, 333-7	9
2006	Utilizing rapid multiple-locus variable-number tandem-repeat analysis typing to aid control of hospital-acquired Clostridium difficile Infection: a multicenter study. 2012 , 50, 3244-8	10
2005	Clostridium difficile: Changing Epidemiology, Treatment and Infection Prevention Measures. 2012 , 14, 612-9	17
2004	Using rapid diagnostic tests to optimize antimicrobial selection in antimicrobial stewardship programs. 2012 , 32, 677-87	51
2003	Characterization of continued antibacterial therapy after diagnosis of hospital-onset Clostridium difficile infection: implications for antimicrobial stewardship. 2012 , 32, 744-54	13
2002	Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment. 2012 , 12, 342	16
2001	Clostridium difficile 027 infection in Central Italy. 2012 , 12, 370	16
2000	Clostridium difficile 027-associated pseudomembranous colitis after short-term treatment with cefuroxime and cephalexin in an elderly orthopedic patient: a case report. 2012 , 5, 609	5
1999	Implementation of an antimicrobial stewardship program on the medical-surgical service of a 100-bed community hospital. 2012 , 1, 32	40
1998	Optimizing drug therapy in the surgical intensive care unit. 2012 , 92, 1573-620	2
1997	Acute Diarrhea. 2012 , 299-304	

1996	Can we identify patients at high risk of recurrent Clostridium difficile infection?. 2012 , 18 Suppl 6, 21-7	200
1995	Consequences of Clostridium difficile infection: understanding the healthcare burden. 2012 , 18 Suppl 6, 5-12	134
1994	Outcome of Clostridium difficile-associated disease in solid organ transplant recipients: a prospective and multicentre cohort study. 2012 , 25, 1275-81	34
1993	Antimicrobial Surfaces. 2012 , 485-499	
1992	Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. 2012 , 107, 1079-87	502
1991	Infections in the Neurocritical Care Unit. 2012 , 109-122	
1990	Detection, treatment, and prevention of Clostridium difficile infection. 2012 , 10, 581-92	73
1989	Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. 2012 , 40, 1-8	176
1988	Acquisition of spores on gloved hands after contact with the skin of patients with Clostridium difficile infection and with environmental surfaces in their rooms. 2012 , 40, 556-8	83
1987	Real-time polymerase chain reaction testing for Clostridium difficile reduces isolation time and improves patient management in a small community hospital. 2012 , 40, 663-6	34
1986	Comparative contamination rate of toys in kindergartens and households. 2012 , 40, 577-8	1
1985	Pediatric physicians' knowledge, attitudes, and beliefs regarding Clostridium difficile-associated disease prevention, testing, and treatment. 2012 , 40, 577	4
1984	Clostridium difficile-associated infection: a disease of varying severity. 2012 , 204, 836-42	23
1983	Clostridium difficile clinical isolates exhibit variable susceptibility and proteome alterations upon exposure to mammalian cationic antimicrobial peptides. 2012 , 18, 614-20	25
1982	Outcomes in patients tested for Clostridium difficile toxins. 2012 , 74, 369-73	35
1981	Epidemiological features of Clostridium difficile infection among inpatients at Hamad General Hospital in the state of Qatar, 2006-2009. 2012 , 10, 179-85	13
1980	Clostridium difficile Infections: A Continuing Problem. 2012 , 8, 569-570	
1979	The burden of Clostridium difficile-associated disease following digestive tract surgery in Japan. <i>Journal of Hospital Infection</i> , 2012 , 82, 175-80	6.9 32

1978	Changing incidence and clinical manifestations of Clostridium difficile-associated diarrhea detected by combination of glutamate dehydrogenase and toxin assay in Northern Taiwan. 2012 , 45, 287-95	24
1977	Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. 2012 , 87, 636-42	48
1976	Molecular techniques for diagnosis of Clostridium difficile infection: systematic review and meta-analysis. 2012 , 87, 643-51	55
1975	Clostridium difficile infection in patients with chronic kidney disease. 2012 , 87, 1046-53	55
1974	Clostridium difficile infection: new insights into management. 2012 , 87, 1106-17	98
1973	The role of probiotics in the prevention and treatment of antibiotic-associated diarrhea and Clostridium difficile colitis. 2012 , 41, 763-79	24
1972	Immunization strategies for Clostridium difficile infections. 2012 , 11, 469-79	28
1971	Epidemiology, diagnosis and treatment of Clostridium difficile infection. 2012 , 10, 1405-23	53
1970	Choosing optimal antimicrobial therapies. 2012 , 96, 1079-94	10
1969	Management of Other Infections. 2012 , 333-338	
1968	PPI therapy and albumin are better predictors of recurrent Clostridium difficile colitis than choice of antibiotics. 2012 , 16, 2267-73	25
1967	Enfermedad asociada a Clostridium difficile: prevalencia y diagnóstico por laboratorio. 2012 , 16, 211-222	2
1966	Infectious disease emergencies: frontline clinical pearls. 2012 , 96, 1033-66	
1965	Glucopéptidos. 2012 , 16, 1-5	
1964	Un tratamiento no convencional: la bacterioterapia fecal. 2012 , 30, 26-29	
1963	Novel management strategies in the treatment of severe Clostridium difficile infection. 2012 , 46, 111-35	5
1962	Management of Severe Traumatic Brain Injury. 2012 ,	4
1961	Microevolutionary analysis of Clostridium difficile genomes to investigate transmission. 2012 , 13, R118	151

1960	Inflammatory bowel diseases phenotype, <i>C. difficile</i> and NOD2 genotype are associated with shifts in human ileum associated microbial composition. 2012 , 7, e26284	178
1959	<i>Clostridial Infections</i> . 2012 , 1841-1847	
1958	A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics. 2012 , 26, 457-62	50
1957	A cohort study for derivation and validation of a clinical prediction scale for hospital-onset <i>Clostridium difficile</i> infection. 2012 , 26, 885-8	10
1956	<i>Clostridium difficile</i> -Associated Diarrhea at a Community Hospital: Ten-Year Analysis of Infection Rates and the Relationship with Proton Pump Inhibitor Use. 2012 , 47, 446-450	1
1955	A 5-year retrospective review of experience with <i>Clostridium difficile</i> -associated diarrhea. 2012 , 177, 456-9	8
1954	[<i>Clostridium difficile</i> associated infections: an updated view]. 2012 , 29, 434-45	10
1953	Evaluation of the Xpert <i>Clostridium difficile</i> assay for the diagnosis of <i>Clostridium difficile</i> infection. 2012 , 32, 355-8	38
1952	<i>Clostridium difficile</i> outbreaks: prevention and treatment strategies. 2012 , 5, 55-64	20
1951	Sepsis, the Liver and the Gut. 2012 ,	
1950	Constipation in <i>Clostridium difficile</i> infection. 2012 , 2012,	4
1949	[Treatment of refractory or recurrent <i>Clostridium difficile</i> infection]. 2012 , 60, 71-8	3
1948	A real-world evaluation of oral vancomycin for severe <i>Clostridium difficile</i> infection: implications for antibiotic stewardship programs. 2012 , 32, 129-34	22
1947	Characterizations of clinical isolates of <i>clostridium difficile</i> by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 3943-9	5.9 40
1946	Strategies for prevention of <i>Clostridium difficile</i> infection. 2012 , 7 Suppl 3, S14-7	16
1945	Current strategies for management of initial <i>Clostridium difficile</i> infection. 2012 , 7 Suppl 3, S5-10	20
1944	Meeting the challenge of recurrent <i>Clostridium difficile</i> infection. 2012 , 7 Suppl 3, S11-3	5
1943	Toxin assay is more reliable than ICD-9 data and less time-consuming than chart review for public reporting of <i>Clostridium difficile</i> hospital case rates. 2012 , 7, 170-5	7

1942	[Not Available]. 2012 , 41, 146-8		0
1941	Microbiota-targeted therapies: an ecological perspective. 2012 , 4, 137rv5		171
1940	Therapien gegen Bakterientoxine. 2012 , 124, 4098-4121		2
1939	Targeting bacterial toxins. 2012 , 51, 4024-45		46
1938	Recurrence of Clostridium difficile infection after total colectomy in an allogeneic stem cell transplant patient. 2012 , 47, 610-1		6
1937	Antibiotikaassoziierte Diarrh�e. 2012 , 7, 220-227		3
1936	Stool transplants: ready for prime time?. 2012 , 14, 313-6		15
1935	A multiplex, internally controlled real-time PCR assay for detection of toxigenic Clostridium difficile and identification of hypervirulent strain 027/ST-1. 2012 , 31, 1073-9		12
1934	Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency. 2012 , 31, 1551-9		31
1933	Outcomes in community-acquired Clostridium difficile infection. 2012 , 35, 613-8		59
1932	Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. 2012 , 35, 789-95		63
1931	Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. 2012 , 34, 1-13		61
1930	U.K. laboratory diagnosis of Clostridium difficile infection: in a state of transition, confusion, or both?. <i>Journal of Hospital Infection</i> , 2012 , 80, 273-4	6.9	1
1929	Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. <i>Journal of Hospital Infection</i> , 2012 , 81, 1-14	6.9	223
1928	Risk of secondary cases of Clostridium difficile infection among household contacts of index cases. 2012 , 64, 387-90		25
1927	Implementation of standardised surveillance for Clostridium difficile infections in Australia: initial report from the Victorian Healthcare Associated Infection Surveillance System. 2012 , 42, 715-8		11
1926	Infections, bacterial resistance, and antimicrobial stewardship: the emerging role of hospitalists. 2012 , 7 Suppl 1, S34-43		12
1925	Infections ^ Clostridium difficile : aspects cliniques �pidmiologiques et th�rapeutiques. 2012 , 21, 373-383		2

1924	Clostridium difficile infection in the inflammatory bowel disease patient. 2013 , 19, 194-204	96
1923	Changing Epidemiology and Control of Clostridium difficile in Older Adults. 2013 , 2, 143-150	
1922	Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection. 2013 , 41, 579-82	17
1921	Intracolonic vancomycin for severe Clostridium difficile colitis. <i>Surgical Infections</i> , 2013 , 14, 532-9	2 30
1920	Clostridium difficile: a European perspective. 2013 , 66, 115-28	108
1919	Issues Surrounding Antibiotic Use in Older Adults. 2013 , 2, 151-158	3
1918	Effect of age on treatment outcomes in Clostridium difficile infection. 2013 , 61, 222-30	57
1917	Preventing clostridium difficile infection in the intensive care unit. 2013 , 29, 11-8	14
1916	Clostridium difficile as a cause of acute diarrhea: a prospective study in a tertiary care center. 2013 , 32, 179-83	15
1915	Indeterminate tcdB using a Clostridium difficile PCR assay: a retrospective cohort study. 2013 , 13, 324	3
1914	A unique strain of community-acquired Clostridium difficile in severe complicated infection and death of a young adult. 2013 , 13, 299	6
1913	Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. 2013 , 13, 148	85
1912	Clinical factors associated with development of severe-complicated Clostridium difficile infection. 2013 , 11, 1466-71	47
1911	Fecal microbiota transplantation: indications, methods, evidence, and future directions. 2013 , 15, 337	159
1910	Clostridium difficile infection in patients with HIV/AIDS. 2013 , 10, 273-82	26
1909	Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection. 2013 , 32, 1517-23	23
1908	Antibiotics-related adverse events in the infectious diseases department of a French teaching hospital: a prospective study. 2013 , 32, 1611-6	8
1907	Appropriateness of empiric therapy in patients with suspected Clostridium difficile infection. 2013 , 29, 985-8	13

1906	Utility of two novel multiplexing assays for the detection of gastrointestinal pathogens - a first experience. 2013 , 2, 106	34
1905	Clostridium difficile Colitis, Treatment and Management. 2013 , 1, 141-144	
1904	Community-Acquired Clostridium difficile Infection: An Emerging Problem. 2013 , 1, 149-153	6
1903	Epidemiology of Clostridium difficile-associated disease in internal medicine wards in northern Italy. 2013 , 8, 717-23	17
1902	Treating foodborne illness. 2013 , 27, 555-76	5
1901	SP8-1 Vaccination prevents resistance in pneumococcal infections. 2013 , 42, S11-S12	
1900	Appendectomy is not associated with adverse outcomes in clostridium difficile infection: a population-based study. 2013 , 108, 626-7	11
1899	[Infections caused by Clostridium difficile]. 2013 , 31, 254-63	13
1898	Community-Acquired Infection: Awareness and Clinical Implications. 2013 , 9, 1-6	8
1897	Calcineurin inhibitors and Clostridium difficile infection in adult lung transplant recipients: the effect of cyclosporine versus tacrolimus. 2013 , 184, 599-604	5
1896	SP6-3 Treatment strategies for sexually transmitted diseases (STD) in Eastern Asia. 2013 , 42, S10	
1895	Impact of toxigenic Clostridium difficile polymerase chain reaction testing on the clinical microbiology laboratory and inpatient epidemiology. 2013 , 76, 534-8	7
1894	Intérêt et technique de la transplantation fécale. 2013 , 15, 187-192	
1893	Novel avenues for Clostridium difficile infection drug discovery. 2013 , 8, 459-77	13
1892	Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond. 2013 , 7, 615-28	16
1891	A systematic evaluation of methods to optimize culture-based recovery of Clostridium difficile from stool specimens. 2013 , 19, 39-43	51
1890	Molecular methods in the diagnosis of Clostridium difficile infections: an update. 2013 , 13, 681-92	7
1889	Clostridium difficile Infection in children. 2013 , 167, 567-73	72

1888	Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection. 2013 , 42, 553-8	21
1887	Clostridium difficile Infection. 2013 , 97, 523-36, ix	14
1886	Clostridium difficile infections: do we know the real dimensions of the problem?. 2013 , 42 Suppl, S36-40	10
1885	Correlation between Clostridium difficile bacterial load, commercial real-time PCR cycle thresholds, and results of diagnostic tests based on enzyme immunoassay and cell culture cytotoxicity assay. 2013 , 51, 3624-30	64
1884	Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. 2013 , 68, 1951-61	264
1883	Histologic findings and clinical characteristics in acutely symptomatic ulcerative colitis patients with superimposed Clostridium difficile infection. 2013 , 140, 831-7	10
1882	Fulminant colitis. 2013 , 27, 771-82	1
1881	Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Surgical Infections</i> , 2013 , 14, 73-156 2	567
1880	Is fidaxomicin worth the cost? An economic analysis. 2013 , 57, 555-61	88
1879	Laboratory diagnosis of Clostridium difficile infections: there is light at the end of the colon. 2013 , 57, 1175-81	67
1878	Assessment of 30-day all-cause mortality in metronidazole-treated patients with Clostridium difficile infection. 2013 , 45, 786-90	4
1877	Rapid detection of Clostridium difficile toxins from stool samples using real-time multiplex PCR. 2013 , 62, 1350-1356	8
1876	Infectiologie en ranimation. 2013 ,	
1875	Diagnosis and management of Clostridium difficile infection. 2013 , 11, 1216-23; quiz e73	43
1874	Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. 2013 , 13, 936-45	320
1873	Evaluation of the new CE-IVD marked BD MAX Cdiff Assay for the detection of toxigenic Clostridium difficile harboring the tcdB gene from clinical stool samples. 2013 , 94, 58-60	5
1872	Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. 2013 , 56, 1713-21	108
1871	Fidaxomicin: a review of its use in patients with Clostridium difficile infection. 2013 , 73, 1733-47	22

1870	Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection (RCDI) among infectious disease physicians. 2013 , 24, 20-4		49
1869	Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. 2013 , 11, 458-64; quiz e37-8		76
1868	Prevalence of Clostridium difficile colonization among healthcare workers. 2013 , 13, 459		21
1867	Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model. 2013 , 13, 376		30
1866	Epidemiology of Clostridium difficile infection among active duty United States military personnel (1998-2010). 2013 , 13, 609		6
1865	Impact of intensive infection control team activities on the acquisition of methicillin-resistant Staphylococcus aureus, drug-resistant Pseudomonas aeruginosa and the incidence of Clostridium difficile-associated disease. 2013 , 19, 1047-52		10
1864	Epidemiology of Clostridium difficile-associated disease (CDAD): a shift from hospital-acquired infection to long-term care facility-based infection. 2013 , 58, 3407-12		30
1863	[Drug therapy of infectious diarrhea: part 1: acute diarrhea]. 2013 , 54, 1383-92		3
1862	It's a microscopic world after all: prebiotics, probiotics, and synbiotics. 2013 , 34, 323-5		1
1861	Impact of change to molecular testing for Clostridium difficile infection on healthcare facility-associated incidence rates. <i>Infection Control and Hospital Epidemiology</i> , 2013 , 34, 1055-61	2	51
1860	Abdominal catastrophes in the intensive care unit setting. 2013 , 29, 1017-44		9
1859	Overview of severe Clostridium difficile infection. 2013 , 29, 827-39		18
1858	Diverse sources of C. difficile infection identified on whole-genome sequencing. 2013 , 369, 1195-205		471
1857	[Clostridium difficile infections - still a major challenge]. 2013 , 155, 57-9		
1856	Clostridium difficile infection in children: a comprehensive review. 2013 , 29, 967-84		40
1855	Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain. 2013 , 51, 1465-73		69
1854	Protective efficacy induced by recombinant Clostridium difficile toxin fragments. 2013 , 81, 2851-60		33
1853	War on the spore: Clostridium difficile disease among patients in a long-term acute care hospital. 2013 , 35, 15-21		12

1852	Clostridium difficile infection in infants and children. 2013 , 131, 196-200		193
1851	Fidaxomicin in the treatment of Clostridium difficile-associated diarrhoea. 2013 , 33, 93-4		3
1850	Laboratory Technical Advances in the Diagnosis of Clostridium difficile. 2013 , 769-783		
1849	Antimicrobial susceptibilities of Clostridium difficile isolated in Japan. 2013 , 19, 360-2		10
1848	The 2012 guidelines for severe sepsis and septic shock: an update for emergency nursing. 2013 , 39, 652-6		2
1847	Asymptomatic carriage of toxigenic Clostridium difficile by hospitalized patients. <i>Journal of Hospital Infection</i> , 2013 , 85, 155-8	6.9	57
1846	Secular trends in the epidemiology of Clostridium difficile infection (CDI): relationship with alcohol gel and antimicrobial usage in a hospital. 2013 , 17, e418-21		5
1845	Investigation of inpatient probiotic use at an academic medical center. 2013 , 17, e321-4		18
1844	Laboratory tests for diagnosis of Clostridium difficile infection: past, present, and future. 2013 , 31, 65-7		9
1843	SP7-3 Alleviating the burden of CDI: current and emerging treatment options. 2013 , 42, S11		
1842	Algorithm proposal based on the C. Diff Quik Chek Complete ICT device for detecting Clostridium difficile infection. 2013 , 31, 97-9		11
1841	Clostridium difficile infection increases mortality risk in lung transplant recipients. 2013 , 32, 1020-6		33
1840	SP7-4 Tackling the big issue â€” CDI recurrence. 2013 , 42, S11		
1839	Fulminant Clostridium difficile colitis: a complication of perioperative antibiotic prophylaxis. 2013 , 71, 1880-5		17
1838	Risk of Clostridium difficile infection with acid-suppressive therapy; pitfalls in accurate estimation. 2013 , 108, 277-8		5
1837	Infection prevention and control in residential facilities for pediatric patients and their families. <i>Infection Control and Hospital Epidemiology</i> , 2013 , 34, 1003-41	2	10
1836	Variations in virulence and molecular biology among emerging strains of Clostridium difficile. 2013 , 77, 567-81		64
1835	Knowledge, attitudes and practice regarding Clostridium difficile: a survey of physicians in an academic medical center. 2013 , 41, 266-9		7

1834	[Which alternatives are at our disposal in the anti-infectious therapeutics face to multi-drug resistant bacteria?]. 2013 , 71, 150-8		3
1833	[Infections caused by Clostridium difficile. Addendum]. 2013 , 31, 557		
1832	[Reply to «infections caused by Clostridium difficile. Addendum»]. 2013 , 31, 558		
1831	Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection. <i>Journal of Hospital Infection</i> , 2013 , 83, 294-9	6.9	13
1830	Role of the environment in the transmission of Clostridium difficile in health care facilities. 2013 , 41, S105-10		54
1829	Improved detection of toxigenic Clostridium difficile using the Cepheid Xpert C difficile assay and impact on C difficile infection rates in a tertiary hospital: a double-edged sword. 2013 , 41, 270-2		16
1828	SP7-1 CDI: Update in epidemiology, pathogenesis and treatment. 2013 , 42, S10		
1827	Prospective comparison of a commercial multiplex real-time polymerase chain reaction and an enzyme immunoassay with toxigenic culture in the diagnosis of Clostridium difficile-associated infections. 2013 , 75, 361-5		15
1826	In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden. 2013 , 20, 32-5		29
1825	Re-evaluating endoscopy-associated infection risk estimates and their implications. 2013 , 41, 734-6		33
1824	Clinical and microbiological features of Clostridium difficile infections in France: the ICD-RAISIN 2009 national survey. 2013 , 43, 67-74		49
1823	Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. <i>Journal of Hospital Infection</i> , 2013 , 85, 28-32	6.9	23
1822	Influence of cohorting patients with Clostridium difficile infection on risk of symptomatic recurrence. <i>Journal of Hospital Infection</i> , 2013 , 85, 17-21	6.9	13
1821	Clostridium difficile: infeñ e ribotipos. 2013 , 20, 240-242		
1820	Electronic screening of patients for predisposition to Clostridium difficile infection in a community hospital. 2013 , 41, 232-5		6
1819	Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection. <i>Journal of Hospital Infection</i> , 2013 , 85, 22-7	6.9	17
1818	Implementation of hospital-wide enhanced terminal cleaning of targeted patient rooms and its impact on endemic Clostridium difficile infection rates. 2013 , 41, 537-41		52
1817	SP7-2 The impact of CDI: morbidity, mortality and healthcare burden. 2013 , 42, S10-S11		

1816	Clinical impact of switching conventional enzyme immunoassay with nucleic acid amplification test for suspected <i>Clostridium difficile</i> -associated diarrhea. 2013 , 41, 373-5	5
1815	Kinetic spectrophotometric H-point standard addition method for the simultaneous determination of diloxanide furoate and metronidazole in binary mixtures and biological fluids. 2013 , 114, 592-8	14
1814	Asymptomatic <i>Clostridium difficile</i> colonization in a tertiary care hospital: admission prevalence and risk factors. 2013 , 41, 390-3	73
1813	Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent <i>Clostridium difficile</i> infection. 2013 , 11, 1036-8	158
1812	SP6-2 <i>Mycoplasma genitalium</i> : should we treat and how?. 2013 , 42, S9-S10	
1811	Predicting recurrence of <i>C. difficile</i> colitis using bacterial virulence factors: binary toxin is the key. 2013 , 17, 118-24; discussion p.124-5	76
1810	Rifaximin in the treatment of recurrent <i>Clostridium difficile</i> infection. 2013 , 37, 122-8	48
1809	Stool substitute transplant therapy for the eradication of <i>Clostridium difficile</i> infection: 'RePOOPulating' the gut. 2013 , 1, 3	503
1808	<i>Clostridium difficile</i> Infection in travelers--a neglected pathogen?. 2013 , 20, 37-43	16
1807	Guidelines for diagnosis, treatment, and prevention of <i>Clostridium difficile</i> infections. 2013 , 108, 478-98; quiz 499	1147
1806	An improved qPCR protocol for rapid detection and quantification of <i>Clostridium difficile</i> in cattle feces. 2013 , 341, 115-21	12
1805	<i>Clostridium difficile</i> infections in solid organ transplantation. 2013 , 13 Suppl 4, 42-9	69
1804	Changing epidemiology of <i>Clostridium difficile</i> -associated disease during stem cell transplantation. 2013 , 19, 405-9	63
1803	Fecal microbiome transplantation for recurrent <i>Clostridium difficile</i> infection: report on a case series. 2013 , 19, 22-6	90
1802	Concurrent outbreaks with co-infection of norovirus and <i>Clostridium difficile</i> in a long-term-care facility. 2013 , 141, 1598-603	11
1801	Fecal microbiota transplantation for <i>Clostridium difficile</i> infection: systematic review and meta-analysis. 2013 , 108, 500-8	619
1800	Germination efficiency of clinical <i>Clostridium difficile</i> spores and correlation with ribotype, disease severity and therapy failure. 2013 , 62, 1405-1413	30
1799	Abdominal Infections. 2013 , 113-144	

1798	Antibacterial and cytotoxic activity of isoprenylated coumarin mammea A/AA isolated from <i>Mammea africana</i> . 2013 , 147, 259-62	32
1797	Does improving surface cleaning and disinfection reduce health care-associated infections?. 2013 , 41, S12-9	172
1796	Clinical and economic outcomes from a community hospital's antimicrobial stewardship program. 2013 , 41, 145-8	112
1795	<i>Clostridium difficile</i> infection. 2013 , 50, 302-37	26
1794	Protective effect of bifidobacteria in an experimental model of <i>Clostridium difficile</i> associated colitis. 2013 , 80, 263-9	14
1793	Fidaxomicin for treatment of <i>clostridium difficile</i> -associated diarrhea and its potential role for prophylaxis. 2013 , 14, 1529-36	6
1792	Detection of <i>Clostridium difficile</i> toxins A, B and binary toxin with slow off-rate modified aptamers. 2013 , 76, 278-85	27
1791	Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of <i>Clostridium difficile</i> infection in the United States. 2013 , 16, 297-304	63
1790	An overview of fecal microbiota transplantation: techniques, indications, and outcomes. 2013 , 78, 240-9	158
1789	Challenges and opportunities for faecal microbiota transplantation therapy. 2013 , 141, 2235-42	9
1788	Antimicrobial susceptibility and resistance mechanisms of clinical <i>Clostridium difficile</i> from a Chinese tertiary hospital. 2013 , 41, 80-4	52
1787	Therapy of <i>Clostridium difficile</i> infection: perspectives on a changing paradigm. 2013 , 14, 2375-86	3
1786	The role of vancomycin and metronidazole for the treatment of <i>Clostridium difficile</i> -associated diarrhea. 2013 , 26, 488-90	7
1785	Intestinal inflammatory biomarkers and outcome in pediatric <i>Clostridium difficile</i> infections. 2013 , 163, 1697-1704.e2	50
1784	Diagnosis of <i>Clostridium difficile</i> infection: the molecular approach. 2013 , 8, 1587-98	8
1783	Infections in psychiatric facilities, with an emphasis on outbreaks. <i>Infection Control and Hospital Epidemiology</i> , 2013 , 34, 80-8	2 24
1782	Unnecessary antimicrobial use in patients with current or recent <i>Clostridium difficile</i> infection. <i>Infection Control and Hospital Epidemiology</i> , 2013 , 34, 109-16	2 43
1781	If not now, when? Seizing the moment for antibiotic stewardship. <i>Infection Control and Hospital Epidemiology</i> , 2013 , 34, 117-8	2 3

1780	Effectiveness of hand hygiene for removal of <i>Clostridium difficile</i> spores from hands. <i>Infection Control and Hospital Epidemiology</i> , 2013 , 34, 302-5	2	52
1779	Electronic health record-based detection of risk factors for <i>Clostridium difficile</i> infection relapse. <i>Infection Control and Hospital Epidemiology</i> , 2013 , 34, 407-14	2	39
1778	Transfer of <i>Clostridium difficile</i> spores by nonsporocidal wipes and improperly used hypochlorite wipes: practice + product = perfection. <i>Infection Control and Hospital Epidemiology</i> , 2013 , 34, 441-2	2	25
1777	Attributable burden of hospital-onset <i>Clostridium difficile</i> infection: a propensity score matching study. <i>Infection Control and Hospital Epidemiology</i> , 2013 , 34, 588-96	2	65
1776	Burden of hospital-onset <i>Clostridium difficile</i> infection in patients discharged from Rhode Island hospitals, 2010-2011: application of present on admission indicators. <i>Infection Control and Hospital Epidemiology</i> , 2013 , 34, 700-8	2	9
1775	Bed occupancy rates and hospital-acquired <i>Clostridium difficile</i> infection: a cohort study. <i>Infection Control and Hospital Epidemiology</i> , 2013 , 34, 1062-9	2	10
1774	Epidemiology of <i>Clostridium difficile</i> infection. 2013 , 26, 464-75		143
1773	Impact of ribotype 027 on <i>Clostridium difficile</i> infection in a geriatric department. 2013 , 32, 1177-82		11
1772	Epidemiology, risk factors, and outcomes of <i>Clostridium difficile</i> infection in kidney transplant recipients. 2013 , 15, 134-41		38
1771	Poor functional status as a risk factor for severe <i>Clostridium difficile</i> infection in hospitalized older adults. 2013 , 61, 1738-42		41
1770	Role of the hospital environment in disease transmission, with a focus on <i>Clostridium difficile</i> . 2013 , 18, 14-22		8
1769	<i>Clostridium difficile</i> in a HIV-infected cohort: incidence, risk factors, and clinical outcomes. 2013 , 27, 2799-807		44
1768	Treatment of infection: recent trial results. 2013 , 3, 875-886		4
1767	The epidemiology of <i>Clostridium difficile</i> infection in children: a population-based study. 2013 , 56, 1401-6		158
1766	Artificial stool transplantation: progress towards a safer, more effective and acceptable alternative. 2013 , 7, 291-3		11
1765	A tool to assess student performance in a <i>Clostridium difficile</i> infection simulation scenario. 2013 , 77, 149		2
1764	Length of stay and hospital costs among high-risk patients with hospital-origin <i>Clostridium difficile</i> -associated diarrhea. 2013 , 16, 440-8		37
1763	Relationship between bacterial strain type, host biomarkers, and mortality in <i>Clostridium difficile</i> infection. 2013 , 56, 1589-600		167

1762	Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections. 2013 , 11, 767-76	7
1761	CAGS Clinical Practice Committee report: the science of Clostridium difficile and surgery. 2013 , 56, 367-71	3
1760	A new strategy for the prevention of Clostridium difficile infection. 2013 , 207, 1498-504	61
1759	Long term effect of infection control practices and associated factors during a major Clostridium difficile outbreak in Costa Rica. 2013 , 7, 914-21	9
1758	Do bay closures prevent the spread of C. difficile?. 2013 , 14, 26-29	
1757	[Outcomes of Clostridium difficile enterocolitis after administration of antibiotics along with probiotic supplement]. 2013 , 66, 209-13	
1756	Detection of mixed infection from bacterial whole genome sequence data allows assessment of its role in Clostridium difficile transmission. 2013 , 9, e1003059	65
1755	Impact of regular collaboration between infectious diseases and critical care practitioners on antimicrobial utilization and patient outcome. 2013 , 41, 2099-107	77
1754	PCR vs "PCAre'n't": limitations of PCR-based assays performed on formalin-fixed, paraffin-embedded mucosal biopsy specimens. 2013 , 139, 705-7	
1753	Duodenal infusion of stool is more effective than vancomycin in patients with recurrent Clostridium difficile. 2013 , 18, 220-1	2
1752	Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. 2013 , 56, 67-73	178
1751	Diagnostic testing for Clostridium difficile infection in patients with inflammatory bowel disease. 2013 , 47, 737-8	3
1750	Metabolic syndrome and colorectal neoplasm. 2013 , 47, 738-9	
1749	Fecal microbiota transplantation: past, present and future. 2013 , 29, 79-84	228
1748	Impact of 2-Step Laboratory Testing Procedures for Clostridium difficile Infection on Physicians' Treatment Decisions. 2013 , 21, 123-125	
1747	Moving fecal microbiota transplantation into the mainstream. 2013 , 28, 589-98	10
1746	Use of Lactobacillus in Prevention of Recurrences of Clostridium difficile Infection in Solid Organ Transplant Recipients. 2013 , 21, 292-298	4
1745	New developments in chemotherapeutic options for Clostridium difficile colitis. 2013 , 26, 461-70	19

1744	The changing face of <i>Clostridium difficile</i> in critical care. 2013 , 8, 26-34	
1743	Appendectomy and Risk of <i>Clostridium difficile</i> Recurrence. 2013 , 21, 28-32	4
1742	Probiotics for Recurrent <i>Clostridium difficile</i> Infection in Solid Organ Transplant Recipients. 2013 , 21, 281-282	2
1741	C-reactive protein is a useful predictor of metronidazole treatment failure in mild-to-moderate <i>Clostridium difficile</i> infection. 2013 , 25, 33-6	7
1740	<i>Clostridium difficile</i> : biological therapies. 2013 , 26, 454-60	8
1739	Recent trends in the epidemiology and treatment of <i>C. difficile</i> infection in children. 2013 , 25, 116-21	26
1738	<i>Clostridium difficile</i> carriage and serum antitoxin responses in children with inflammatory bowel disease. 2013 , 19, 2744-52	51
1737	<i>Clostridium difficile</i> infection in newly diagnosed pediatric inflammatory bowel disease in the mid-southern United States. 2013 , 57, 487-8	18
1736	<i>Clostridium difficile</i> infection among hematopoietic stem cell transplant recipients: beyond colitis. 2013 , 26, 326-31	40
1735	Comparison of ChromID <i>C. difficile</i> agar and cycloserine-cefoxitin-fructose agar for the recovery of <i>Clostridium difficile</i> . 2013 , 45, 495-500	12
1734	<i>Clostridium difficile</i> testing: have we got it right?. 2013 , 51, 377-8	13
1733	Quantitative fecal lactoferrin in toxin-positive and toxin-negative <i>Clostridium difficile</i> specimens. 2013 , 51, 311-3	23
1732	Intestinal dysbiosis and depletion of butyrogenic bacteria in <i>Clostridium difficile</i> infection and nosocomial diarrhea. 2013 , 51, 2884-92	325
1731	Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of <i>Clostridium difficile</i> infection in mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 689-96	5.9 38
1730	<i>Clostridium difficile</i> infection is associated with increased risk of death and prolonged hospitalization in children. 2013 , 57, 1-8	88
1729	Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). 2013 , 24, 1189-202	24
1728	Candidemia subsequent to severe infection due to <i>Clostridium difficile</i> : is there a link?. 2013 , 57, 772-4	23
1727	Performance of <i>Clostridium difficile</i> toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. 2013 , 51, 869-73	78

1726	Virulence and clinical outcomes in <i>Clostridium difficile</i> infection: a complex business. 2013 , 56, 906-7	10
1725	<i>Clostridium difficile</i> in foods and animals: history and measures to reduce exposure. 2013 , 14, 11-29	68
1724	Interobserver variability and feasibility of polymerase chain reaction-based assay in distinguishing ischemic colitis from <i>Clostridium difficile</i> colitis in endoscopic mucosal biopsies. 2013 , 139, 730-5	4
1723	Fecal microbiota transplantation and emerging treatments for <i>Clostridium difficile</i> infection. 2013 , 26, 498-505	8
1722	Does empirical <i>Clostridium difficile</i> infection (CDI) therapy result in false-negative CDI diagnostic test results?. 2013 , 57, 494-500	34
1721	Antimicrobial activity of LFF571 and three treatment agents against <i>Clostridium difficile</i> isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. 2013 , 68, 1305-11	30
1720	The host immune response to <i>Clostridium difficile</i> infection. 2013 , 1, 19-35	46
1719	The nose knows not: poor predictive value of stool sample odor for detection of <i>Clostridium difficile</i> . 2013 , 56, 615-6	6
1718	<i>Clostridium difficile</i> in children: a review of existing and recently uncovered evidence. 2013 , 764, 57-72	4
1717	The microbiome and <i>Clostridium difficile</i> infection. 2013 , 46-59	
1716	An alternative for managing severe <i>Clostridium difficile</i> . 2013 , 8, 18-20	
1715	Acute kidney injury is an independent marker of severity in <i>Clostridium difficile</i> infection: a nationwide survey. 2013 , 47, 481-4	16
1714	<i>Clostridium difficile</i> infection and inflammatory bowel disease. 2013 , 47, 666-71	37
1713	Editorial commentary: <i>Clostridium difficile</i> in children: colonization and consequences. 2013 , 57, 9-12	5
1712	Risk factors associated with <i>Clostridium difficile</i> infection after kidney and pancreas transplantation. 2013 , 15, 502-9	19
1711	Analysis of anti- <i>Clostridium difficile</i> activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2882-6	5,9 31
1710	Multicenter evaluation of the Verigene <i>Clostridium difficile</i> nucleic acid assay. 2013 , 51, 4120-5	27
1709	Easily modified factors contribute to delays in diagnosis of <i>Clostridium difficile</i> infection: a cohort study and intervention. 2013 , 51, 2365-70	15

1708	Fecal transplantation for the treatment of recurrent clostridium difficile infection. 2013 , 5, 339-43	18
1707	Fecal microbiota transplantation: the state of the art. 2013 , 5, e13	21
1706	Reply to M.R. Green et al. 2013 , 31, 4379	
1705	Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients. 2013 , 15, 493-501	11
1704	Evaluation of an algorithmic approach in comparison with the Illumigene assay for laboratory diagnosis of Clostridium difficile infection. 2013 , 51, 1152-7	19
1703	Impact of pretransplant hepatic encephalopathy on liver posttransplantation outcomes. 2013 , 2013, 952828	18
1702	Analysis of the intestinal microbiome of a recovered Clostridium difficile patient after fecal transplantation. 2013 , 88, 243-51	30
1701	Putting evidence into nursing practice: four traditional practices not supported by the evidence. 2013 , 33, 28-42	21
1700	Infections digestives ^ Clostridium difficile: diagnostic et traitement. 2013 , 441-460	
1699	Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic. 2013 , 1291, 33-41	18
1698	Distinguishing community-associated from hospital-associated Clostridium difficile infections in children: implications for public health surveillance. 2013 , 57, 1665-72	33
1697	The rise of Clostridium difficile infection in lung transplant recipients in the modern era. 2013 , 27, 303-10	18
1696	Overview of Clostridium difficile infection: implications for China. 2013 , 1, 153-8	11
1695	Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2690-3	5.9 28
1694	Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. 2013 , 26, 604-30	264
1693	Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. 2013 , 31, 2493-9	75
1692	An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant organisms. 2013 , 56, 27-35	156
1691	Isolation of Clostridium difficile from faecal specimens--a comparison of chromID C. difficile agar and cycloserine-cefoxitin-fructose agar. 2013 , 62, 1423-1427	24

1690	Systematic analysis underlying the quality of the scientific evidence and conflicts of interest in gastroenterology practice guidelines. 2013 , 108, 1686-93		18
1689	Clostridium difficile surveillance: harnessing new technologies to control transmission. 2013 , 11, 1193-205		15
1688	Antibiotic-associated diarrhea: a refresher on causes and possible prevention with probiotics--continuing education article. 2013 , 26, 476-82		20
1687	Role of fidaxomicin for the treatment of Clostridium difficile infection. 2013 , 26, 491-7		6
1686	infection in older adults. 2013 , 9, 403-414		44
1685	Vancomycin Use for Pediatric Clostridium difficile Infection Is Increasing and Associated with Specific Patient Characteristics. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 4307-4313	5.9	6
1684	Is fidaxomicin the drug of choice for treating Clostridium difficile-associated diarrhea in patients with cancer?. 2013 , 31, 4376-8		3
1683	Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. 2013 , 56, 1059-60		21
1682	Comparison of perirectal versus rectal swabs for detection of asymptomatic carriers of toxigenic Clostridium difficile. 2013 , 51, 3421-2		12
1681	Clostridium difficileinfection: a global threat. 2013 , 6-18		
1680	Clinical practice guidelines for antimicrobial prophylaxis in surgery. 2013 , 70, 195-283		1231
1679	Characteristics of patients with Clostridium difficile infection in Taiwan. 2013 , 141, 2031-8		6
1678	Viral co-infections are common and are associated with higher bacterial burden in children with clostridium difficile infection. 2013 , 57, 813-6		27
1677	Management of the elderly patients with inflammatory bowel disease: practical considerations. 2013 , 19, 2257-72		17
1676	Clostridium difficile infection: a multicenter study of epidemiology and outcomes in mechanically ventilated patients. 2013 , 41, 1968-75		40
1675	Treatment of an initial infection with clostridium difficile in patients with inflammatory bowel disease. 2013 , 19, 2223-6		2
1674	Risk factors and outcome of PCR-detected Clostridium difficile infection in ileal pouch patients. 2013 , 19, 397-403		48
1673	Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance?. 2013 , 47, 205-11		19

1672	Polymerase chain reaction test for Clostridium difficile toxin B gene reveals similar prevalence rates in children with and without inflammatory bowel disease. 2013 , 57, 293-7		20
1671	Evaluation of a hand hygiene campaign in outpatient health care clinics. 2013 , 113, 36-42; quiz 43-4		11
1670	Clostridium difficile infection in pediatric acute myeloid leukemia: from the Canadian Infections in Acute Myeloid Leukemia Research Group. 2013 , 32, 610-3		15
1669	Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy. <i>Infection Control and Hospital Epidemiology</i> , 2013 , 34, 127-32	2	29
1668	Eye, ear, nose, and throat emergencies in the elderly. 153-169		
1667	Gastrointestinal emergencies in the elderly. 207-218		1
1666	Incidence and clinical features of Clostridium difficile infection in Korea: a nationwide study. 2013 , 141, 189-94		39
1665	A Clostridium difficile infection (CDI) stewardship initiative improves adherence to practice guidelines for management of CDI. <i>Infection Control and Hospital Epidemiology</i> , 2013 , 34, 1222-4	2	18
1664	Concomitant typhlitis and Clostridium difficile colitis developed after first R-CHOP chemotherapy in a non-Hodgkin lymphoma patient. 2013 , 2013,		4
1663	Reducing Clostridium difficile incidence, colectomies, and mortality in the hospital setting: a successful multidisciplinary approach. 2013 , 39, 298-305		23
1662	Fecal transplant in refractory Clostridium difficile colitis. 2013 , 110, 108-15		16
1661	Emerging therapies for Clostridium difficile infection - focus on fidaxomicin. 2013 , 6, 41-53		20
1660	Management and prophylaxis of infections after BMT/SCT. 330-347		
1659	[Laboratory diagnosis of Clostridium difficile infection]. 2013 , 71, 395-400		2
1658	Treatment Strategies for Recurrent Clostridium difficile Infection. 2013 , 66, 361-8		14
1657	Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7577-85	5.6	101
1656	Combination of culture, antigen and toxin detection, and cytotoxin neutralization assay for optimal Clostridium difficile diagnostic testing. 2013 , 24, 89-92		4
1655	Possible association between obesity and Clostridium difficile infection. 2013 , 19, 1791-8		41

1654	The Clostridium difficile problem: a South African tertiary institution's prospective perspective. 2013 , 103, 168-72		22
1653	Potential for transmission of spores by patients awaiting laboratory testing to confirm suspected Clostridium difficile infection. <i>Infection Control and Hospital Epidemiology</i> , 2013 , 34, 306-8	2	18
1652	Safety and Efficacy of Fidaxomicin in Patients with Clostridium Difficile Infection. 2013 , 5, CMT.S7279		
1651	Clostridium difficile infection in hospitalized patients at university clinical center tuzla, bosnia and herzegovina: a 4 year experience. 2013 , 25, 153-7		8
1650	Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. 2013 , 8, e76269		66
1649	Something old, something new, something borrowed. 2013 , 24, 63-4		1
1648	New drugs and devices from 2011 - 2012 that might change your practice. 2013 , 14, 619-28		0
1647	Clinical use of anti-TNF therapy and increased risk of infections. 2013 , 5, 79-99		147
1646	The combined use of proton pump inhibitors and antibiotics as risk factors for Clostridium difficile infection. 2013 , 18, 76-79		3
1645	Probiotics for the Prevention of Antibiotic-Associated Diarrhea. 2013 , 6, 148-151		1
1644	Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. 2014 , 14, 152-75		22
1643	Evaluation of the Liaison C. difficile GDH System. 2013 , 28,		
1642	Clostridium difficile Colitis after Topical Ophthalmic Use of Levofloxacin. 2013 , 36, S5		1
1641	Incidence of diarrhea by Clostridium difficile in hematologic patients and hematopoietic stem cell transplantation patients: risk factors for severe forms and death. 2014 , 56, 325-31		21
1640	Nosocomial transmission of C. difficile in English hospitals from patients with symptomatic infection. 2014 , 9, e99860		3
1639	Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. 2014 , 9, e102848		18
1638	The magnitude and duration of Clostridium difficile infection risk associated with antibiotic therapy: a hospital cohort study. 2014 , 9, e105454		45
1637	Physician attitudes toward the use of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection. 2014 , 28, 319-24		36

1636	Nutrition economic evaluation of a probiotic in the prevention of antibiotic-associated diarrhea. 2014, 5, 13		22
1635	Controversies Surrounding Clostridium difficile Infection in Infants and Young Children. 2014, 1, 40-7		6
1634	Structural and functional changes in the gut microbiota associated to Clostridium difficile infection. 2014, 5, 335		65
1633	Clostridium difficile infection in patients with inflammatory bowel disease. 2014, 9, 125-9		4
1632	Community-acquired Clostridium difficile infection: an increasing public health threat. 2014, 7, 63-72		146
1631	Clostridium difficile infection: guideline-based diagnosis and treatment. 2014, 111, 723-31		43
1630	Probiotics for antibiotic-associated diarrhea: do we have a verdict?. <i>World Journal of Gastroenterology</i> , 2014, 20, 17788-95	5.6	37
1629	Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada. 2014, 25, 87-94		24
1628	Performance of severity of illness classification for Clostridium difficile infection to predict need-for-colectomy or inpatient death. 2014, 4,		1
1627	[Performance of prognostic index in severe Clostridium difficile-associated infection: retrospective analysis in a university hospital]. 2014, 31, 659-65		2
1626	Clostridium difficile in Children: To Treat or Not to Treat?. 2014, 17, 80-4		14
1625	An Unusual Case of Clostridium difficile Infection in Trinidad and Tobago. 2014, 03,		
1624	Factors associated with Clostridium difficile diarrhea in a hospital in Beijing, China. 2014, 47, 1085-90		10
1623	A mathematical model to evaluate the routine use of fecal microbiota transplantation to prevent incident and recurrent Clostridium difficile infection. <i>Infection Control and Hospital Epidemiology</i> , 2014, 35, 18-27	2	25
1622	Community Hospital Experience of Refractory Clostridium difficile Colitis: Treatment and Efficacy of Diverting Loop Ileostomy and Colonic Lavage. 2014, 80, 247-249		4
1621	A case of Clostridium difficile infection complicated by acute respiratory distress syndrome treated with fecal microbiota transplantation. <i>World Journal of Gastroenterology</i> , 2014, 20, 12687-90	5.6	4
1620	. 2014,		1
1619	8.3 Grundlagen der Antibiotikatherapie. 2014,		

1618	Reply to Simon, Shah et al, and Hartzema and Chen. 2014 , 58, 605-7	
1617	Place de lâEndoscopie dans le diagnostic des diarrhées sâves aux antibiotiques. 2014 , 44, 352-357	
1616	Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance. 2014 , 5, 69-84	37
1615	Clostridium difficile infection: current, forgotten and emerging treatment options. 2014 , 3, 547-57	4
1614	Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection. 2014 , 3, 321-31	28
1613	Clostridium-difficile-assozierte Kolitis. 2014 , 11, 48-57	
1612	Clinical comparison of Simplexa universal direct and BD GeneOhm tests for detection of toxigenic Clostridium difficile in stool samples. 2014 , 52, 281-2	6
1611	Towards point of care testing for infection by volatile profiling, using the combination of a short multi-capillary gas chromatography column with metal oxide sensor detection. 2014 , 25,	19
1610	Clinical update for the diagnosis and treatment of Clostridium difficile infection. 2014 , 5, 1-26	47
1609	Cost and Impact on Patient Length of Stay of Rapid Molecular Testing for Clostridium difficile. 2014 , 3, 281-93	10
1608	Stability and recovery of DIFICID(®) (Fidaxomicin) 200-mg crushed tablet preparations from three delivery vehicles, and administration of an aqueous dispersion via nasogastric tube. 2014 , 14, 309-14	11
1607	Clostridium difficile infection: management strategies for a difficult disease. 2014 , 7, 72-86	35
1606	Peritoneal dialysis-related peritonitis triggered by Clostridium difficile-associated colitis. 2014 , 34, 139-40	8
1605	Gastrointestinal pathogens detected by multiplex nucleic acid amplification testing in stools of pediatric patients and patients returning from the tropics. 2014 , 42, 961-70	47
1604	The potential for emerging therapeutic options for Clostridium difficile infection. 2014 , 5, 696-710	29
1603	Challenges and opportunities in the management of Clostridium difficile infection. 2014 , 8, 863-74	1
1602	Implementation of Polymerase Chain Reaction to Rule Out Clostridium difficile Infection Is Associated With Reduced Empiric Antibiotic Duration of Therapy. 2014 , 49, 639-43	8
1601	Real-time cellular analysis for quantitative detection of functional Clostridium difficile toxin in stool. 2014 , 14, 281-91	5

1600	Implementation and first-year results of an antimicrobial stewardship program at a community hospital. 2014 , 71, 943-9		38
1599	In vitro activity of MCB3681 against Clostridium difficile strains. 2014 , 28, 216-9		24
1598	Comparative nutritional and chemical phenome of Clostridium difficile isolates determined using phenotype microarrays. 2014 , 27, 20-5		18
1597	Severity and frequency of community-onset Clostridium difficile infection on an Australian tertiary referral hospital campus. 2014 , 29, 152-5		10
1596	Comparative performance of the GeneXpert C. difficile PCR assay and C. diff Quik Chek Complete kit assay for detection of Clostridium difficile antigen and toxins in symptomatic community-onset infections. 2014 , 29, 244-8		15
1595	Portrait Toxigenic Clostridium difficile assay, an isothermal amplification assay detects toxigenic C. difficile in clinical stool specimens. 2014 , 14, 17-26		5
1594	Clostridium difficile with Moxifloxacin/Clindamycin Resistance in Vegetables in Ohio, USA, and Prevalence Meta-Analysis. 2014 , 2014, 158601		17
1593	An economic analysis: is fidaxomicin worth the cost?. 2014 , 58, 603-4		2
1592	Transfer and transport: incorporating causal methods for improving predictive models. 2014 , 21, e374-5		
1591	Multi-institution case-control and cohort study of risk factors for the development and mortality of Clostridium difficile infections in Japan. 2014 , 4, e005665		31
1590	Fidaxomicin: a novel macrolide antibiotic for Clostridium difficile infection. 2014 , 29, 614-24		4
1589	Attributable inpatient costs of recurrent Clostridium difficile infections. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 1400-7	2	38
1588	[Clostridium difficile infection (CDI) in the course of time - an issue only for the internist?]. 2014 , 139, 460-8		6
1587	Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells. 2014 , 14, 177		42
1586	Clostridium difficile infections in Veterans Health Administration acute care facilities. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 1037-42	2	30
1585	Lessons learned from implementing Clostridium difficile-focused antibiotic stewardship interventions. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35 Suppl 3, S86-95	2	7
1584	The prediction of complicated Clostridium difficile infections in children. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 901-3	2	12
1583	Infections and Chronic Inflammatory Bowel Disease. 2014 , 30, 326-32		14

1582	Economic impact of redundant antimicrobial therapy in US hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 1229-35	2	34
1581	Practical implementation of faecal transplantation. 2014 , 20, 1098-105		10
1580	Infección por clostridium difficile: epidemiología, diagnóstico y estrategias terapéuticas. 2014 , 25, 473-484		2
1579	Predicting a complicated course of Clostridium difficile infection at the bedside. 2014 , 20, O301-8		37
1578	Toxicidad antibacterianos: farmacocinética-farmacodinamia: prevención y manejo. 2014 , 25, 445-456		0
1577	NAP1 strain type predicts outcomes from Clostridium difficile infection. 2014 , 58, 1394-400		130
1576	The impact of hospital-onset Clostridium difficile infection on outcomes of hospitalized patients with sepsis. 2014 , 9, 411-7		15
1575	Epidemiology of Clostridium difficile infection in two tertiary-care hospitals in Perth, Western Australia: a cross-sectional study. 2014 , 2, 64-71		48
1574	Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection. 2015 , 211, 1334-41		24
1573	Clostridium difficile infection after cardiac surgery: prevalence, morbidity, mortality, and resource utilization. 2014 , 148, 3157-65.e1-5		12
1572	Neurotoxicity with antimicrobials in the elderly: a review. 2014 , 36, 1489-1511.e4		60
1571	Fulminant Clostridium difficile enteritis causing abdominal compartment syndrome. <i>Surgical Infections</i> , 2014 , 15, 821-5	2	9
1570	Phenotypic and genotypic analysis of Clostridium difficile isolates: a single-center study. 2014 , 52, 4260-6		31
1569	Comparison of testing approaches for Clostridium difficile infection at a large community hospital. 2014 , 20, 65-9		15
1568	Clinical predictors of recurrent Clostridium difficile infection in out-patients. 2014 , 40, 518-22		24
1567	Clostridium difficile infection in liver transplant recipients: a retrospective study of rates, risk factors and outcomes. 2014 , 14, 1901-7		34
1566	Pharmacology. 2014 , 29-64		
1565	Epidemiological study of Clostridium difficile infection in critical patients admitted to the Intensive Care Unit. 2014 , 38, 558-566		

1564	Asymptomatic <i>Clostridium difficile</i> colonization as a reservoir for <i>Clostridium difficile</i> infection. 2014 , 12, 967-80		27
1563	Environmental sampling for <i>Clostridium difficile</i> on alcohol-based hand rub dispensers in an academic medical center. <i>Surgical Infections</i> , 2014 , 15, 581-4	2	6
1562	Clinical differences in <i>Clostridium difficile</i> infection based on age: a multicenter study. 2014 , 46, 46-51		6
1561	<i>Clostridium difficile</i> carriage in hospitalized cancer patients: a prospective investigation in eastern China. 2014 , 14, 523		23
1560	Determinants of <i>Clostridium difficile</i> Infection Incidence Across Diverse United States Geographic Locations. 2014 , 1, ofu048		28
1559	Vaccines against <i>Clostridium difficile</i> . 2014 , 10, 1466-77		44
1558	Concordance of the SHEA-IDSa severity classification for <i>Clostridium difficile</i> infection and the ATLAS bedside scoring system in hospitalized adult patients. 2014 , 42, 999-1005		11
1557	Single nucleotide polymorphisms of the <i>tcdC</i> gene and presence of the binary toxin gene predict recurrent episodes of <i>Clostridium difficile</i> infection. 2014 , 260, 299-304		13
1556	<i>Clostridium difficile</i> infection in the postcolectomy patient. 2014 , 20, 2450-69		12
1555	Diarrhea after kidney transplantation: a new look at a frequent symptom. 2014 , 98, 806-16		41
1554	<i>Clostridium difficile</i> infection in hospitalized patients at a Czech tertiary center: analysis of epidemiology, clinical features, and risk factors of fulminant course. 2014 , 26, 880-7		9
1553	Validation of a clinical prediction scale for hospital-onset <i>Clostridium difficile</i> infection. 2014 , 48, 419-22		18
1552	Treatment of <i>Clostridium difficile</i> Infection With Tigecycline. 2014 , 22, 216-218		
1551	Patients With Recalcitrant <i>Clostridium difficile</i> Associated Diarrhea Treated Successfully With Fidaxomicin. 2014 , 22, 92-95		2
1550	Fever in acute and critical care: a diagnostic approach. 2014 , 25, 237-48; quiz 249-50		2
1549	Antibiotics for the therapy of gastrointestinal diseases. 2014 , 185-203		
1548	<i>Clostridium difficile</i> colitis: review of the therapeutic approach. 2014 , 21, 385-94		10
1547	Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients*. 2014 , 42, 809-15		27

1546	Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. 2014 , 48, 693-702	298
1545	The changing epidemiology of Clostridium difficile infection. 2014 , 30, 54-62	40
1544	Intracolonic administration of vancomycin for Clostridium difficile infection. 2014 , 44, 58-60	1
1543	Fecal microbiota transplantation for Clostridium difficile infection: benefits and barriers. 2014 , 30, 47-53	22
1542	Stool management systems for preventing environmental spread of Clostridium difficile: a comparative trial. 2014 , 41, 460-5	2
1541	Opportunistic infections due to inflammatory bowel disease therapy. 2014 , 20, 196-212	84
1540	Point-of-Care Glucose Meter Testing in 2014. 2014 , 13, 84-87	0
1539	Clostridium difficile infection in solid organ transplant recipients. 2014 , 27, 336-41	12
1538	In the Literature. 2014 , 58, iii-iv	
1537	Editorial Commentary: the trials and tribulations of treating Clostridium difficile infection-one step backward, one step forward, but still progress. 2014 , 59, 355-7	8
1536	A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. 2014 , 20, 172-82	35
1535	Non-pulmonary Infectious Complications. 2014 , 135-163	
1534	What's your subtype? The epidemiologic utility of bacterial whole-genome sequencing. 2014 , 60, 586-8	6
1533	Emerging Clostridium difficile Infections. 2014 , 229-238	
1532	Clostridium difficile infection: clinical challenges and management strategies. 2014 , 34, 24-34; quiz 35	16
1531	Antibiotic overuse and Clostridium difficile: a teachable moment. 2014 , 174, 1219-20	9
1530	The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer. 2014 , 34, 1220-5	11
1529	Non-Pulmonary Complications of Critical Care. 2014 ,	

1528	Role of microbiota and innate immunity in recurrent Clostridium difficile infection. 2014 , 2014, 462740	31
1527	Clostridium difficile Infection: Epidemiology, Pathogenesis, Risk Factors, and Therapeutic Options. 2014 , 2014, 916826	55
1526	Current treatments in familial dysautonomia. 2014 , 15, 2653-71	44
1525	Risk factors for the development of Clostridium difficile infection in hospitalized children. 2014 , 26, 568-72	17
1524	Antimicrobial stewardship: another focus for patient safety?. 2014 , 27, 348-55	29
1523	Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection. 2014 , 20, 1343-51	34
1522	Real-time cellular analysis coupled with a specimen enrichment accurately detects and quantifies Clostridium difficile toxins in stool. 2014 , 52, 1105-11	25
1521	Antibiotic therapy for Clostridium difficile infection. 2014 , 25, 143-149	4
1520	Reduction in the incidence of hospital-acquired Clostridium difficile infection through infection control interventions other than the restriction of antimicrobial use. 2014 , 22, 9-10	12
1519	Comparison between oral antibiotics and probiotics as bowel preparation for elective colon cancer surgery to prevent infection: prospective randomized trial. 2014 , 155, 493-503	86
1518	The emergence of community-onset Clostridium difficile infection in a tertiary hospital in Singapore: a cause for concern. 2014 , 43, 47-51	18
1517	Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis. 2014 , 20, 823-8	37
1516	Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile Infection. 2014 , 12, 1572-6	60
1515	[Surgical site infections: antibiotic prophylaxis in surgery]. 2014 , 32, 48-53	6
1514	Contemporary approaches for the laboratory diagnosis of Clostridium difficile infections. 2014 , 25, 137-142	5
1513	[Severe colitis due to community-acquired ribotype 027 Clostridium difficile]. 2014 , 32, 471-2	0
1512	Complicated Clostridium difficile colitis in children with cystic fibrosis: association with gastric acid suppression?. 2014 , 13, 37-42	9
1511	Treatment of recurrent Clostridium difficile infection: a systematic review. 2014 , 42, 43-59	58

1510	Clostridium difficile colitis acquired in the intensive care unit: outcome and prognostic factors. 2014 , 42, 23-30	11
1509	Time from onset of SIRS to antibiotic administration and outcomes after subarachnoid hemorrhage. 2014 , 21, 85-90	7
1508	Does a rapid diagnosis of Clostridium difficile infection impact on quality of patient management?. 2014 , 20, 136-44	49
1507	Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality. 2014 , 33, 1045-51	18
1506	The incidence and clinical symptomatology of Clostridium difficile infections in a community setting in a cohort of Danish patients attending general practice. 2014 , 33, 957-67	14
1505	Comment traier une infection digestive ^ Clostridium difficile en 2014 ?. 2014 , 23, 284-297	0
1504	Pediatric Hematology-Oncology in Countries with Limited Resources. 2014 ,	6
1503	Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. 2014 , 58, 1507-14	107
1502	Development of a recombinant toxin fragment vaccine for Clostridium difficile infection. 2014 , 32, 2812-8	19
1501	Patients' experience and perception of hospital-treated Clostridium difficile infections: a qualitative study. 2014 , 7, 97-105	19
1500	Fidaxomicin: a guide to its use in Clostridium difficile infection. 2014 , 30, 85-91	
1499	Severe clinical outcome is uncommon in Clostridium difficile infection in children: a retrospective cohort study. 2014 , 14, 28	31
1498	Clostridium difficile infection in children hospitalized due to diarrhea. 2014 , 33, 201-9	27
1497	Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities-a systematic review. 2014 , 18, 223-32	35
1496	Harnessing microbiota to kill a pathogen: the sweet tooth of Clostridium difficile. 2014 , 20, 248-9	16
1495	Clostridium difficile enteritis: a new role for an old foe. 2014 , 12, 256-62	10
1494	Harnessing microbiota to kill a pathogen: Fixing the microbiota to treat Clostridium difficile infections. 2014 , 20, 246-7	31
1493	Findings of a hospital surveillance-based outcome evaluation study for Clostridium difficile-associated colitis. 2014 , 20, 1085-90	2

1492	What nurses need to know about fecal microbiota transplantation: education, assessment, and care for children and young adults. 2014 , 29, 354-61		5
1491	Development and validation of a recurrent <i>Clostridium difficile</i> risk-prediction model. 2014 , 9, 418-23		41
1490	Trends and changes in <i>Clostridium difficile</i> diagnostic policies and their impact on the proportion of positive samples: a national survey. 2014 , 20, O904-10		10
1489	Evaluation of the diagnostic performance of the xpert <i>Clostridium difficile</i> assay and its comparison with the toxin A/B enzyme-linked fluorescent assay and in-house real-time PCR assay used for the detection of toxigenic <i>C. difficile</i> . 2014 , 28, 124-9		6
1488	Comparison of Illumigene, Simplexa, and AmpliVue <i>Clostridium difficile</i> molecular assays for diagnosis of <i>C. difficile</i> infection. 2014 , 52, 960-3		24
1487	Clinical characteristics and outcome of patients with <i>Clostridium difficile</i> infection diagnosed by PCR versus a three-step algorithm. 2014 , 20, 1067-73		31
1486	Emergence of a ribotype 244 strain of <i>Clostridium difficile</i> associated with severe disease and related to the epidemic ribotype 027 strain. 2014 , 58, 1723-30		93
1485	Discrepancies among three laboratory methods for <i>Clostridium difficile</i> detection and a proposal for their optimal use. 2014 , 350, 133-7		1
1484	Comparison of Simplexa universal direct PCR with cytotoxicity assay for diagnosis of <i>Clostridium difficile</i> infection: performance, cost, and correlation with disease. 2014 , 52, 275-80		13
1483	Strategies to prevent <i>Clostridium difficile</i> infections in acute care hospitals: 2014 Update. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 628-45	2	122
1482	A review of the economics of treating <i>Clostridium difficile</i> infection. 2014 , 32, 639-50		22
1481	Multicenter evaluation of the Quidel Lyra Direct <i>C. difficile</i> nucleic acid amplification assay. 2014 , 52, 1998-2002		12
1480	Antibiotics and hospital-acquired <i>Clostridium difficile</i> infection: update of systematic review and meta-analysis. 2014 , 69, 881-91		343
1479	Diagnosis and Management of <i>Clostridium difficile</i> Infection by Pediatric Infectious Diseases Physicians. 2014 , 3, 43-8		21
1478	Utility of a commercial PCR assay and a clinical prediction rule for detection of toxigenic <i>Clostridium difficile</i> in asymptomatic carriers. 2014 , 52, 315-8		19
1477	Protection from <i>Clostridium difficile</i> infection in CD4 T Cell- and polymeric immunoglobulin receptor-deficient mice. 2014 , 82, 522-31		29
1476	Colonic decompression and direct intraluminal medical therapy for <i>Clostridium difficile</i> -associated megacolon using a tube placed endoscopically in the proximal colon. 2014 , 16, O71-4		7
1475	European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for <i>Clostridium difficile</i> infection. 2014 , 20 Suppl 2, 1-26		748

1474	Persistent fever in the ICU. 2014 , 145, 158-165		30
1473	Economic evaluation of laboratory testing strategies for hospital-associated <i>Clostridium difficile</i> infection. 2014 , 52, 489-96		32
1472	A cost-effective approach for detection of toxigenic <i>Clostridium difficile</i> : toxigenic culture using ChromID <i>Clostridium difficile</i> agar. 2014 , 52, 671-3		4
1471	<i>Clostridium difficile</i> : deleterious impact on hematopoietic stem cell transplantation. 2014 , 9, 85-90		15
1470	From stool transplants to next-generation microbiota therapeutics. 2014 , 146, 1573-1582		129
1469	Acute inflammatory surgical disease. 2014 , 94, 1-30		13
1468	Modern trends in infection control practices in intensive care units. 2014 , 29, 311-26		13
1467	Dielectrophoretic monitoring and interstrain separation of intact <i>Clostridium difficile</i> based on their S(Surface)-layers. 2014 , 86, 10855-63		27
1466	<i>Clostridium difficile</i> increases the risk for venous thromboembolism. 2014 , 208, 703-709		9
1465	Extraintestinal <i>Clostridium difficile</i> infections: a single-center experience. 2014 , 89, 1525-36		27
1464	Relative incidences and outcomes of <i>Clostridium difficile</i> infection following transplantation of unrelated cord blood, unrelated bone marrow, and related peripheral blood in adult patients: a single institute study. 2014 , 16, 412-20		14
1463	Full functionalization of the imidazole scaffold by selective metalation and sulfoxide/magnesium exchange. 2014 , 53, 1430-4		26
1462	<i>Clostridium difficile</i> Infection Update for the Hospital-Based Physician. 2014 , 2, 214-223		
1461	Detection of nosocomial <i>Clostridium difficile</i> infections with toxigenic strains despite negative toxin A and B testing on stool samples. 2014 , 20, O590-2		11
1460	Point-prevalence of healthcare-associated infection in china in 2010: a large multicenter epidemiological survey. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 1436-7	2	14
1459	<i>Clostridium difficile</i> : improving the prevention paradigm in healthcare settings. 2014 , 12, 1087-102		12
1458	Infection control in the intensive care unit. 2014 , 94, 1175-94		16
1457	Review of the emerging treatment of <i>Clostridium difficile</i> infection with fecal microbiota transplantation and insights into future challenges. 2014 , 34, 787-98		27

1456	Recovery of the gut microbiome following fecal microbiota transplantation. 2014 , 5, e00893-14		209
1455	Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. 2014 , 69, 2901-12		61
1454	Time to positivity of blood cultures supports antibiotic de-escalation at 48 hours. 2014 , 48, 33-40		41
1453	Recurrent Clostridium difficile infection: The scope of the problem and management decisions. 2014 , 25, 158-162		1
1452	Molecular test based on isothermal helicase-dependent amplification for detection of the Clostridium difficile toxin A gene. 2014 , 52, 2386-9		12
1451	Tigecycline for severe Clostridium difficile infection. 2014 , 26, 171-2		27
1450	Clostridium difficile infection: a review of the literature. 2014 , 7S1, S6-S13		27
1449	Clostridium difficile infection: update on diagnosis, epidemiology, and treatment strategies. <i>Surgical Infections</i> , 2014 , 15, 490-502	2	32
1448	Risk factors of Clostridium difficile infections among patients in a university hospital in Shanghai, China. 2014 , 30, 65-9		34
1447	Update on Clostridium difficile infections. 2014 , 44, 354-65		15
1446	Clostridium difficile infection in diabetes. 2014 , 105, 285-94		18
1445	Use of data envelopment analysis to quantify opportunities for antibacterial targets for reduction of health care-associated Clostridium difficile infection. 2014 , 29, 437-44		2
1444	Incidence of polymerase chain reaction-diagnosed Clostridium difficile in a large high-risk cohort, 2011-2012. 2014 , 89, 1229-38		13
1443	[Nosocomial infection in patients receiving a solid organ transplant or haematopoietic stem cell transplant]. 2014 , 32, 386-95		4
1442	First clinical and microbiological characterization of Clostridium difficile infection in a Croatian University Hospital. 2014 , 30, 18-23		16
1441	Community-acquired diarrhea associated with Clostridium difficile in an HIV-positive cancer patient: first case report in Latin America. 2014 , 26, 138-9		6
1440	Preclinical studies of amixicile, a systemic therapeutic developed for treatment of Clostridium difficile infections that also shows efficacy against Helicobacter pylori. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4703-12	5.9	13
1439	Outcomes from rectal vancomycin therapy in patients with Clostridium difficile infection. 2014 , 109, 924-5		8

1438	PACSIN2 does not influence thiopurine-related toxicity in patients with inflammatory bowel disease. 2014 , 109, 925-7	7	
1437	Response to Kolber et al. 2014 , 109, 1082-3	1	
1436	The evolution of urban <i>C. difficile</i> infection (CDI): CDI in 2009-2011 is less severe and has better outcomes than CDI in 2006-2008. 2014 , 109, 1265-76	23	
1435	Evaluation of the illumigene <i>C. difficile</i> assay for toxigenic <i>Clostridium difficile</i> detection: a prospective study of 302 consecutive clinical fecal samples. 2014 , 80, 177-80	10	
1434	Emerging technologies for the clinical microbiology laboratory. 2014 , 27, 783-822	178	
1433	Severe <i>Clostridium difficile</i> infection: incidence and risk factors at a tertiary care university hospital in Vienna, Austria. 2014 , 126, 427-30	12	
1432	Predictors of mortality attributable to <i>Clostridium difficile</i> infection in patients with underlying malignancy. 2014 , 22, 2039-48	19	
1431	The outcome and long-term follow-up of 94 patients with recurrent and refractory <i>Clostridium difficile</i> infection using single to multiple fecal microbiota transplantation via retention enema. 2014 , 33, 1425-8	84	
1430	An antimicrobial stewardship program's real-world experience with fidaxomicin for treatment of <i>Clostridium difficile</i> infection: a case series. 2014 , 34, 901-9	15	
1429	Antimicrobial prophylaxis for surgery--2014 update. 2014 , 29, 155-8	2	
1428	Prevention of <i>Clostridium difficile</i> infection in rural hospitals. 2014 , 42, 311-5	0	
1427	New drugs and strategies for management of <i>Clostridium difficile</i> colitis. 2014 , 29, 190-9	10	
1426	A population-based spatio-temporal analysis of <i>Clostridium difficile</i> infection in Queensland, Australia over a 10-year period. 2014 , 69, 447-55	18	
1425	Community-associated <i>Clostridium difficile</i> infection among veterans with spinal cord injury and disorder. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 577-80	2	7
1424	<i>Clostridium-difficile</i> -Kolitis. 2014 , 9, 350-359	1	
1423	A case of severe pseudomembranous colitis diagnosed by colonoscopy after <i>Helicobacter pylori</i> eradication. 2014 , 7, 247-50	5	
1422	Outbreak of <i>Clostridium difficile</i> PCR ribotype 027--the recent experience of a regional hospital. 2014 , 14, 209	15	
1421	A systematic review for pursuing the presence of antibiotic associated enterocolitis caused by methicillin resistant <i>Staphylococcus aureus</i> . 2014 , 14, 247	13	

1420	Risk factors for recurrent <i>Clostridium difficile</i> infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study. 2014 , 14, 306		51
1419	Vancomycin, metronidazole, or tolevamer for <i>Clostridium difficile</i> infection: results from two multinational, randomized, controlled trials. 2014 , 59, 345-54		341
1418	Prevalence and risk factors for asymptomatic <i>Clostridium difficile</i> carriage. 2014 , 59, 216-22		119
1417	Cystic fibrosis: An update for clinicians. Part 1: Nutrition and gastrointestinal complications. 2014 , 29, 1344-55		17
1416	Antibiotics for Treatment of <i>Clostridium difficile</i> Infection in Hospitalized Patients with Inflammatory Bowel Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 5054-9	5.9	40
1415	Clinical characteristics of patients who test positive for <i>Clostridium difficile</i> by repeat PCR. 2014 , 52, 3853-5		10
1414	<i>Clostridium difficile</i> infection: prevention, treatment, and surgical management. 2014 , 94, 1335-49		22
1413	Prevalence and risk factors of <i>Clostridium difficile</i> infection in patients hospitalized for flare of inflammatory bowel disease: a retrospective assessment. 2014 , 46, 1086-92		31
1412	Fecal microbiota transplant for treatment of <i>Clostridium difficile</i> infection in immunocompromised patients. 2014 , 109, 1065-71		426
1411	<i>Clostridium difficile</i> infection among children across diverse US geographic locations. 2014 , 133, 651-8		96
1410	<i>Clostridium difficile</i> as a cause of healthcare-associated diarrhoea among children in Auckland, New Zealand: clinical and molecular epidemiology. 2014 , 33, 1741-7		11
1409	Cost-effectiveness of a modified two-step algorithm using a combined glutamate dehydrogenase/toxin enzyme immunoassay and real-time PCR for the diagnosis of <i>Clostridium difficile</i> infection. 2014 , 47, 75-8		22
1408	<i>Clostridium difficile</i> infection in the elderly. 2014 , 30, 79-93		52
1407	Overview and changing epidemiology of <i>Clostridium difficile</i> infection. 2014 , 25, 118-123		5
1406	Recurrence of <i>Clostridium difficile</i> infection among veterans with spinal cord injury and disorder. 2014 , 42, 168-73		16
1405	<i>Clostridium difficile</i> colonization and disease in patients undergoing hematopoietic stem cell transplantation. 2014 , 20, 1329-34		56
1404	Pharmacist participation in infection prevention: an innovative approach to monitoring compliance with the Five Moments for Hand Hygiene in a large academic medical center. 2014 , 42, 331-2		6
1403	Epidemiological study of <i>Clostridium difficile</i> infection in critical patients admitted to the Intensive Care Unit. 2014 , 38, 558-66		10

1402	Fulminant colitis from Clostridium difficile infection, the epidemic strain ribotype 027, in Japan. 2014 , 20, 380-3		10
1401	Effects of Clostridium difficile infection in patients with alcoholic hepatitis. 2014 , 12, 1745-52.e2		22
1400	Surgery for fulminant Clostridium difficile infection. 2014 , 25, 150-152		
1399	Role of endoscopy in the assessment and treatment of Clostridium difficile infection. 2014 , 25, 128-133		4
1398	Point sur lâémergence des infections r�cidivantes � Clostridium difficile chez le sujet g�. 2014 , 14, 26-31		
1397	Clostridium difficile Infection (CDI) in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. 2014 , 16, 414		23
1396	Healthcare workers' hands and Clostridium difficile spores: making progress?. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 16-7	2	2
1395	Maintaining the momentum of change: the role of the 2014 updates to the compendium in preventing healthcare-associated infections. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 460-3 ²		16
1394	Control of Clostridium difficile infection in the hospital setting. 2014 , 12, 457-69		3
1393	Role of doxycycline in Clostridium difficile infection acquisition. 2014 , 48, 772-6		11
1392	Effect of treatment variation on outcomes in patients with Clostridium difficile. 2014 , 127, 865-70		17
1391	Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review. <i>Journal of Hospital Infection</i> , 2014 , 88, 12-21	6.9	66
1390	Staggered and tapered antibiotic withdrawal with administration of kefir for recurrent Clostridium difficile infection. 2014 , 59, 858-61		33
1389	The effect of pharmacy restriction of clindamycin on Clostridium difficile infection rates in an orthopedics ward. 2014 , 42, e71-3		17
1388	Investigation of a Clostridium difficile cluster by multilocus sequence typing in a bone marrow transplant unit. 2014 , 42, 691-3		2
1387	Ischemic enterocolitis and its differential diagnosis. 2014 , 31, 152-64		7
1386	Clinical pearls in infectious diseases. 2014 , 60, 394-401		
1385	Clinical manifestations of Clostridium difficile infection in a medical center in Taiwan. 2014 , 47, 491-6		8

1384	Validation of the 3-day rule for stool bacterial tests in Japan. <i>Internal Medicine</i> , 2014 , 53, 533-9	1.1	5
1383	Rational Therapy of Clostridium difficile Infections. 2014 , 30, 304-9		7
1382	Recurrent Clostridium difficile infections: the importance of the intestinal microbiota. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7416-23	5.6	31
1381	Discrepancies between surveillance definition and the clinical incidence of Clostridium difficile infection in a Veterans Affairs long-term care facility. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 1435-6	2	4
1380	Lessons Learned from Implementing Clostridium difficile-Focused Antibiotic Stewardship Interventions. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, S86-S95	2	12
1379	Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 667-73		86
1378	Comparison of 3 severity criteria for Clostridium difficile infection. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 196-9	2	21
1377	Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35 Suppl 2, S48-65	2	66
1376	Perioperative Infections after Organ Transplantation. 2014 , 1105-1116		
1375	The injured patient in the ICU. 261-276		
1374	The patient with gastrointestinal problems. 374-390		
1373	Meningoencephalitis due to adenovirus in a healthy infant mimicking severe bacterial sepsis. 2014 , 33, 416-9		12
1372	Fulminant Clostridium difficile colitis: prospective development of a risk scoring system. 2014 , 76, 424-30		35
1371	Clostridium difficile infection is on the rise. 2014 , 114, 62-7		
1370	Vollständige Funktionalisierung des Imidazolgerüsts durch selektive Metallierung und Sulfoxid-Magnesium-Austausch. 2014 , 126, 1454-1458		5
1369	Effectiveness of screening hospital admissions to detect asymptomatic carriers of Clostridium difficile: a modeling evaluation. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 1043-50	2	41
1368	Predictors of first recurrence of Clostridium difficile infections in children. 2014 , 33, 414-6		29
1367	Diagnosis and management of common gastrointestinal tract infectious diseases in ulcerative colitis and Crohn's disease patients. 2014 , 20, 2503-10		13

1366	Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals: 2014 Update. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 628-645	2	99
1365	Predictors of mortality after emergency colectomy for Clostridium difficile colitis: an analysis of ACS-NSQIP. 2014 , 259, 148-56		42
1364	Impact of Toxigenic Clostridium difficile Colonization on the Risk of Subsequent C. difficile Infection in Intensive Care Unit Patients. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 1324-9	2	34
1363	Outcomes of Clostridium difficile infection in hospitalized leukemia patients: a nationwide analysis. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 794-801	2	38
1362	Identification of Recurrent Clostridium difficile Infection Using Administrative Codes: Accuracy and Implications for Surveillance. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 893-8	2	8
1361	Excess Length of Stay Attributable to Clostridium difficile Infection (CDI) in the Acute Care Setting: A Multistate Model. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 1024-30	2	20
1360	Clostridium difficile Infection Among Veterans Health Administration Patients. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 1038-45	2	15
1359	Quantifying the Exposure to Antibiotic-Resistant Pathogens Among Patients Discharged From a Single Hospital Across All California Healthcare Facilities. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 1275-82	2	12
1358	Skin and Environmental Contamination in Patients Diagnosed With Clostridium difficile Infection but Not Meeting Clinical Criteria for Testing. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 1348-50	2	7
1357	The cost-benefit of federal investment in preventing Clostridium difficile infections through the use of a multifaceted infection control and antimicrobial stewardship program. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 681-7	2	21
1356	Causes, Burden, and Prevention of Infection. 2015 , 23, 281-288		7
1355	Leaping Forward in the Treatment of Infection: Update in 2015. 2015 , 22, 259-267		4
1354	Hygiene life âWas in keinem Lehrbuch steht. 2015 , 10, 161-171		
1353	Management of bacterial severe sepsis and septic shock. 2014 , 3, 227-242		
1352	Risk factors for in-hospital mortality among a cohort of children with Clostridium difficile infection. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 1183-9	2	9
1351	Vancomycin treatment and butyrate supplementation modulate gut microbe composition and severity of neointimal hyperplasia after arterial injury. 2015 , 3, e12627		17
1350	Emergency department visits related to Clostridium difficile infection: results from the nationwide emergency department sample, 2006 through 2010. 2015 , 22, 117-9		3
1349	Transplanting fresh donor faeces to cure symptomatic relapsing Clostridium difficile infection: a literature review. 2015 , 13, 48-54		

1348	Preparation and preliminary application of monoclonal antibodies to the receptor binding region of Clostridium difficile toxin B. 2015 , 12, 7712-20		1
1347	Continuous Administration of Vancomycin through a Long Intestinal Tube for Clostridium difficile Infection. <i>Internal Medicine</i> , 2015 , 54, 1559-62	1.1	3
1346	Clostridium difficile Infection Is More Severe When Toxin Is Detected in the Stool than When Detected Only by a Toxigenic Culture. <i>Internal Medicine</i> , 2015 , 54, 2155-9	1.1	7
1345	Lack of Correlation between Bristol Stool Scale and Quantitative Bacterial Load in Clostridium difficile Infection. 2015 , 8, 1-4		5
1344	A prediction model for Clostridium difficile recurrence. 2015 , 5, 26033		20
1343	Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination. 2015 , 2, e000038		18
1342	Impact of Antimicrobial Stewardship Program (ASP) on Outcomes in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in an Acute-Tertiary Care Hospital. 2015 , 4, 15-25		18
1341	Evaluating risk factors for Clostridium difficile infection in adult and pediatric hematopoietic cell transplant recipients. 2015 , 4, 41		26
1340	WSES guidelines for management of Clostridium difficile infection in surgical patients. 2015 , 10, 38		60
1339	Loss of Vancomycin-Resistant Enterococcus Fecal Dominance in an Organ Transplant Patient With Clostridium difficile Colitis After Fecal Microbiota Transplant. 2015 , 2, ofv078		64
1338	Evidence-based care pathway for cellulitis improves process, clinical, and cost outcomes. 2015 , 10, 780-6		18
1337	Probiotics and Fecal Microbiota Transplant for Primary and Secondary Prevention of Clostridium difficile Infection. 2015 , 35, 1016-25		24
1336	Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications. 2015 , 15, 516		121
1335	Comparison of a novel chemiluminescent based algorithm to three algorithmic approaches for the laboratory diagnosis of Clostridium difficile infection. 2015 , 7, 33		4
1334	Probiotics: Prevention of ventilator-associated pneumonia and endotracheal colonization trial-PROSPECT: protocol for a feasibility randomized pilot trial. 2015 , 1, 19		12
1333	Reducing Unnecessary and Duplicate Ordering for Ovum and Parasite Examinations and Clostridium difficile PCR in Immunocompromised Patients by Using an Alert at the Time of Request in the Order Management System. 2015 , 53, 2745-8		16
1332	Evaluation of a Clostridium difficile infection management policy with clinical pharmacy and medical microbiology involvement at a major Canadian teaching hospital. 2015 , 40, 655-60		7
1331	Exposure to Gastric Acid-Suppression Therapy Is Associated With Health Care- and Community-Associated Clostridium difficile Infection in Children. 2015 , 61, 208-11		24

1330	Antimicrobial use in critically ill horses. 2015 , 25, 89-100	9
1329	How do Clostridium difficile infections affect nurses' everyday hospital work: A qualitative study. 2015 , 21 Suppl 2, 38-45	11
1328	Diarrhea in solid organ transplant recipients. 2015 , 28, 308-16	37
1327	Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection. 2015 , 35, 119-26	29
1326	Clostridium difficile infection in the pediatric transplant patient. 2015 , 19, 792-8	10
1325	A Multicenter Evaluation of Off-Label Medication Use and Associated Adverse Drug Reactions in Adult Medical ICUs. 2015 , 43, 1612-21	22
1324	Risk Factors for Community-associated Clostridium difficile-associated Diarrhea in Children. 2015 , 34, 919-23	27
1323	Acute Clostridium Difficile Infection in two Polish Pregnant Women with Premature Rupture of Membranes. 2015 , s5,	
1322	A case of toxic megacolon caused by clostridium difficile infection and treated with fecal microbiota transplantation. 2015 , 9, 247-50	27
1321	Updated Management of Clostridium difficile Infections in Post-Acute Care Settings. 2015 , s1,	
1320	[Clinic and epidemiologic description of Clostridium difficile infection in a pediatric population]. 2015 , 32, 523-9	0
1319	[Fecal microbiota transplantation in recurrent Clostridium difficile infection. Report of one case]. 2015 , 143, 531-5	3
1318	Isolation and Identification of Clostridium difficile Using ChromID C. difficile Medium Combined With Gram Staining and PRO Disc Testing: A Proposal for a Simple Culture Process. 2015 , 35, 404-9	7
1317	Risk factors for recurrent hospital-acquired Clostridium difficile infection in a Japanese university hospital. 2015 , 8, 191-6	19
1316	Flooding and Clostridium difficile Infection: A Case-Crossover Analysis. 2015 , 12, 6948-64	13
1315	Antibiotic-associated diarrhea. 349-351	1
1314	[Treatment of a severe Clostridium difficile infection with colonic lavages. Report of one case]. 2015 , 143, 668-72	2
1313	Serum 25-Hydroxyvitamin D Levels are not Associated with Adverse Outcomes in Clostridium Difficile Infection. 2015 , 7, 5979	3

1312	Adherence to and Outcomes Associated with a Clostridium difficile Guideline at a Large Teaching Institution. 2015 , 50, 042-050	9
1311	Metronidazole. 2015 , 350-357.e2	4
1310	The Antimicrobial Stewardship Approach to Combating Clostridium Difficile. 2015 , 4, 198-215	11
1309	Colonization Resistance of the Gut Microbiota against Clostridium difficile. 2015 , 4, 337-57	36
1308	A Review of Management of Clostridium difficile Infection: Primary and Recurrence. 2015 , 4, 411-23	8
1307	Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of Clostridium difficile From Stool Samples. 2015 , 35, 306-13	14
1306	Fecal microbiota transplantation: current clinical efficacy and future prospects. 2015 , 8, 285-91	24
1305	Asymptomatic carriers of toxigenic C. difficile in long-term care facilities: a meta-analysis of prevalence and risk factors. 2015 , 10, e0117195	46
1304	Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. 2015 , 10, e0124483	71
1303	Defined Nutrient Diets Alter Susceptibility to Clostridium difficile Associated Disease in a Murine Model. 2015 , 10, e0131829	16
1302	Gut Dysbiosis in Patients with Anorexia Nervosa. 2015 , 10, e0145274	119
1301	Risk Factors, Clinical Characteristics, and Treatment Differences Between Residents With and Without Nursing Home- and Non-Nursing Home-Acquired Clostridium difficile Infection. 2015 , 21, 585-95	9
1300	Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection. 2015 , 26, 305-12	41
1299	In Vitro Selection of a Single-Stranded DNA Molecular Recognition Element against Clostridium difficile Toxin B and Sensitive Detection in Human Fecal Matter. 2015 , 2015, 808495	5
1298	The epidemiology and economic burden of Clostridium difficile infection in Korea. 2015 , 2015, 510386	27
1297	Evaluation of metronidazole suspensions. 2015 , 9, 439-450	4
1296	Gastroenteritis. 334-341	3
1295	Syndromes of Enteric Infection. 2015 , 1238-1247.e2	

1294	Glycopeptides (Vancomycin and Teicoplanin), Streptogramins (Quinupristin-Dalfopristin), Lipopeptides (Daptomycin), and Lipoglycopeptides (Telavancin). 2015 , 377-400.e4		9
1293	[Clostridium difficile associated diarrhea in children]. 2015 , 32, 550-8		2
1292	Risk Factors for Recurrent Clostridium difficile Infections and Strategies to Decrease Readmissions in a Community Hospital. 2015 , 50, 1003-10		9
1291	Implementation of a Clinical Decision Support Alert for the Management of Clostridium difficile Infection. 2015 , 4, 667-74		13
1290	Antibiotic Use and Need for Antimicrobial Stewardship in Long-Term Care. 2015 , 68, 445-9		7
1289	Editorial Commentary: Critically Ill Patients With Clostridium difficile Infection: Are 2 Antibiotics Better Than One?. 2015 , 61, 942-4		1
1288	Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and caucasian subjects. 2015 , 35, 375-84		9
1287	Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1435-40	5.9	69
1286	Characteristics and Antibiotic Use Associated With Short-Term Risk of Clostridium difficile Infection Among Hospitalized Patients. 2015 , 143, 895-900		8
1285	Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature. 2015 , 46, 8-12		12
1284	Optimizing diagnostic testing for Clostridium difficile: The perceptions of physicians and nurses on when to order testing for C difficile. 2015 , 43, 889-91		2
1283	The Addition of Intravenous Metronidazole to Oral Vancomycin is Associated With Improved Mortality in Critically Ill Patients With Clostridium difficile Infection. 2015 , 61, 934-41		63
1282	Hospitalized Patients with Cirrhosis Should Be Screened for Clostridium difficile Colitis. 2015 , 60, 3124-9		13
1281	Predictors of asymptomatic Clostridium difficile colonization on hospital admission. 2015 , 43, 248-53		30
1280	Fecal microbiota transplantation (FMT) for Clostridium difficile infection: focus on immunocompromised patients. 2015 , 21, 230-7		58
1279	Antibiotic overuse and Clostridium difficile infections: the Indian paradox and the possible role of dietary practices. 2015 , 31, 1052-3		7
1278	Clostridium difficile infection: A brief update on emerging therapies. 2015 , 72, 1007-12		20
1277	Clostridium difficile infection among hospitalized HIV-infected individuals: epidemiology and risk factors: results from a case-control study (2002-2013). 2015 , 15, 194		9

1276	Pathway to Prevention of Nosocomial Clostridium difficile Infection. 2015 , 60 Suppl 2, S148-58		48
1275	Microbiology for Radiologists: How to Minimize Infection Transmission in the Radiology Department. 2015 , 35, 1231-44		26
1274	Surgical Management of Severe Colitis in the Intensive Care Unit. 2015 , 30, 451-61		7
1273	Administraci3n de vancomicina en el colon para infecci3n por Clostridium difficile. 2015 , 32, 56-58		
1272	Clostridium difficile Infections after Blunt Trauma: A Different Patient Population?. <i>Surgical Infections</i> , 2015 , 16, 421-7	2	4
1271	Incidence and Costs of Clostridium difficile Infections in Canada. 2015 , 2, ofv076		38
1270	Concomitant Medical Conditions and Therapies Preclude Accurate Classification of Children With Severe or Severe Complicated Clostridium difficile Infection. 2015 , 4, e139-42		9
1269	Clostridium difficile Infection: Current and Emerging Therapeutics. 2015 , 7, 317-334		2
1268	Infection prevention and control in nursing homes: a qualitative study of decision-making regarding isolation-based practices. 2015 , 24, 630-6		22
1267	Regional and seasonal variation in Clostridium difficile infections among hospitalized patients in the United States, 2001-2010. 2015 , 43, 435-40		22
1266	From ESKAPE to ESCAPE, from KPC to CCC. 2015 , 60, 1289-90		31
1265	Practical Guidance for Clinical Microbiology Laboratories: Diagnosis of Bacterial Gastroenteritis. 2015 , 28, 3-31		104
1264	Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting: focus on therapeutic and adverse events. 2015 , 14, 269-80		11
1263	The contribution of strains and hosts to outcomes in Clostridium difficile infection. 2015 , 29, 51-61		8
1262	Small molecule inhibitors of Clostridium difficile toxin B-induced cellular damage. 2015 , 22, 175-85		54
1261	Epidemiology of Clostridium difficile: a hospital-based descriptive study in Argentina and Mexico. 2015 , 19, 8-14		19
1260	Missed diagnosis of Clostridium difficile infection; a prospective evaluation of unselected stool samples. 2015 , 70, 264-72		14
1259	Chemical biology applied to the study of bacterial pathogens. 2015 , 83, 456-69		16

1258	Fidaxomicin therapy in critically ill patients with <i>Clostridium difficile</i> infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1776-81	5.9	26
1257	Diagnostic yields in solid organ transplant recipients admitted with diarrhea. 2015 , 60, 729-37		63
1256	Diagnostic pitfalls in <i>Clostridium difficile</i> infection. 2015 , 29, 63-82		35
1255	<i>Clostridium difficile</i> infection: risk factors, diagnosis and management. 2015 , 13, 121-9		13
1254	Treatment of <i>Clostridium difficile</i> infections. 2015 , 29, 93-108		11
1253	[<i>Clostridium difficile</i> isolation in children hospitalized with diarrhea]. 2015 , 82, 417-25		8
1252	How to eradicate <i>Clostridium difficile</i> from the environment. <i>Journal of Hospital Infection</i> , 2015 , 89, 287-95		43
1251	Burden of <i>Clostridium difficile</i> infection in the United States. 2015 , 372, 825-34		1768
1250	Seek and you shall find: prevalence of <i>Clostridium difficile</i> in Wuhan, China. 2015 , 43, 301-2		14
1249	Investigational new treatments for <i>Clostridium difficile</i> infection. 2015 , 20, 602-8		12
1248	Comparison of GenomEra <i>C. difficile</i> and Xpert <i>C. difficile</i> as confirmatory tests in a multistep algorithm for diagnosis of <i>Clostridium difficile</i> infection. 2015 , 53, 332-5		11
1247	Effects of tigecycline and vancomycin administration on established <i>Clostridium difficile</i> infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1596-604	5.9	10
1246	Mechanisms of protection against <i>Clostridium difficile</i> infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. 2015 , 83, 822-31		68
1245	Colonization with toxinogenic <i>C. difficile</i> upon hospital admission, and risk of infection: a systematic review and meta-analysis. 2015 , 110, 381-90; quiz 391		139
1244	Risk of <i>Clostridium difficile</i> infection in intensive care unit patients with sepsis exposed to metronidazole. 2015 , 47, 197-202		4
1243	Burden of <i>Clostridium difficile</i> infection in the United States. 2015 , 372, 2369-70		203
1242	Diversity and Evolution in the Genome of <i>Clostridium difficile</i> . 2015 , 28, 721-41		162
1241	A prospective study of community-associated <i>Clostridium difficile</i> infection in Kuwait: Epidemiology and ribotypes. 2015 , 35, 28-32		35

- 1240 Clostridium difficile Relapse Secondary to Medication Access Issue. **2015**, 102, 108, 63
- 1239 [Clostridium difficile infections in Internal Medicine Departments. Addendum]. **2015**, 33, 367-8
- 1238 Comparing visual inspection, aerobic colony counts, and adenosine triphosphate bioluminescence assay for evaluating surface cleanliness at a medical center. **2015**, 43, 882-6 37
- 1237 Proton pump inhibition may promote Clostridium difficile recurrences. **2015**, 128, e13
- 1236 Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trial. **2015**, 44, 26-32 7
- 1235 Community-acquired Clostridium difficile infection in children: A retrospective study. **2015**, 47, 842-6 22
- 1234 A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters. **2015**, 11, 2215-22 10
- 1233 A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model. **2015**, 22, 711-25 27
- 1232 Fecal microbiota transplantation in patients with cancer undergoing treatment. **2015**, 19, 111-4 5
- 1231 Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1441-5 5.9 25
- 1230 Treatment of Clostridium difficile infection in pediatric patients. **2015**, 9, 747-55 8
- 1229 Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection. **2015**, 75, 1095-118 6
- 1228 Adherence to and Outcomes Associated with a Clostridium difficile Guideline at a Large Teaching Institution. **2015**, 50, 042-050 3
- 1227 Clinical characterization and risk factors of Clostridium difficile infection in elderly patients in a Chinese hospital. **2015**, 9, 381-7 6
- 1226 Pediatric severe pseudomembranous enteritis treated with fecal microbiota transplantation in a 13-month-old infant. **2015**, 3, 173-175 17
- 1225 Clostridium Difficile Infection from a Surgical Perspective. **2015**, 19, 1363-77 27
- 1224 Fecal Microbiota Transplantation Eliminates Clostridium difficile in a Murine Model of Relapsing Disease. **2015**, 83, 3838-46 76
- 1223 The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study. **2015**, 36, 31-8 17

1222	Risk Factors for Recurrent <i>Clostridium difficile</i> Infection in Children: A Nested Case-Control Study. 2015 , 167, 384-9		22
1221	Age-Stratified Treatment Response Rates in Hospitalized Patients with <i>Clostridium difficile</i> Infection Treated with Metronidazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 6113-6	5.9	9
1220	In vitro activity of surotomycin against contemporary clinical isolates of toxigenic <i>Clostridium difficile</i> strains obtained in Spain. 2015 , 70, 2311-5		8
1219	Pitfalls in Diagnosis of Pediatric <i>Clostridium difficile</i> Infection. 2015 , 29, 465-76		22
1218	Association between prehospital vitamin D status and hospital-acquired <i>Clostridium difficile</i> infections. 2015 , 39, 47-55		20
1217	The State of Antimicrobial Stewardship in Michigan: Results of a Statewide Survey on Antimicrobial Stewardship Efforts in Acute Care Hospitals. 2015 , 50, 180-4		6
1216	Antibiotic Regimen after a Total Abdominal Colectomy with Ileostomy for Fulminant <i>Clostridium difficile</i> Colitis: A Multi-Institutional Study. <i>Surgical Infections</i> , 2015 , 16, 455-60	2	8
1215	<i>Clostridium difficile</i> isolation in children hospitalized with diarrhoea. 2015 , 82, 417-425		
1214	Low Prevalence of <i>Clostridium difficile</i> in Slaughter Pigs in Korea. 2015 , 78, 1034-6		11
1213	Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent <i>Clostridium difficile</i> infection. 2015 , 15, 191		108
1212	Differences of the Fecal Microflora With <i>Clostridium difficile</i> Therapies. 2015 , 60 Suppl 2, S91-7		20
1211	<i>Clostridium difficile</i> Infection in Long-term Care Facilities: A Call to Action for Antimicrobial Stewardship. 2015 , 60 Suppl 2, S72-6		39
1210	<i>Lactobacillus acidophilus</i> CL1285, <i>Lactobacillus casei</i> LBC80R, and <i>Lactobacillus rhamnosus</i> CLR2 (Bio-K+): Characterization, Manufacture, Mechanisms of Action, and Quality Control of a Specific Probiotic Combination for Primary Prevention of <i>Clostridium difficile</i> Infection. 2015 , 60 Suppl 2, S135-43		40
1209	One-pot three-component strategy for functionalized 2-aminoimidazoles via ring opening of Nitro epoxides. 2015 , 17, 1157-9		19
1208	The reply. 2015 , 128, e19		
1207	Risk factors and clinical outcomes of candidaemia in patients treated for <i>Clostridium difficile</i> infection. 2015 , 21, 493.e1-4		19
1206	Treatment of <i>Clostridium difficile</i> infection in a French university hospital. 2015 , 50, 1253-60		3
1205	Current Status of the Treatment of Fulminant Colitis. 2015 , 93, 276-282		

1204	Clostridium difficile infection, a descriptive analysis of solid organ transplant recipients at a single center. 2015 , 81, 299-304	18
1203	[Clostridium difficile, are all our patients diagnosed?]. 2015 , 30, 79-85	1
1202	Impact of Clostridium difficile recurrence on hospital readmissions. 2015 , 43, 318-22	44
1201	Current Status of the Treatment of Fulminant Colitis. 2015 , 93, 276-82	1
1200	Clostridium difficile infection. 2015 , 372, 1539-48	639
1199	Impact of a clinical pharmacist stress ulcer prophylaxis management program on inappropriate use in hospitalized patients. 2015 , 128, 905-13	44
1198	Clostridium-difficile-assoziierte Infektionen im Kindes- und Jugendalter. 2015 , 163, 427-436	4
1197	Struhltransfer bei rezidivierenden Infektionen mit Clostridium difficile. 2015 , 10, 122-126	1
1196	in the Long-Term Care Facility: Prevention and Management. 2015 , 4, 60-69	17
1195	Pseudomembranous colitis. 2015 , 61, 181-206	64
1194	Differential immunodetection of toxin B from highly virulent Clostridium difficile BI/NAP-1/027. 2015 , 53, 1705-8	8
1193	Vancomycin Enemas as Adjunctive Therapy for Clostridium difficile Infection. 2015 , 7, 422-7	27
1192	Inhibition of adhesion of Clostridium difficile to human intestinal cells after treatment with serum and intestinal fluid isolated from mice immunized with nontoxigenic C. difficile membrane fraction. 2015 , 81, 1-5	5
1191	Clostridium difficile infection: New insights into therapeutic options. 2016 , 42, 773-9	2
1190	Current Trends in the Epidemiology and Outcomes of Clostridium difficile Infection. 2015 , 60 Suppl 2, S66-71	179
1189	Blood and Marrow Transplant Handbook. 2015 ,	5
1188	Novel handwashes are superior to soap and water in removal of Clostridium difficile spores from the hands. 2015 , 43, 530-2	4
1187	Diagnosis and management of Clostridium difficile infection. 2015 , 36, 31-43	15

1186	Recurrent <i>Clostridium difficile</i> infection: From colonization to cure. 2015 , 34, 59-73	60
1185	Fecal microbiota transplant to treat recurrent <i>Clostridium difficile</i> infections. 2015 , 35, 51-64; quiz 65	15
1184	Diarrhoea in the critically ill. 2015 , 21, 142-53	33
1183	Novel risk factors for recurrent <i>Clostridium difficile</i> infection in children. 2015 , 60, 18-22	53
1182	Accuracy of the GastroPanel test in the detection of atrophic gastritis. 2015 , 27, 102-4	9
1181	The evaluation of <i>Clostridium difficile</i> infection (CDI) in a community hospital. 2015 , 8, 155-60	9
1180	<i>Clostridium difficile</i> infection (CDI) severity and outcome among patients infected with the NAP1/BI/027 strain in a non-epidemic setting. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 280-6	22
1179	Infection prevention and the medical director: uncharted territory. 2015 , 10, 863-74	4
1178	The molecular basis of <i>Clostridium difficile</i> disease and host response. 2015 , 31, 24-9	19
1177	Practice parameters for the management of <i>Clostridium difficile</i> infection. 2015 , 58, 10-24	33
1176	<i>Clostridium difficile</i> ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. 2015 , 61, 233-41	93
1175	Ambulatory-treated <i>Clostridium difficile</i> infection: a comparison of community-acquired vs. nosocomial infection. 2015 , 143, 1225-35	12
1174	Accuracy of loop-mediated isothermal amplification for the diagnosis of <i>Clostridium difficile</i> infection: a systematic review. 2015 , 82, 4-10	9
1173	Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent <i>Clostridium difficile</i> Infection. 2015 , 175, 784-91	142
1172	[Current treatment and epidemiology of <i>Clostridium difficile</i> infections]. 2015 , 36, 596-602	3
1171	Which severity indices for <i>Clostridium difficile</i> infection. 2015 , 27, 102	7
1170	Similar proportions of stool specimens from hospitalized children with and without diarrhea test positive for <i>Clostridium difficile</i> . 2015 , 34, 261-6	35
1169	Molecular methods for detecting and typing of <i>Clostridium difficile</i> . 2015 , 47, 211-8	15

1168	Diagnosis and treatment of Clostridium difficile in adults: a systematic review. 2015 , 313, 398-408		304
1167	Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 438-44	2	55
1166	Is Clostridium difficile infection an increasingly common severe disease in adult intensive care units? A 10-year experience. 2015 , 30, 543-9		19
1165	Hospital management of Clostridium difficile infection: a review of the literature. <i>Journal of Hospital Infection</i> , 2015 , 90, 91-101	6.9	16
1164	Risk for Clostridium difficile infection after radical cystectomy for bladder cancer: Analysis of a contemporary series. 2015 , 33, 503.e17-22		13
1163	Using a Novel Lysin To Help Control Clostridium difficile Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 7447-57	5.9	31
1162	Evaluation of a bedside scoring system for predicting clinical cure and recurrence of Clostridium difficile infections. 2015 , 72, 1871-5		9
1161	Clostridium difficile recurrence is a strong predictor of 30-day rehospitalization among patients in intensive care. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 273-9	2	9
1160	Low incidence of Clostridium difficile infection (CDI) in patients treated with outpatient parenteral antimicrobial therapy (OPAT). <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 110-2	2	8
1159	Comparative genomic and phenomic analysis of Clostridium difficile and Clostridium sordellii, two related pathogens with differing host tissue preference. 2015 , 16, 448		15
1158	Clostridium difficile infections before and during use of ultraviolet disinfection. 2015 , 43, 940-5		48
1157	The challenge of Clostridium difficile infection: Overview of clinical manifestations, diagnostic tools and therapeutic options. 2015 , 46 Suppl 1, S47-50		17
1156	Reply to Planche et al. 2015 , 61, 1211-2		2
1155	Transplant related outcomes in patients with hematopoietic stem cell transplant with Clostridium difficile associated diarrhea. 2015 , 56, 260-2		2
1154	Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options. 2015 , 32, 639-47		19
1153	Delirium and other clinical factors with Clostridium difficile infection that predict mortality in hospitalized patients. 2015 , 43, 690-3		17
1152	Multicenter evaluation of the BioFire FilmArray gastrointestinal panel for etiologic diagnosis of infectious gastroenteritis. 2015 , 53, 915-25		317
1151	Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients. 2015 , 21, 998.e9-998.e15		29

1150	Increased risk of functional gastrointestinal sequelae after <i>Clostridium difficile</i> infection among active duty United States military personnel (1998-2010). 2015 , 149, 1408-14	21
1149	How next-generation sequencing and multiscale data analysis will transform infectious disease management. 2015 , 61, 1695-702	29
1148	Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of <i>Clostridium difficile</i> infection. 2015 , 70, 3061-9	19
1147	Cirrhosis and <i>C. difficile</i> : A Deadly Duo?. 2015 , 60, 2865-7	2
1146	[S2k-guideline gastrointestinal infectious diseases and Whipple's disease]. 2015 , 53, 418-59	71
1145	Diagnostic yield of repeat sampling with immunoassay, real-time PCR, and toxigenic culture for the detection of toxigenic <i>Clostridium difficile</i> in an epidemic and a non-epidemic setting. 2015 , 34, 2325-30	11
1144	Persistent and Recurrent <i>Clostridium difficile</i> Colitis. 2015 , 28, 65-9	12
1143	Use of tigecycline in elderly patients for <i>Clostridium difficile</i> infection. 2015 , 15, 230-1	3
1142	<i>Clostridium difficile</i> ribotypes in Austria: a multicenter, hospital-based survey. 2015 , 127, 587-93	11
1141	Impact of <i>Clostridium difficile</i> infection among pneumonia and urinary tract infection hospitalizations: an analysis of the Nationwide Inpatient Sample. 2015 , 15, 254	17
1140	Point-Counterpoint: Large Multiplex PCR Panels Should Be First-Line Tests for Detection of Respiratory and Intestinal Pathogens. 2015 , 53, 3110-5	76
1139	Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of <i>Clostridium difficile</i> Toxins in Stool. 2015 , 53, 3204-12	39
1138	Multidisciplinary team review of best practices for collection and handling of blood cultures to determine effective interventions for increasing the yield of true-positive bacteremias, reducing contamination, and eliminating false-positive central line-associated bloodstream infections. 2015 , 43, 1222-37	59
1137	Gut check: <i>Clostridium difficile</i> testing and treatment in the molecular testing era. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 217-21	2 41
1136	Factors Associated With Complications of <i>Clostridium difficile</i> Infection in a Multicenter Prospective Cohort. 2015 , 61, 1781-8	36
1135	Building a Better Crystal Ball for Predicting Complications of <i>Clostridium difficile</i> Infection. 2015 , 61, 1789-91	1
1134	A meta-analysis of metronidazole and vancomycin for the treatment of <i>Clostridium difficile</i> infection, stratified by disease severity. 2015 , 19, 339-49	21
1133	Epidemiology of <i>Clostridium difficile</i> in Germany based on a single center long-term surveillance and German-wide genotyping of recent isolates provided to the advisory laboratory for diagnostic reasons. 2015 , 305, 807-13	22

1132	Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 7007-10	5.9	35
1131	Optimising gut colonisation resistance against Clostridium difficile infection. 2015 , 34, 2161-6		4
1130	Emergence of an outbreak-associated Clostridium difficile variant with increased virulence. 2015 , 53, 1216-26		47
1129	Diagnosis of Clostridium difficile Infection: Treat the Patient, Not the Test. 2015 , 175, 1801-2		29
1128	Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection. 2015 , 46, 205-8		12
1127	Application of the ATLAS score for evaluating the severity of Clostridium difficile infection in teaching hospitals in Mexico. 2015 , 19, 399-402		13
1126	Role of intravenous immune globulin in streptococcal toxic shock syndrome and Clostridium difficile infection. 2015 , 72, 1013-9		20
1125	DIARREA ASOCIADA A ANTIBIÓTICOS. 2015 , 26, 687-695		1
1124	Regional infection control assessment of antibiotic resistance knowledge and practice. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 381-6	2	10
1123	How well does physician selection of microbiologic tests identify Clostridium difficile and other pathogens in paediatric diarrhoea? Insights using multiplex PCR-based detection. 2015 , 21, 179.e9-15		42
1122	Endospores, Sporulation and Germination. 2015 , 163-178		3
1121	Comparing the economic and health benefits of different approaches to diagnosing Clostridium difficile infection. 2015 , 21, 77.e1-9		17
1120	Recurrent Clostridium difficile infection is associated with increased mortality. 2015 , 21, 164-70		100
1119	[Fecal microbiota transplantation]. 2015 , 38, 123-34		5
1118	Clostridium difficile isolates with high linezolid MICs harbor the multiresistance gene cfr. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 586-9	5.9	46
1117	Implementing an intensified antibiotic stewardship programme targeting cephalosporin and fluoroquinolone use in a 200-bed community hospital in Germany. 2015 , 43, 45-50		28
1116	Vitamin D status and severity of Clostridium difficile infections: a prospective cohort study in hospitalized adults. 2015 , 39, 465-70		15
1115	Single domain antibody coated gold nanoparticles as enhancer for Clostridium difficile toxin detection by electrochemical impedance immunosensors. 2015 , 101, 153-8		44

1114	Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection. 2015 , 60, 181-5	60
1113	Comparison of oral vancomycin capsule and solution for treatment of initial episode of severe Clostridium difficile Infection. 2015 , 28, 183-8	8
1112	Fecal and Other Gastrointestinal Cultures and Toxin Assays. 2016 , 3.8.1.1-3.8.6.4	
1111	Evaluation of a new molecular method illumigene for detection of Clostridium difficile associated diarrhoea. 2016 , 34, 253-4	
1110	Hospital-Associated Infections. 2016 , 735-758	0
1109	Clostridium Difficile Enteritis Causing Small Bowel Perforation in the Absence of Common Risk Factors. 2016 , 1, 85-87	1
1108	Pharmacologic Considerations in Oncology Critical Care. 2016 ,	1
1107	Increase of Clostridium difficile in Community; Another Worrisome Burden for Public Health. 2016 , 19, 7	9
1106	12. Clostridium difficile und andere gastrointestinale Infektionen. 2016 ,	
1105	. 2016 ,	5
1104	Clostridium difficile-associated diarrhoea in primary joint arthroplasty in Aneurin Bevan University Health Board South. 2016 , 98, 222-5	2
1103	Identification of Factors Impacting Recurrent Clostridium difficile Infection and Development of a Risk Evaluation Tool. 2016 , 19, 349-356	4
1102	Clostridium difficile: Current Status and Treatment Perspectives. 2016 , 2,	
1101	Factors Determining PhysiciansâDecision Making In Treatment and the Outcomes of Nosocomial Diarrhea in a Tertiary Care Hospital: A Prospective Cohort. 2016 , 4,	
1100	An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes. 2016 , 9, 143-8	4
1099	Clinical Impact of Probiotics among Patients Receiving Antibiotics with a High Risk of Acquiring Clostridium difficile Infection. 2016 , 2,	1
1098	Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation. 2017 , 9, e2017002	8
1097	Hand Hygiene Analyzed by Video Recording. 2016 , 05,	4

1096	Incidence and Clinical Outcomes of Clostridium difficile Infection after Treatment with Tuberculosis Medication. 2016 , 10, 250-4	11
1095	Clinical Characterization of Clostridium difficile Infection in Elderly Patients. 2016 , 67, 61-3	1
1094	Clinical Outcomes in Hospitalized Patients with Clostridium difficile Infection by Age Group. 2016 , 67, 81-6	13
1093	Re-evaluating the Inhibition of Stress Erosions (REVISE): a protocol for pilot randomized controlled trial. 2016 , 36, 427-433	7
1092	Clostridium difficile infection: a review of current and emerging therapies. 2016 , 29, 147-54	71
1091	Elderly patients and inflammatory bowel disease. 2016 , 7, 51-65	36
1090	Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes. 2016 , 2016, 8048757	14
1089	Tea and Recurrent Clostridium difficile Infection. 2016 , 2016, 4514687	4
1088	Fecal Microbiota Transplantation Using Upper Gastrointestinal Tract for the Treatment of Refractory or Severe Complicated Clostridium difficile Infection in Elderly Patients in Poor Medical Condition: The First Study in an Asian Country. 2016 , 2016, 2687605	23
1087	Fulminant Pseudomembranous Colitis Presenting as Sigmoid Stricture and Severe Polyposis with Clinical Response to Intracolonic Vancomycin. 2016 , 2016, 4609824	2
1086	Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. <i>World Journal of Gastroenterology</i> , 2016 , 22, 3078-104	5.6 81
1085	Burden of Nursing Home-Onset Clostridium difficile Infection in the United States: Estimates of Incidence and Patient Outcomes. 2016 , 3, ofv196	34
1084	Antimicrobial Stewardship for a Geriatric Behavioral Health Population. 2016 , 5,	6
1083	Trends in Antimicrobial Resistance Among Enteric Pathogens. 2016 , 63-92	2
1082	Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. 2016 , 9, 27-37	100
1081	Advances in the Microbiome: Applications to Clostridium difficile Infection. 2016 , 5,	17
1080	Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach. 2016 , 16, 303	98
1079	Clostridium difficile Infections in Medical Intensive Care Units of a Medical Center in Southern Taiwan: Variable Seasonality and Disease Severity. 2016 , 11, e0160760	4

1078	Clinical Characteristics and Treatment Outcomes of Clostridium difficile Infections by PCR Ribotype 017 and 018 Strains. 2016 , 11, e0168849	28
1077	Role of Full-Time or Full-Time Equivalent Infection Control Practitioners in The Prevention and Control of Healthcare-Associated Infections: A Questionnaire Survey. 2016 , 31, 48-54	
1076	. 2016 ,	8
1075	Analysis of two Clostridium difficile outbreaks in an acute health care facility. 2016 , 1, 23-31	
1074	Faecal microbiota transplantation: a review of FMT as an alternative treatment for Clostridium difficile infection. 2016 , 9, hzw007	4
1073	Fecal Transplant for Treatment of Toxic Megacolon Associated With Clostridium Difficile Colitis in a Patient With Duchenne Muscular Dystrophy. 2016 , 23, e609-13	9
1072	Initial Therapy for Mild to Moderate Clostridium difficile Infection. 2016 , 24, 210-216	17
1071	Development and Validation of a Risk Score for Clostridium difficile Infection in Medicare Beneficiaries: A Population-Based Cohort Study. 2016 , 64, 1690-5	11
1070	Clinical Significance of Clostridium difficile in Children Less Than 2 Years Old: A Case-Control Study. 2016 , 35, 281-5	22
1069	Fecal Microbiota Transplantation for Treatment of Severe, Recurrent, and Refractory Clostridium difficile Infection in a Severely Immunocompromised Patient. 2016 , 24, 237-240	1
1068	Procalcitonin Association With Clinical Course of Clostridium difficile Infection. 2016 , 24, 60-61	1
1067	Epidemiology and Risk Factors for Community-Associated Clostridium difficile Infection: A Narrative Review. 2016 , 5, 231-51	50
1066	Clostridium difficile infection epidemiology and management: Comparison of results of a prospective study with a retrospective one in a reference teaching and research hospital in Northern Italy. 2016 , 44, 1214-1218	4
1065	Reducing Overutilization of Testing for Clostridium difficile Infection in a Pediatric Hospital System: A Quality Improvement Initiative. 2016 , 6, 9-14	13
1064	Clinical Diagnosis, Viral PCR, and Antibiotic Utilization in Community-Acquired Pneumonia. 2016 , 23, e766-72	5
1063	Possible Interplay Between Hospital and Community Transmission of a Novel Clostridium Difficile Sequence Type 295 Recognized by Next-Generation Sequencing. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 680-4	2 3
1062	Potential Cost-effectiveness of Early Identification of Hospital-acquired Infection in Critically Ill Patients. 2016 , 13, 401-13	11
1061	Risk Factors for Clostridium Difficile Diarrhea in Patients With Solid Organ Transplantation. 2016 , 26, 231-7	12

1060	How to Diagnose and Treat IBD Mimics in the Refractory IBD Patient Who Does Not Have IBD. 2016 , 22, 1262-74		24
1059	Clinical and Microbiologic Assessment of Cases of Pediatric Community-associated Clostridium difficile Infection Reveals Opportunities for Improved Testing Decisions. 2016 , 35, 157-61		15
1058	Cost Averted With Timely Fecal Microbiota Transplantation in the Management of Recurrent Clostridium difficile Infection in Alberta, Canada. 2016 , 50, 747-53		17
1057	Treatment for Positive Urine Cultures in Hospitalized Adults: A Survey of Prevalence and Risk Factors in 3 Medical Centers. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 319-26	2	25
1056	Antimicrobial stewardship programs that target only high-cost, broad-spectrum antimicrobials miss opportunities to reduce Clostridium difficile infections. 2016 , 44, 1684-1686		9
1055	The incidence and drug resistance of Clostridium difficile infection in Mainland China: a systematic review and meta-analysis. 2016 , 6, 37865		37
1054	BACTERIA. 2016 , 347-410		
1053	Clostridium difficile associated diarrhoea: An increased problem. 2016 , 147, 543-546		1
1052	Molecular Diagnostics for Clostridium difficile. 2016 , 185-196		
1051	Accessory Gene Regulator-1 Locus Is Essential for Virulence and Pathogenesis of Clostridium difficile. 2016 , 7,		31
1050	Inappropriate Clostridium difficile Testing and Consequent Overtreatment and Inaccurate Publicly Reported Metrics. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 1395-1400	2	31
1049	The Challenge of Clostridium difficile Infection. 2016 , 77, 206-10		2
1048	Mortality and Costs in Clostridium difficile Infection Among the Elderly in the United States. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 1331-1336	2	27
1047	Antibiotic Treatment of Hospitalized Patients with Pneumonia Complicated by Clostridium Difficile Infection. 2016 , 1		
1046	Clostridium difficile Infection. 2016 , 4,		9
1045	Role of Coinfecting Strains in Recurrent Clostridium difficile Infection. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 1481-1484	2	2
1044	The Epidemiology and Clinical Features of Clostridium difficile Infection in Liver Transplant Recipients. 2016 , 100, 1939-43		16
1043	Role of binary toxin in the outcome of Clostridium difficile infection in a non-027 ribotype setting. 2016 , 144, 268-73		19

1042	Novel therapies for severe Clostridium difficile colitis. 2016 , 22, 167-73	6
1041	New and emerging therapies for Clostridium difficile infection. 2016 , 29, 546-554	34
1040	Clostridium difficile Infection Is Associated With Lower Inpatient Mortality When Managed by GI Surgeons. 2016 , 59, 855-61	3
1039	Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. 2016 , 22, 2402-9	106
1038	Preventing avoidable central line-associated bloodstream infections: Implications for probiotic administration and surveillance. 2016 , 44, 1427-1428	4
1037	Clostridium difficile associated diarrhoea: An increased problem. 2016 , 147, 543-546	4
1036	Hospital-Associated Infections. 2016 , 4,	15
1035	When to Operate After Failed Nonoperative Management. 2016 , 45-51	
1034	Community-acquired Clostridium difficile infections. 2016 , 46, 131-9	3
1033	Clostridium difficile infection: Early history, diagnosis and molecular strain typing methods. 2016 , 97, 59-78	25
1032	Clostridium difficile ribotype 176 - A predictor for high mortality and risk of nosocomial spread?. 2016 , 40, 35-40	23
1031	Toxic Megacolon: A Review for Emergency Department Clinicians. 2016 , 42, 481-486	4
1030	Disposable single-use receptacles in a tertiary hospital: A large survey of staff after a hospital-wide implementation. 2016 , 44, 1041-3	2
1029	Impact of sink location on hand hygiene compliance after care of patients with Clostridium difficile infection: a cross-sectional study. 2016 , 16, 203	27
1028	Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 215-8	2 14
1027	Probiotics as adjunctive therapy for preventing Clostridium difficile infection - What are we waiting for?. 2016 , 41, 51-57	29
1026	Administration of probiotic kefir to mice with Clostridium difficile infection exacerbates disease. 2016 , 40, 54-7	15
1025	Epidemiology of Clostridium difficile Infection-Associated Reactive Arthritis in Children: An Underdiagnosed, Potentially Morbid Condition. 2016 , 170, e160217	8

1024	Clostridium Difficile Infection in Children: A Review. 2016 , 63, e130-e140		27
1023	Clostridium difficile--To Test or Not to Test? Response to Kundrapu et al. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 361-2	2	3
1022	Risk factors associated with interfacility transfers among patients with Clostridium difficile infection. 2016 , 44, 1027-31		1
1021	Reply to: Re: The challenge of Clostridium difficile infection: overview of clinical manifestations, diagnostic tools and therapeutic options. 2016 , 47, 243		
1020	Epidemiology and factors associated with candidaemia following Clostridium difficile infection in adults within metropolitan Atlanta, 2009-2013. 2016 , 144, 1440-4		8
1019	Impact of a Healthcare Provider Educational Intervention on Frequency of Clostridium difficile Polymerase Chain Reaction Testing in Children: A Segmented Regression Analysis. 2017 , 6, 142-148		9
1018	Elevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults. 2016 , 48, 663-9		20
1017	[Identifying gaps between guidelines and clinical practice in Clostridium difficile infection]. 2016 , 31, 152-8		1
1016	Organism burden, toxin concentration, and lactoferrin concentration do not distinguish between clinically significant and nonsignificant diarrhea in patients with Clostridium difficile. 2016 , 84, 343-6		19
1015	Challenges to Diagnosis and Management of Infections in Older Adults. 2016 , 31-47		1
1014	Invasive Fungal Infections Acquired from Contaminated Food or Nutritional Supplements: A Review of the Literature. 2016 , 13, 343-9		50
1013	Clostridium difficile infection in patients hospitalized with type 2 diabetes mellitus and its impact on morbidity, mortality, and the costs of inpatient care. 2016 , 116, 68-79		7
1012	Clostridium difficile Infection. 2016 , 929-949		
1011	Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. 2016 , 18, 19		11
1010	Environmental Contamination in Households of Patients with Recurrent Clostridium difficile Infection. 2016 , 82, 2686-2692		23
1009	Developing a Clinical Prediction Rule for First Hospital-Onset Clostridium difficile Infections: A Retrospective Observational Study. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 896-900	2	8
1008	The Burden of Clostridium difficile after Cervical Spine Surgery. 2016 , 6, 314-21		11
1007	Clostridium difficile infection. 2016 , 2, 16020		342

1006	Infectious Diarrhea: Norovirus and Clostridium difficile in Older Adults. 2016 , 32, 509-22	5
1005	Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaks. 2016 , 5, e42	12
1004	A multi-center study of fidaxomicin use for Clostridium difficile infection. 2016 , 5, 1224	8
1003	Pyrexia: aetiology in the ICU. 2016 , 20, 247	23
1002	False Negative Results in Clostridium difficile Testing. 2016 , 16, 430	7
1001	Comparison of agar dilution and broth microdilution methods for Clostridium difficile antimicrobial susceptibility testing. 2016 , 7, 43-45	10
1000	Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study. 2016 , 22, 990-995	31
999	The epidemiology of Clostridium difficile infection in patients with cancer. 2016 , 14, 1077-1085	8
998	Effect of an antimicrobial stewardship intervention on outcomes for patients with Clostridium difficile infection. 2016 , 44, 1539-1543	8
997	Antibiotic Strategy and Stewardship. 2016 , 251-256	
996	Hospitalized Patients with Heart Failure and Common Bacterial Infections: A Nationwide Analysis of Concomitant Clostridium Difficile Infection Rates and In-Hospital Mortality. 2016 , 22, 891-900	27
995	Clostridium difficile Infection and Fecal Microbiota Transplant. 2016 , 27, 324-337	31
994	High prevalence of nontoxigenic Clostridium difficile isolated from hospitalized and non-hospitalized individuals in rural Ghana. 2016 , 306, 652-656	23
993	The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series. 2016 , 16, 316	20
992	ECCMID 2016: addressing the burden of recurrent Clostridium difficile infections. 2016 , 11, 1217-1221	
991	Effect of metronidazole use on tacrolimus concentrations in transplant patients treated for Clostridium difficile. 2016 , 18, 714-720	2
990	Microbiome in Transplantation. 2016 , 939-949	
989	Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial-PROSPECT: a pilot trial. 2016 , 17, 377	29

988	Other Bacterial Infections After Hematopoietic Stem Cell or Solid Organ Transplantation. 2016 , 397-414	
987	Host response to Clostridium difficile infection: Diagnostics and detection. 2016 , 7, 93-101	14
986	Predictors of Clostridium difficile infection-related mortality among older adults. 2016 , 44, 1219-1223	4
985	Nursing home residence is associated with spread of Clostridium difficile ribotype 027 in central Italy. <i>Journal of Hospital Infection</i> , 2016 , 94, 201-3	6.9 4
984	Emerging Infectious Diseases. 2016 , 386-413	
983	Bacterial Infections. 2016 , 1038-1062	
982	Frequency and risks associated with Clostridium difficile-associated diarrhea after pediatric solid organ transplantation: a single-center retrospective review. 2016 , 18, 706-713	19
981	The microbiota as target for therapeutic intervention in pediatric intestinal diseases. 2016 , 483-496	1
980	Clostridium difficile. 2016 ,	2
979	Effects of distribution of infection rate on epidemic models. 2016 , 94, 022409	7
978	Intestinal Epithelial Cell Response to Clostridium difficile Flagella. 2016 , 1476, 103-16	2
977	A Practical Method for Preparation of Fecal Microbiota Transplantation. 2016 , 1476, 259-67	6
976	Risk and Severity of Hospital-Acquired Clostridium difficile Infection in Patients Taking Proton Pump Inhibitors. 2016 , 36, 986-93	17
975	European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. 2016 , 22 Suppl 4, S63-81	323
974	Optimizing the diagnostic testing of Clostridium difficile infection. 2016 , 14, 801-8	3
973	Fecal microbiota transplantation for the treatment of Clostridium difficile infection. 2016 , 11, 56-61	34
972	Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. 2016 , 46, 479-93	65
971	Review article: the practical management of acute severe ulcerative colitis. 2016 , 43, 482-513	55

970	A Comparison of Current Guidelines of Five International Societies on Clostridium difficile Infection Management. 2016 , 5, 207-30		30
969	Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. 2016 , 16, 447		149
968	Hospital acquired Clostridium difficile infection in pediatric wards: a retrospective case-control study. 2016 , 5, 1329		6
967	The tipping point: patients predisposed to Clostridium difficile infection and a hospital antimicrobial stewardship programme. <i>Journal of Hospital Infection</i> , 2016 , 94, 242-248	6.9	5
966	Clostridium difficile in Crete, Greece: epidemiology, microbiology and clinical disease. 2016 , 144, 161-70		3
965	Fecal microbiota transplantation for severe clostridium difficile infection after left ventricular assist device implantation: a case control study and concise review on the local and regional therapies. 2016 , 16, 234		5
964	Clostridium difficile infection health disparities by race among hospitalized adults in the United States, 2001 to 2010. 2016 , 16, 454		7
963	Clostridium difficile Infection in Special High-Risk Populations. 2016 , 5, 253-69		34
962	Optimal Infection Control Practices in the OR Environment. 2016 , 104, 516-522		1
961	Transmissibility of Clostridium difficile Without Contact Isolation: Results From a Prospective Observational Study With 451 Patients. 2017 , 64, 393-400		24
960	Selected Topics in Anaerobic Bacteriology. 2016 , 4,		1
959	National age group trends in Clostridium difficile infection incidence and health outcomes in United States Community Hospitals. 2016 , 16, 682		30
958	Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections. 2016 , 111, 1834-1840		57
957	Antibiotic Treatment of Hospitalized Patients with Pneumonia Complicated by Clostridium Difficile Infection. 2016 , 952, 59-64		4
956	Risk factors for short- and long-term mortality in very old patients with Clostridium difficile infection: A retrospective study. 2017 , 17, 1378-1383		7
955	Clostridium difficile presence in Spanish and Belgian hospitals. 2016 , 100, 141-148		4
954	Risk Factors for Recurrent Clostridium difficile Infection in Pediatric Inpatients. 2016 , 6, 339-44		11
953	New antibiotics in clinical trials for Clostridium difficile. 2016 , 14, 789-800		3

952	Impact of malignancy on Clostridium difficile infection. 2016 , 35, 1771-1776		19
951	Antibiotics and the Intestinal Microbiome : Individual Responses, Resilience of the Ecosystem, and the Susceptibility to Infections. 2016 , 398, 123-146		22
950	The Human Microbiome in Health and Disease. 2016 , 57-76		4
949	Nosocomial transmission of Clostridium difficile ribotype 027 in a Chinese hospital, 2012-2014, traced by whole genome sequencing. 2016 , 17, 405		26
948	Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial. 2016 , 165, 609-616		344
947	Rethinking Strategies to Select Antibiotic Therapy in Clostridium difficile infection. 2016 , 36, 1281-1289		4
946	Advancements in Clinical Research. 2016 ,		0
945	Work System Barriers and Facilitators to Compliance with Infection Prevention Intervention: Initial Findings Regarding Hand Hygiene from Three Target Roles. 2016 , 60, 546-550		1
944	Policy and regulations in light of the human body as a "superorganism" containing multiple, intertwined symbiotic relationships. 2016 , 33, 39-48		8
943	[Clostridium difficile infections in geriatric patients]. 2016 , 49, 743-761		2
942	Reduction of Clinical Culture Contamination in an Inpatient Medical Unit by Revisiting Microbiology Education. 2016 , 47, 446-448		1
941	Laboratory Experience with the Liaison Analyzer in the Diagnosis of -Associated Diarrhea. 2016 , 6, 215-218		5
940	Clostridium difficile Infections in Veterans Health Administration Long-Term Care Facilities. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 295-300	2	13
939	Clostridium difficile Infection. 2016 , 24, 193-194		
938	The Cost-efficiency and Care Effectiveness of Probiotic Administration with Antibiotics to Prevent Hospital-Acquired Clostridium difficile Infection. 2016 , 25, 238-243		1
937	Severe complicated Clostridium difficile infection: Can the UPMC proposed scoring system predict the need for surgery?. 2016 , 81, 221-8		5
936	Complications of Hospital-Onset Healthcare Facility-Associated Clostridium difficile Infections Among Veterans. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 717-9	2	3
935	Impact of Targeted Educational Interventions on Clostridium difficile Infection Treatment in Critically Ill Adults. 2016 , 51, 901-906		4

934	Use of Risk Stratification Tools to Enhance Antimicrobial Stewardship Practices. 2016 , 24, 204-209		
933	Significance of a positive Clostridium difficile toxin test after hematopoietic stem cell transplantation. 2016 , 30, 703-8		11
932	Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection. 2016 , 8, 47		75
931	Predominance of Clostridium difficile ribotypes 012, 027 and 046 in a university hospital in Chile, 2012. 2016 , 144, 976-9		12
930	Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection. 2016 , 16, 309		20
929	Comparison of the Vidas C. difficile and Quik Chek-60 glutamate dehydrogenase assays for the detection of Clostridium difficile in faecal samples. 2016 , 48, 506-8		1
928	Clostridium difficile Infections in Children: Impact of the Diagnostic Method on Infection Rates. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 1087-93	2	6
927	Understanding the mechanisms of faecal microbiota transplantation. 2016 , 13, 508-16		245
926	Comparison of enzyme immunoassays and rapid diagnostic tests for clostridium difficile glutamate dehydrogenase and toxin a + B to toxinogenic culture on a highly selective chromogenic medium. 2016 , 35, 1655-9		2
925	Effect of a Clostridium difficile Infection Prevention Initiative in Veterans Affairs Acute Care Facilities. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 720-2	2	33
924	Use of Concomitant Antibiotics During Treatment for Clostridium difficile Infection (CDI) in Pediatric Inpatients: An Observational Cohort Study. 2016 , 5, 45-51		1
923	Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine. 2016 , 1,		216
922	High morbidity and mortality of Clostridium difficile infection and its associations with ribotype 002 in Hong Kong. 2016 , 73, 115-22		18
921	Fecal microbiota transplant for Clostridium difficile infection in older adults. 2016 , 9, 273-81		11
920	The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases. 2016 , 16, 177		27
919	Health care worker hand contamination at critical moments in outpatient care settings. 2016 , 44, 1198-1202		19
918	Outcomes in children with Clostridium difficile infection: results from a nationwide survey. 2016 , 4, 293-298		10
917	A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. 2016 , 15, 22		9

916	Evaluation of the VIDAS glutamate dehydrogenase assay for the detection of Clostridium difficile. 2016 , 40, 68-72	11
915	Ridinilazole: a novel therapy for Clostridium difficile infection. 2016 , 48, 137-43	32
914	Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. 2016 , 22, 1744-54	37
913	A Fatal Case of Clostridium difficile Enterocolitis following Diverting Loop Ileostomy Reversal. 2016 , 1, 16-18	3
912	Intracolonic vancomycin for Clostridium difficile infection. 2016 , 11, 9-11	
911	Editorial Commentary: Potential Risks and Rewards With Prophylaxis for Clostridium difficile Infection. 2016 , 63, 654-5	8
910	Routine prophylaxis with proton pump inhibitors and post-transplant complications in kidney transplant recipients undergoing early corticosteroid withdrawal. 2016 , 30, 694-702	10
909	Efficacy of perioperative synbiotics treatment for the prevention of surgical site infection after laparoscopic colorectal surgery: a randomized controlled trial. 2016 , 46, 479-90	40
908	Treat Clostridium difficile infection in the elderly based on disease severity and history of recurrence. 2016 , 32, 149-153	
907	Older Is Not Wiser, Immunologically Speaking: Effect of Aging on Host Response to Clostridium difficile Infections. 2016 , 71, 916-22	28
906	Genome-Based Infection Tracking Reveals Dynamics of Clostridium difficile Transmission and Disease Recurrence. 2016 , 62, 746-752	52
905	Fecal Microbiota Transplant. 2016 , 5, 58-70	0
904	Effects of a predictive preventive model for prevention of Clostridium difficile infection in patients in intensive care units. 2016 , 44, 421-4	11
903	Effect of an antimicrobial stewardship bundle for patients with Clostridium difficile infection. 2016 , 71, 836-40	24
902	Novel approaches to treating Clostridium difficile-associated colitis. 2016 , 10, 193-204	5
901	Subinhibitory concentrations of metronidazole increase biofilm formation in Clostridium difficile strains. 2016 , 74,	36
900	Ultrasensitive Detection and Quantification of Toxins for Optimized Diagnosis of Clostridium difficile Infection. 2016 , 54, 259-64	27
899	Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies. 2016 , 84, 395-406	28

898	Luminal Toxin-Binding Agents for Clostridium difficile Infection. 2016 , 29, 361-7		10
897	Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. 2016 , 62, 596-602		98
896	Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. 2016 , 71, 1245-51		38
895	Re: The challenge of Clostridium difficile infection: Overview of clinical manifestations, diagnostic tools and therapeutic options. 2016 , 47, 243-4		
894	Diagnosis and Treatment of Infection (CDI). 2016 , 24, 3-10		18
893	A prospective study of two isothermal amplification assays compared with real-time PCR, CCNA and toxigenic culture for the diagnosis of Clostridium difficile infection. 2016 , 16, 19		5
892	Surgical Management of Clostridium difficile Infection: The Role of Colectomy. <i>Surgical Infections</i> , 2016 , 17, 343-5	2	2
891	Toxin B PCR cycle threshold as a predictor of poor outcome of Clostridium difficile infection: a derivation and validation cohort study. 2016 , 71, 1380-5		35
890	Clostridium difficile outbreak caused by NAP1/BI/027 strain and non-027 strains in a Mexican hospital. 2016 , 20, 8-13		21
889	A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection. 2016 , 214, 173-81		205
888	Breakthroughs in the treatment and prevention of Clostridium difficile infection. 2016 , 13, 150-60		87
887	Gastrointestinal Infections. 2016 , 707-734		
886	Prevalence of probiotic use among inpatients: A descriptive study of 145 U.S. hospitals. 2016 , 44, 548-53		34
885	Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model. 2016 , 71, 1300-6		8
884	Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571. 2016 , 6, a025445		11
883	Use of probiotics in prevention and treatment of patients with Clostridium difficile infection. 2016 , 30, 111-8		21
882	Alternative stethoscope decontamination methods: old practices die hard. <i>Journal of Hospital Infection</i> , 2016 , 92, 411-2		6.9
881	Emergency Surgery Course (ESC) Manual. 2016 ,		1

- 880 Tigecycline as last resort in severe refractory *Clostridium difficile* infection: a case report. *Journal of Hospital Infection*, **2016**, 92, 296-8 6.9 4
- 879 [Laboratory diagnosis of *Clostridium difficile* infection]. **2016**, 34, 595-602 10
- 878 Clinical implications of antibiotic impact on gastrointestinal microbiota and *Clostridium difficile* infection. **2016**, 10, 1145-1152 22
- 877 Clinical significance of direct cytotoxicity and toxigenic culture in *Clostridium difficile* infection. **2016**, 37, 38-42 12
- 876 The never-ending struggle with laboratory testing for *Clostridium difficile* infection. **2016**, 5, 113-6 5
- 875 Vancomycin Treatment Alters Humoral Immunity and Intestinal Microbiota in an Aged Mouse Model of *Clostridium difficile* Infection. **2016**, 214, 130-9 26
- 874 Diagnosis of *Clostridium difficile* Infections in Children. **2016**, 54, 1425-1433 22
- 873 *Clostridium difficile* infection: epidemiology, diagnosis and understanding transmission. **2016**, 13, 206-16 187
- 872 *Clostridium difficile* associated reactive arthritis: Case report and literature review. **2016**, 38, 76-80 14
- 871 *Clostridium difficile* flagella predominantly activate TLR5-linked NF- κ B pathway in epithelial cells. **2016**, 38, 116-124 25
- 870 Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent *Clostridium difficile* Infection: A Randomized Clinical Trial. **2016**, 315, 142-9 401
- 869 Risk factors for recurrent *Clostridium difficile* infection in allogeneic hematopoietic cell transplant recipients. **2016**, 51, 713-7 16
- 868 Discovery and development of surotomycin for the treatment of *Clostridium difficile*. **2016**, 43, 195-204 29
- 867 Incidence of *Clostridium difficile* infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor. *Journal of Hospital Infection*, **2016**, 92, 173-7 6.9 34
- 866 Clinical and Healthcare Burden of Multiple Recurrences of *Clostridium difficile* Infection. **2016**, 62, 574-580 91
- 865 Evaluation of advanced age as a risk factor for severe *Clostridium difficile* infection. **2016**, 7, 12-16 10
- 864 The Use of Prebiotics, Probiotics, and Synbiotics in the Critically Ill. **2016**, 723-739
- 863 Prolonged *Clostridium difficile* Infection May Be Associated With Vitamin D Deficiency. **2016**, 40, 682-7 5

862	Multidisciplinary performance improvement team for reducing health care-associated Clostridium difficile infection. 2016 , 44, 352-4	6
861	Isolation and quantitation of Clostridium difficile in aqueous and fecal matter using two types of selective media. 2016 , 49, 445-7	5
860	Factors predictive of severe Clostridium difficile infection depend on the definition used. 2016 , 37, 43-8	21
859	Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 252-7	5.9 30
858	PCR cycle threshold value predicts the course of Clostridium difficile infection. 2016 , 22, e7-e8	26
857	The potential risks of probiotics among HIV-infected persons: Bacteraemia due to Lactobacillus acidophilus and review of the literature. 2016 , 27, 1223-1230	38
856	Clostridium Difficile Colonization in Hematopoietic Stem Cell Transplant Recipients: A Prospective Study of the Epidemiology and Outcomes Involving Toxigenic and Nontoxigenic Strains. 2016 , 22, 157-63	48
855	Fecal Microbiota Transplant: Treatment Options for Clostridium difficile Infection in the Intensive Care Unit. 2016 , 31, 577-86	17
854	Nosocomial Clostridium difficile-associated diarrhoea in Assiut University Children's Hospital, Egypt. 2016 , 36, 39-44	7
853	Upper Versus Lower Gastrointestinal Delivery for Transplantation of Fecal Microbiota in Recurrent or Refractory Clostridium difficile Infection: A Collaborative Analysis of Individual Patient Data From 14 Studies. 2017 , 51, 145-150	39
852	Clostridium difficile infection incidence prediction in hospitals (CDIIPH): a predictive model based on decision tree and fuzzy techniques. 2017 , 31, 417-430	7
851	A Curiously Rare Case of Septic Shock From Clostridium difficile Colitis. 2017 , 33, 576-578	1
850	Management of Clostridium difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute. 2017 , 15, 166-174	79
849	C. difficile PCR-ribotype 023 might go undetected when using ChromId C. difficile agar. 2017 , 44, 34-35	3
848	Clostridium difficile infection in cancer patients. 2017 , 148, 91	2
847	Geriatric Infectious Diseases: Current Concepts on Diagnosis and Management. 2017 , 65, 631-641	31
846	Impact of Antibiotics on Necrotizing Enterocolitis and Antibiotic-Associated Diarrhea. 2017 , 46, 61-76	43
845	Neurotrauma Management for the Severely Injured Polytrauma Patient. 2017 ,	2

844	Clostridium difficile colitis: A clinical review. 2017 , 213, 565-571	32
843	Clostridium difficile rates in asymptomatic and symptomatic hospitalized patients using nucleic acid testing. 2017 , 87, 365-370	21
842	Is Follow-Up Testing with the FilmArray Gastrointestinal Multiplex PCR Panel Necessary?. 2017 , 55, 1154-1161	13
841	Evaluation of Risk Factors for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Recipients. 2017 , 37, 420-428	7
840	Effect of Mutation on Sporulation in the Epidemic Strain R20291. 2017 , 2,	23
839	Clostridium difficile-Associated Diarrhea in the Oncology Patient. 2017 , 13, 25-30	25
838	Comparative performance study of six commercial molecular assays for rapid detection of toxigenic Clostridium difficile. 2017 , 23, 567-572	12
837	Evaluation of the performance of C. DIFF QUIK CHEK COMPLETE and its usefulness in a hospital setting with a high prevalence of Clostridium difficile infection. 2017 , 65, 88-92	10
836	Clostridium difficile infection in inflammatory bowel disease: challenges in diagnosis and treatment. 2017 , 10, 112-123	17
835	Clostridium difficile disease: Diagnosis, pathogenesis, and treatment update. 2017 , 162, 325-348	77
834	Factors associated with Clostridium difficile infection: A nested case-control study in a three year prospective cohort. 2017 , 44, 117-123	26
833	Strategies for Optimizing the Diagnostic Predictive Value of Clostridium difficile Molecular Diagnostics. 2017 , 55, 1244-1248	21
832	Clostridium difficile Infection Among US Emergency Department Patients With Diarrhea and No Vomiting. 2017 , 70, 19-27.e4	13
831	Role of the leukocyte response in normal and immunocompromised host after Clostridium difficile infection. 2017 , 45, 101-105	10
830	Risks factors and outcomes of Clostridium difficile infection in patients with cancer: a matched case-control study. 2017 , 25, 1923-1930	16
829	Impact of a national antimicrobial stewardship mentoring program: Insights and lessons learned. 2017 , 74, 224-231	10
828	Laboratory diagnosis of Clostridium difficile infection: Comparison of Techlab C. diff Quik Chek Complete, Xpert C. difficile, and multistep algorithmic approach. 2017 , 31,	9
827	Lack of Benefit With Combination Therapy for Clostridium difficile Infection. <i>Infection Control and Hospital Epidemiology</i> , 2017 , 38, 602-605	2 1

826	Effect of Aging on the Composition of Fecal Microbiota in Donors for FMT and Its Impact on Clinical Outcomes. 2017 , 62, 1002-1008		26
825	Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. 2017 , 3, CD004610		55
824	Real-Time Electronic Tracking of Diarrheal Episodes and Laxative Therapy Enables Verification of Clostridium difficile Clinical Testing Criteria and Reduction of Clostridium difficile Infection Rates. 2017 , 55, 1276-1284		56
823	Clostridium difficile Infection and Patient-Specific Antimicrobial Resistance Testing Reveals a High Metronidazole Resistance Rate. 2017 , 62, 1035-1042		33
822	Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. 2017 , 152, 1889-1900.e9		163
821	Recurrent Clostridium difficile Infection in Children: Patient Risk Factors and Markers of Intestinal Inflammation. 2017 , 36, 379-383		12
820	Risk Factors for Community-Associated Clostridium difficile Infection in Children. 2017 , 186, 105-109		44
819	Response to "Re-Thinking the Definition of Complicated Intra-Abdominal Infection". <i>Surgical Infections</i> , 2017 , 18, 375-376	2	1
818	Effect of Clostridium difficile Prevalence in Hospitals and Nursing Homes on Risk of Infection. 2017 , 65, 1527-1534		2
817	Risk of Clostridium difficile Infection in Hematology-Oncology Patients Colonized With Toxigenic C. difficile. <i>Infection Control and Hospital Epidemiology</i> , 2017 , 38, 718-720	2	22
816	Toxic Megacolon - A Three Case Presentation. 2017 , 3, 39-44		4
815	Rational Selection and Use of Antimicrobials in Patients with Burn Injuries. 2017 , 44, 521-534		5
814	Toxigenic Clostridium difficile colonization among hospitalised adults; risk factors and impact on survival. 2017 , 75, 20-25		10
813	Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing. 2017 , 55, 1998-2008		124
812	Prise en charge des infections à Clostridium difficile. Révolution thérapeutique. 2017 , 38, A35-A39		
811	Risk for Infection After Allogeneic Hematopoietic Cell Transplant Remains Elevated in the Postengraftment Period. 2017 , 3, e145		14
810	Current challenges in the treatment of severe infection: early treatment potential of fecal microbiota transplantation. 2017 , 10, 373-381		25
809	Scientific and Clinical Abstracts From the WOCN Society's 49th Annual Conference. 2017 , 44, S1-S72		1

808	An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy. 2017 , 36, 1777-1786	25
807	Clostridium difficile Infection in Older Adults: Systematic Review of Efforts to Reduce Occurrence and Improve Outcomes. 2017 , 32, 24-41	3
806	Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?. 2017 , 51, 804-810	12
805	Clostridium-difficile-Infektion. 2017 , 12, 237-252	
804	Outcomes of Fecal Microbiota Transplantation for Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. 2017 , 62, 2870-2875	20
803	A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection. 2017 , 47, 94-103	22
802	Clostridium difficile Infection: An Orthopaedic Surgeon's Guide to Epidemiology, Management, and Prevention. 2017 , 25, 214-223	7
801	Collateral damage during antibiotic treatment of C. difficile infection in the aged host: Insights into why recurrent disease happens. 2017 , 8, 504-510	3
800	A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection. 2017 , 6, 1-35	15
799	Clinical, immunological and microbiological predictors of poor outcome in Clostridium difficile infection. 2017 , 88, 330-334	10
798	Treating Wisely: The Surgeon's Role in Antibiotic Stewardship. 2017 , 265, 871-873	22
797	Fecal microbiota transplantation outcomes in immunocompetent and immunocompromised patients: A single-center experience. 2017 , 19, e12726	19
796	Efficacy of the World Health Organization-recommended handwashing technique and a modified washing technique to remove Clostridium difficile from hands. 2017 , 45, 844-848	5
795	Optimal use of Rapid Diagnostics in Infection Control and Prevention. 2017 , 39, 83-89	
794	Lack of adherence to SHEA-IDSA treatment guidelines for Clostridium difficile infection is associated with increased mortality. 2017 , 72, 574-581	17
793	Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection. 2017 , 11, 611-622	7
792	Effectiveness of probiotics in reducing the incidence of Clostridium difficile-associated diarrhea in elderly patients: a systematic review. 2017 , 15, 140-164	20
791	Clostridium difficile infection. 2017 , 148, 456-463	2

790	Compliance with Clostridium difficile treatment guidelines: effect on patient outcomes. 2017 , 145, 2185-2192	19
789	Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity. 2017 , 24,	57
788	A multicenter, retrospective, case-cohort study of the epidemiology and risk factors for Clostridium difficile infection among cord blood transplant recipients. 2017 , 19, e12728	10
787	Trends in the use of laboratory tests for the diagnosis of Clostridium difficile infection and association with incidence rates in Quebec, Canada, 2010-2014. 2017 , 45, 964-968	11
786	Incidence and Risk Factors for Community and Hospital Acquisition of Clostridium difficile Infection in the Tel Aviv Sourasky Medical Center. <i>Infection Control and Hospital Epidemiology</i> , 2017 , 38, 912-920	2 11
785	Effects of a New Hospital-Wide Surgical Consultation Protocol in Patients with Clostridium difficile Colitis. <i>Surgical Infections</i> , 2017 , 18, 563-569	2 5
784	External Validation of Three Prediction Tools for Patients at Risk of a Complicated Course of Clostridium difficile Infection: Disappointing in an Outbreak Setting. <i>Infection Control and Hospital Epidemiology</i> , 2017 , 38, 897-905	2 6
783	Impact of the use of local fidaxomicin treatment algorithms for managing Clostridium difficile infection in hospitalized patients in southeastern United States. 2018 , 17, 37	1
782	Increasing Age Has Limited Impact on Risk of Infection in an Elderly Population. 2018 , 5, ofy160	14
781	An Observational Cohort Study of Ribotype 027 and Recurrent Infection. 2018 , 3,	14
780	Vulnerability of long-term care facility residents to Clostridium difficile infection due to microbiome disruptions. 2018 , 13, 1537-1547	6
779	Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain. 2018 , 35, 1920-1934	10
778	Reducing risk of infection and overall use of antibiotic in the outpatient treatment of urinary tract infection. 2018 , 10, 283-293	9
777	Variable spectrum of disease and risk factors of peripartum Clostridium difficile infection: report of 14 cases from French hospitals and literature review. 2018 , 37, 2293-2299	3
776	Molecular epidemiology of in two tertiary care hospitals in Shandong Province, China. 2018 , 11, 489-500	15
775	Clinical review of Clostridium difficile infection: an update on treatment and prevention. 2018 , 19, 1759-1769	13
774	Clostridium difficile Infection in Children. 2018 , 47, e359-e365	8
773	Development and Validation of a Prediction Model for Mortality and Adverse Outcomes Among Patients With Peripheral Eosinopenia on Admission for Clostridium difficile Infection. 2018 , 153, 1127-1133	29

772	A Propensity Score Analysis of Clostridium difficile Infection among Adult Trauma Patients. <i>Surgical Infections</i> , 2018 , 19, 661-666	2	3
771	Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials. 2018 , 24, 907-914		11
770	Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent infection. 2018 , 12, 11-21		27
769	Control of Clostridium difficile Infection by Defined Microbial Communities. 2018 , 267-289		0
768	Bis-Cyclic Guanidines as a Novel Class of Compounds Potent against Clostridium difficile. 2018 , 13, 1414-1420	7	
767	Severe infections in critically ill solid organ transplant recipients. 2018 , 24, 1257-1263		12
766	The Need for Antibiotic Stewardship Programs. 1-23		
765	Risk factors associated with Clostridium difficile infection in kidney transplant recipients. 2018 , 20, e12918		7
764	Role of Metronidazole in Mild Clostridium difficile Infections. 2018 , 67, 1956-1958		11
763	Lack of improvement in antimicrobial prescribing after a diagnosis of Clostridium difficile and impact on recurrence. 2018 , 46, 1370-1374		1
762	Presence of multiple Clostridium difficile strains at primary infection is associated with development of recurrent disease. 2018 , 53, 74-81		18
761	Detection of toxigenic Clostridium difficile in paediatric patients. 2018 , 36, 357-361		
760	Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant. 2018 , 11, 233-240		6
759	Molecular epidemiologic study of Clostridium difficile infections in university hospitals: Results of a nationwide study in Japan. 2018 , 24, 641-647		9
758	Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection. 2018 , 3, 71-92		4
757	Risk of meticillin resistant and in patients with a documented penicillin allergy: population based matched cohort study. 2018 , 361, k2400		131
756	Abdominal Pain, Nausea, Vomiting, and Diarrhea. 2018 , 23-28		
755	Glycopeptides, Lipopeptides, and Lipoglycopeptides. 2018 , 139-166		

754	Prevention and Treatment of Clostridium difficile Enterocolitis. 2018 , 52, 29-42		1
753	Evaluation of an UltraFast LabChip V280 assay for detection of toxigenic Clostridium difficile. 2018 , 92, 279-283		1
752	Prevalence of Inappropriate Antibiotic Prescribing in Primary Care Clinics within a Veterans Affairs Health Care System. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	54
751	Primary Prevention of Clostridium difficile-Associated Diarrhea: Current Controversies and Future Tools. 2018 , 20, 32		9
750	Development of vaccine for Clostridium difficile infection using membrane fraction of nontoxigenic Clostridium difficile. 2018 , 123, 42-46		5
749	Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms. 2018 , 2018, 8414257		34
748	An Unusual Case of Ototoxicity with Use of Oral Vancomycin. 2018 , 2018, 2980913		4
747	Detection and Investigation of Eagle Effect Resistance to Vancomycin in With an ATP-Bioluminescence Assay. 2018 , 9, 1420		12
746	Evaluating the Sporicidal Activity of Disinfectants against and Spores by Using the Improved Methods Based on ASTM E2197-11. 2018 , 6, 18		6
745	Infectious Diarrhoeas in the Elderly. 2018 , 179-186		
744	Lipids mediating the interaction of metronidazole with cell membrane models at the air-water interface. 2018 , 171, 377-382		9
743	Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case-Control Study in Japan. 2018 , 36, 1367-1376		7
742	Performance comparison of the cobas Liat and Cepheid GeneXpert systems for Clostridium difficile detection. 2018 , 13, e0200498		4
741	Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). 2018 , 48, 713-722		7
740	Impact of the introduction of a nucleic acid amplification test for diagnosis on stool rejection policies. 2018 , 10, 19		
739	Novel Antimicrobials for the Treatment of Infection. 2018 , 5, 96		31
738	New Insights into (CD) Infection in Latin America: Novel Description of Toxigenic Profiles of Diarrhea-Associated to CD in Bogotá-Colombia. 2018 , 9, 74		10
737	Incidence and Outbreak of Healthcare-Onset Healthcare-Associated Infections Among Intensive Care Patients in a Large Teaching Hospital in China. 2018 , 9, 566		8

736	- From Colonization to Infection. 2018 , 9, 646	68
735	Molecular Characterization of e Isolates in China From 2010 to 2015. 2018 , 9, 845	20
734	A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against. 2018 , 9, 1206	9
733	Cerebrospinal Fluid Presepsin As a Marker of Nosocomial Infections of the Central Nervous System: A Prospective Observational Study. 2018 , 9, 58	3
732	Neurogenic Bowel: Dysfunction and Rehabilitation. 2018 , 143-149.e7	2
731	Serum vancomycin concentrations after oral and intracolonic vancomycin administration in a patient with colonic discontinuity and severe infection. 2018 , 75, e189-e193	4
730	The evolving epidemiology of infection in Canadian hospitals during a postepidemic period (2009-2015). 2018 , 190, E758-E765	31
729	Enhanced Efficacy of High Dose Oral Vancomycin Therapy in Clostridium difficile Diarrhea for Hospitalized Adults Not Responsive to Conventional Oral Vancomycin Therapy: Antibiotic Stewardship Implications. 2018 , 7,	6
728	Infectious Disease. 2018 , 89-96	
727	Common Gastrointestinal Infections. 2018 , 45, 519-532	24
726	Diagnostic stewardship and the 2017 update of the IDSA-SHEA Clinical Practice Guidelines for Clostridium difficile Infection. 2018 , 5, 119-125	12
725	Effect of the Synthetic Bile Salt Analog CamSA on the Hamster Model of Clostridium difficile Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9 12
724	Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. 2018 , 146, 1101-1105	14
723	Reducing rates of infection by switching to a stand-alone NAAT with clear sampling criteria. 2018 , 7, 40	2
722	Role of Antimicrobial Stewardship Programs in Decreasing Hospital-Associated Clostridium difficile Infections. 2018 , 10, 270-280	
721	A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB Inhibitor. 2018 , 58, 1557-1565	5
720	Searching for a Potential Algorithm for Clostridium difficile Testing at a Tertiary Care Hospital: Does Toxin Enzyme Immunoassay Testing Help?. 2018 , 56,	2
719	Genomic survey of Clostridium difficile reservoirs in the East of England implicates environmental contamination of wastewater treatment plants by clinical lineages. 2018 , 4,	11

718	colitis and zoonotic origins-a narrative review. 2018 , 6, 157-166	14
717	Prolonged Mechanical Ventilation Assistance Interacts Synergistically with Carbapenem for Infection in Critically Ill Patients. 2018 , 7,	7
716	Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms. 2018 , 52, 719-723	8
715	Clostridium difficile exosporium cysteine-rich proteins are essential for the morphogenesis of the exosporium layer, spore resistance, and affect C. difficile pathogenesis. 2018 , 14, e1007199	27
714	A low-cost paper-based synthetic biology platform for analyzing gut microbiota and host biomarkers. 2018 , 9, 3347	139
713	A Rapid, Accurate, Single Molecule Counting Method Detects Clostridium difficile Toxin B in Stool Samples. 2018 , 8, 8364	8
712	An Audit of Repeat Testing at an Academic Medical Center: Consistency of Order Patterns With Recommendations and Potential Cost Savings. 2018 , 150, 27-33	3
711	In vitro stability of three oral vancomycin preparations stored at 2- 5 °C and ambient room temperature for up to 60 days against 100 Clostridioides (Clostridium) difficile and 51Staphylococcus aureus strains. 2018 , 52, 83-85	1
710	Economic evaluation of interventions designed to reduce Clostridium difficile infection. 2018 , 13, e0190093	5
709	Diversity of multidrug-resistant epidemic Clostridium difficile NAP1/RT027/ST01 strains in tertiary hospitals from Honduras. 2018 , 52, 75-78	6
708	Observational study of chemotherapy-induced Clostridium difficile infection in patients with lung cancer. 2018 , 23, 1046-1051	1
707	In silico analysis of antibiotic-induced Clostridium difficile infection: Remediation techniques and biological adaptations. 2018 , 14, e1006001	6
706	Factors associated with an outbreak of hospital-onset, healthcare facility-associated Clostridium difficile infection (HO-HCFA CDI) in a Mexican tertiary care hospital: A case-control study. 2018 , 13, e0198212	6
705	Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate infection in hospitalized patients. 2018 , 75, 1110-1121	10
704	Current updates in management of Clostridium difficile infection in cancer patients. 2019 , 35, 473-478	5
703	Clostridium difficile: Investigating Transmission Patterns Between Infected and Colonized Patients Using Whole Genome Sequencing. 2019 , 68, 204-209	27
702	Outcomes of Community and Healthcare-onset Clostridium difficile Infections. 2019 , 68, 1343-1350	10
701	Clostridium difficile, the Difficult "Kloster" Fuelled by Antibiotics. 2019 , 76, 774-782	26

700	Hospital-Acquired Infections in Critically Ill Patients With Cancer. 2019 , 34, 523-536	7
699	Ribotype variability of <i>Clostridioides difficile</i> strains in patients with hospital-acquired <i>C. difficile</i> infections, community-acquired <i>C. difficile</i> infections, and colonization with toxigenic and non-toxigenic strains of <i>C. difficile</i> . 2019 , 60, 102086	3
698	Enterocolitis in a Captive Geoffroy's Spider Monkey () and Common Marmosets (). 2019 , 56, 959-963	0
697	Integrated genomic epidemiology and phenotypic profiling of <i>Clostridium difficile</i> across intra-hospital and community populations in Colombia. 2019 , 9, 11293	5
696	Epidemiology of Severe Acute Diarrhea in Patients Requiring Hospital Admission. 2019 , 57, 290-298	3
695	Comparison of three current <i>Clostridioides difficile</i> infection guidelines: IDSA/SHEA, ESCMID, and ACG guidelines. 2019 , 47, 899-909	3
694	: diagnosis and treatments. 2019 , 366, 14609	36
693	Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent <i>Clostridioides difficile</i> Infection: A Post Hoc Analysis of MODIFY I/II. 2019 , 6,	6
692	Determining the risk factors associated with the development of infection in patients with hematological diseases. 2019 , 54, 120-124	3
691	<i>Clostridium difficile</i> colitis: CT findings and differential diagnosis. 2019 , 124, 1185-1198	15
690	Gastrointestinal Infections and <i>Clostridium difficile</i> Infection. 2019 , 291-301	
689	Seasonality of <i>Clostridium difficile</i> in the natural environment. 2019 , 66, 2440-2449	7
688	An Infectious Diseases Consult in the Neurocritical Care Unit. 2019 , 351-358	
687	Antibiotic use and duration in association with <i>Clostridioides difficile</i> infection in a tertiary academic medical center: A retrospective case-control study. 2019 , 59, 126-130	7
686	Prevalence of <i>Clostridium difficile</i> and its toxins in hospital patients with diarrhoeal diseases in Lusaka, Zambia. 2020 , 114, 86-90	
685	Management of Infection. 2019 , 39, e1-e12	1
684	Effective Dosage of Oral Vancomycin in Treatment for Initial Episode of Infection: A Systematic Review and Meta-Analysis. 2019 , 8,	6
683	Factors associated to <i>Clostridium difficile</i> infection in a hospital-based home care service. 2019 , 153, 319-322	

682	Fast and near-optimal monitoring for healthcare acquired infection outbreaks. 2019 , 15, e1007284	4
681	Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection. 2019 , 19, 51	8
680	Different molecular characteristics and antimicrobial resistance profiles of in the Asia-Pacific region. 2019 , 8, 1553-1562	10
679	Risk Factors for BI/NAP1/027 Infections and Clinical Outcomes Compared With Non-NAP1 Strains. 2019 , 6, ofz433	2
678	Risk for Clostridioides difficile Infection among Older Adults with Cancer. 2019 , 25,	2
677	Fecal microbiota transplantation (FMT) for C. difficile infection, just say 'No'. 2019 , 60, 102092	15
676	Clostridium difficile infection: Description of NAP1/027 and non NAP1/027 strains in a high complexity center in Cali, Colombia, 2012-2015. 2019 , 39, 63-70	1
675	Risk factors and treatment outcomes of severe Clostridioides difficile infection in Singapore. 2019 , 9, 13440	9
674	Effect of Specimen Type and Processing on the Detection of in Piglet Fecal Samples. 2019 , 16, 731-737	
673	Microbiota of MR1 deficient mice confer resistance against Clostridium difficile infection. 2019 , 14, e0223025	14
672	Top 10 evidence-based recommendations from the Brazilian Society of Infectious Diseases for the Choosing Wisely Project. 2019 , 23, 331-335	1
671	Clostridium difficile-associated Diarrhea in Developing Countries: A Systematic Review and Meta-Analysis. 2019 , 8, 87-103	21
670	Simultaneous Intake of and Vegetables Exerts Synergistic Anti-Obesity and Anti-Inflammatory Effects by Modulating the Gut Microbiota in Diet-Induced Obese Mice. 2019 , 11,	14
669	Updated guidelines for diagnosing and managing Clostridium difficile. 2019 , 32, 48-50	1
668	Rapid, label-free genetic detection of enteropathogens in stool without genetic isolation or amplification. 2019 , 130, 73-80	10
667	Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis. 2019 , 14, e0210016	56
666	ASID/ACIPC position statement - Infection control for patients with Clostridium difficile infection in healthcare facilities. 2019 , 24, 32-43	7
665	Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study. 2019 , 25, 987-993	14

664	Fecal microbiota transplantation in recurrent infection: A retrospective single-center chart review. 2019 , 3, 4-9	10
663	Evaluating probiotics for the prevention of ventilator-associated pneumonia: a randomised placebo-controlled multicentre trial protocol and statistical analysis plan for PROSPECT. 2019 , 9, e025228	17
662	Dietary Support in Elderly Patients with Inflammatory Bowel Disease. 2019 , 11,	6
661	High frequency of toxigenic and coinfection among diarrheic patients at health care facility-onset (HCFO) and community-onset (CO) centers in Bogotá, Colombia. 2019 , 11, 27	3
660	Do antimicrobial stewardship programme interventions reduce the rate of and protect against Clostridium difficile infection?. 2019 , 17, 312-315	1
659	Risk factors and outcomes of Clostridium difficile infection in hospitalized patients. 2019 , 42, 99-106	10
658	Enterotoxigenic Clostridia: Infections. 2019 , 7,	4
657	Modelling diverse sources of Clostridium difficile in the community: importance of animals, infants and asymptomatic carriers. 2019 , 147, e152	10
656	Practice measures for controlling and preventing hospital associated Clostridium difficile infections. 2019 , 47, 123-129	2
655	Consensus on the prevention, diagnosis, and treatment of Clostridium difficile infection. 2019 , 84, 204-219	0
654	Management of colitis: insights for the gastroenterologist. 2019 , 12, 1756284819847651	13
653	Pancreatic disease patients are at higher risk for infection compared to those with other co-morbidities. 2019 , 11, 17	5
652	Seasonality and community interventions in a mathematical model of Clostridium difficile transmission. <i>Journal of Hospital Infection</i> , 2019 , 102, 157-164	6.9 3
651	Clostridium difficile Infection-Daily Symptoms (CDI-DaySymsâ) questionnaire: psychometric characteristics and responder thresholds. 2019 , 17, 77	3
650	Predictors of Clostridioides difficile recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings. 2019 , 76, 581-590	14
649	Whole-genome sequencing reveals nosocomial Clostridioides difficile transmission and a previously unsuspected epidemic scenario. 2019 , 9, 6959	14
648	Outcome of Electronic Order Alert Intervention Relative to Toxigenic Clostridium difficile PCR Analysis and Hospital-Onset C difficile Infection in a Multihospital Health Care System. 2019 , 151, 622-627	3
647	Antimicrobial consumption and bacterial resistance pattern in patients admitted in I.C.U at a tertiary care center. 2019 , 12, 695-699	7

646	Cutting Edge: Probiotics and Fecal Microbiota Transplantation in Immunomodulation. 2019 , 2019, 1603758	35
645	Fecal microbiota transplantation for severe complicated C. difficile colitis in a patient with acquired immunodeficiency syndrome. 2019 , 84, 110-112	0
644	New insights for vaccine development against Clostridium difficile infections. 2019 , 58, 73-79	7
643	Predictors of mortality and length of stay in patients with hospital-acquired Clostridioides difficile infection: a population-based study in Alberta, Canada. <i>Journal of Hospital Infection</i> , 2019 , 103, 85-91	6.9 5
642	Clinical practice guidelines for the provision of renal service in Hong Kong: Infection Control in Renal Service. 2019 , 24 Suppl 1, 98-129	
641	Clostridium Difficile Infection: The Effects of Acid Suppression Therapy in Patients With Cancer. 2019 , 23, 165-171	
640	An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial. 2019 , 19, 410-418	54
639	Proton-pump inhibitors and the risk of Clostridium difficile-associated diarrhea in high-risk antibiotics users: A population-based case-crossover study. 2019 , 28, 479-488	1
638	The epidemiology of Clostridioides difficile infection in Brazil: A systematic review covering thirty years. 2019 , 58, 13-21	10
637	The rise of Clostridioides difficile infections and fall of associated mortality in hospitalized advanced cirrhotics. 2019 , 39, 1263-1270	9
636	2019 update of the WSES guidelines for management of () infection in surgical patients. 2019 , 14, 8	59
635	Modified glove use for contact precautions: Health care workers' perceptions and acceptance. 2019 , 47, 938-944	2
634	Epidemiology of Clostridium difficile infection in hospitalized adults and the first isolation of C. difficile PCR ribotype 027 in central China. 2019 , 19, 232	14
633	Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease. 2019 , 25, 969-979	21
632	High delayed mortality after the first episode of Clostridium difficile infection. 2019 , 57, 93-98	2
631	Characteristics, risk factors and outcomes of Clostridium difficile infections in Greek Intensive Care Units. 2019 , 53, 73-78	2
630	Consensus on the prevention, diagnosis, and treatment of Clostridium difficile infection. 2019 , 84, 204-219	3
629	Laboratory Diagnosis of Infection in Korea: The First National Survey. 2019 , 39, 317-321	5

628	Vancomycin Enema in the Treatment of Infection. <i>Surgical Infections</i> , 2019 , 20, 311-316	2	2
627	Suppressive effect of <i>Lactobacillus fermentum</i> Lim2 on <i>Clostridioides difficile</i> 027 toxin production. 2019 , 68, 386-393		6
626	Vancomycin Versus Metronidazole for Nonsevere Infection: Are the Data Adequate to Change Practice?. 2019 , 53, 845-852		2
625	Effectiveness of a Two-Step Testing Algorithm for Reliable and Cost-Effective Detection of <i>Clostridium difficile</i> Infection in a Tertiary Care Hospital in Saudi Arabia. 2019 , 7,		2
624	Quantification of airborne dust, endotoxins, human pathogens and antibiotic and metal resistance genes in Eastern Canadian swine confinement buildings. 2019 , 35, 283-296		12
623	Interest of Eosinophil Count in Bacterial Infections to Predict Antimicrobial Therapy Efficacy-Reply. 2019 , 154, 464-465		
622	<i>Clostridium Difficile</i> Infections: Epidemiology, Diagnosis, and Treatment. 2019 , 284-305		1
621	Composition of gut microbiota in patients with toxigenic <i>Clostridioides (Clostridium) difficile</i> : Comparison between subgroups according to clinical criteria and toxin gene load. 2019 , 14, e0212626		17
620	Interest of Eosinophil Count in Bacterial Infections to Predict Antimicrobial Therapy Efficacy. 2019 , 154, 464		0
619	Quantitative Results of a National Intervention to Prevent <i>Clostridioides difficile</i> Infection: A Pre-Post Observational Study. 2019 , 171, S52-S58		4
618	Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 64,	5.9	8
617	Enterotoxigenic <i>Clostridia</i> : <i>Clostridioides difficile</i> Infections. 2019 , 991-1011		
616	Risk factors for <i>Clostridioides difficile</i> infection and colonization among patients admitted to an intensive care unit in Shanghai, China. 2019 , 19, 961		9
615	Battleground Zero: A Review of Best Practice Recommendations for <i>Clostridioides (Clostridium) difficile</i> Testing. 2019 , 41, 175-183		2
614	Efficacy of a stewardship intervention focused on reducing unnecessary use of non-antibiotics in patients with infection. <i>Infection Control and Hospital Epidemiology</i> , 2020 , 41, 216-218	2	1
613	Risk prediction for 30-day mortality among patients with infections: a retrospective cohort study. 2019 , 8, 175		5
612	Treatment of Severe and Fulminant <i>Clostridioides difficile</i> Infection. 2019 , 17, 524-533		4
611	Incidence Of Infection And Associated Risk Factors Among Hospitalized Children In Qatar. 2019 , 15, 1343-1350		2

610	Nonsteroidal Anti-Inflammatory Drugs Impact on the Outcomes of Hospitalized Patients with Infection. 2019 , 12, 449-456		3
609	Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Pediatric Inflammatory Bowel Disease. 2019 , 68, 343-347		10
608	Risk Factors for Recurrent Community-associated Clostridiodes Difficile Infection in Children. 2019 , 38, 1073-1078		6
607	Decreased Fecal Bacterial Diversity and Altered Microbiome in Children Colonized With Clostridium difficile. 2019 , 68, 502-508		8
606	Limitations of the Infectious Disease Society of America/Society for Hospital Epidemiologists of America 2017 Update of Guidelines for the Treatment of Clostridium Difficile Colitis. 2019 , 62, 1147-1149		
605	Antibiotic stewardship teams and practices in United States hospitals: A national survey in The Joint Commission antibiotic stewardship standard era. <i>Infection Control and Hospital Epidemiology</i> , 2020 , 41, 143-148	2	3
604	Healthcare facility associated Clostridium difficile infection. 2019 , 153, e61		
603	MELD is the only predictor of short-term mortality in cirrhotic patients with C. difficile infection. 2019 , 51, 275-280		7
602	Clostridium difficile Infection. 2019 , 277-281		
601	What Is the Role for Metronidazole in the Treatment of Clostridium difficile Infection? Results From a National Cohort Study of Veterans With Initial Mild Disease. 2019 , 69, 1288-1295		7
600	Effect of Psyllium Fiber Supplementation on Diarrhea Incidence in Enteral Tube-Fed Patients: A Prospective, Randomized, and Controlled Trial. 2019 , 43, 759-767		4
599	Why do clinicians order inappropriate Clostridium difficile testing? An exploratory study. 2019 , 47, 285-289		4
598	Healthcare-Associated Infections in Children. 2019 ,		1
597	Optimizing testing for Clostridium difficile infection: A quality improvement project. 2019 , 47, 340-342		9
596	Comparison of the 2010 and 2017 Infectious Diseases Society of America guidelines on the diagnosis and treatment of Clostridium difficile infection. 2019 , 35, 20-24		4
595	Simultaneous Detection of Glutamate Dehydrogenase and Toxin A/B: Comparison of the C. DIFF QUIK CHEK COMPLETE and RIDASCREEN Assays. 2019 , 39, 214-217		5
594	Risk factors for recurrent percutaneous nephrostomy catheter-related infections. 2019 , 47, 239-245		5
593	Surveillance and Prevention of Hospital-Acquired Infections. 2019 , 121-145		

592	Factors associated to Clostridium difficile infection in a hospital-based home care service. 2019 , 153, 319-322	
591	2,4-Disubstituted 5-Nitroimidazoles Potent against Clostridium difficile. 2019 , 14, 561-569	1
590	Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection. 2019 , 44, 220-228	8
589	Inhibition effect of flavophospholipol on conjugative transfer of the extended-spectrum β -lactamase and vanA genes. 2019 , 72, 79-85	10
588	A systematic review of the use of rifaximin for Clostridium difficile infections. 2019 , 55, 35-39	12
587	Reply to Letter on: 'Risk Factors Associated With Clostridium difficile Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis'. 2019 , 13, 536-537	
586	Bezlotoxumab use as adjunctive therapy with the third fecal microbiota transplant in refractory recurrent Clostridium difficile colitis; a case report and concise literature review. 2019 , 55, 112-116	6
585	Review of European and American guidelines for the diagnosis of Lyme borreliosis. 2019 , 49, 121-132	41
584	Management of adult Clostridium difficile digestive contaminations: a literature review. 2019 , 38, 209-231	7
583	Nosocomial Infections in Pediatric Solid Organ Transplantation. 2019 , 301-321	
582	Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections. 2019 , 1435, 110-138	24
581	Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. 2019 , 25, 610-619	11
580	Disinfection of noncritical equipment on units with high hospital-onset Clostridium difficile infections. 2019 , 47, 220-221	3
579	Successful treatment by fecal microbiota transplantation for Japanese patients with refractory Clostridium difficile infection: A prospective case series. 2019 , 52, 663-666	11
578	Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy. 2019 , 25, 520-528	2
577	Analysis of Treatment Outcomes for Recurrent Clostridium difficile Infections and Fecal Microbiota Transplantation in a Pediatric Hospital. 2019 , 38, 32-36	12
576	Fecal microbiota transplantation for severe complicated C. difficile colitis in a patient with acquired immunodeficiency syndrome. 2019 , 84, 110-112	3
575	Faecal microbiota transplantation for Clostridium difficile infection using a lyophilized inoculum from non-related donors: A case series involving 19 patients. 2019 , 66, 69-78	3

574 C. difficile Infection and Antibiotic Associated Diarrhea. **2020**, 404-417

573 Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of Recurrence. **2020**, 33, 633-639 10

572 Statin Effects on Incidence, Treatment Success, and Mortality of Clostridium difficile Infections. **2020**, 33, 497-505

571 Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults. **2020**, 182, 327-334 19

570 colitis in patients undergoing surgery for hip fractures: an analysis of 17,474 patients. **2020**, 30, 22-32 2

569 Preventing infection in hospitals: what is the endgame?. **2020**, 29, 157-160 2

568 Network analysis of intra-hospital transfers and hospital onset clostridium difficile infection. **2020**, 37, 26-34 4

567 Recent developments in the management of recurrent Clostridioides difficile infection. **2020**, 62, 102108 5

566 Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient. **2020**, 52, 27-30 13

565 Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci. **2020**, 71, 645-651 8

564 Predictors of Clostridioides difficile Infection Among Asymptomatic, Colonized Patients: A Retrospective Cohort Study. **2020**, 70, 2103-2210 9

563 Drivers of Clostridioides difficile hypervirulent ribotype 027 spore germination, vegetative cell growth and toxin production in vitro. **2020**, 26, 941.e1-941.e7 3

562 Burden of community-associated Clostridioides difficile infection in southeastern United States: a population-based study. **2020**, 48, 129-132 5

561 Healthcare facility-onset, healthcare facility-associated infection in Veterans with spinal cord injury and disorder. **2020**, 43, 642-652 1

560 Capsule Commentary on Novosad et al., Treatment of Clostridioides Difficile Infection and Non-compliance with Treatment Guidelines in Adults, 10 US Geographical Locations, 2013-2015. **2020**, 35, 618-619

559 Clostridium Difficile Infection in Long-Term Care Facilities. **2020**, 0

558 Fecal Microbiota Transplant Decreases Mortality in Patients with Refractory Severe or Fulminant Clostridioides difficile Infection. **2020**, 18, 2234-2243.e1 24

557 A Process Approach to Decreasing Hospital Onset Clostridium difficile Infections. **2020**, 46, 146-152 1

556	Faecal microbiota transplantation for recurrent <i>Clostridioides difficile</i> infection: experience with lyophilized oral capsules. <i>Journal of Hospital Infection</i> , 2020 , 105, 319-324	6.9	8
555	Association between statewide adoption of the CDC's Core Elements of Hospital Antimicrobial Stewardship Programs and rates of methicillin-resistant bacteremia and infection in the United States. <i>Infection Control and Hospital Epidemiology</i> , 2020 , 41, 430-437	2	4
554	infection in the Asia-Pacific region. 2020 , 9, 42-52		18
553	Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in <i>Clostridioides difficile</i> clinical isolates. 2020 , 75, 859-867		8
552	Advanced Practice and Leadership in Radiology Nursing. 2020 ,		
551	Incidence of and risk factors for recurrent <i>Clostridioides difficile</i> infection in Japan using a claims database: A retrospective cohort study. 2020 , 61, 102139		1
550	Infection in the Patient With Cancer. 2020 , 544-564.e6		2
549	Treatment of <i>Clostridioides difficile</i> Infection and Non-compliance with Treatment Guidelines in Adults in 10 US Geographical Locations, 2013-2015. 2020 , 35, 412-419		4
548	Evolving Strategies to Manage <i>Clostridium difficile</i> Colitis. 2020 , 24, 484-491		9
547	GABAergic but not Antidepressant Medications Increase Risk for Infection in a National Cohort of Veterans. 2020 , 7, ofaa353		0
546	Development and validation of a simple and robust model to predict 30-day mortality in patients with -associated enterocolitis. 2020 , 7,		
545	A passive monitoring tool using hospital administrative data enables earlier specific detection of healthcare-acquired infections. <i>Journal of Hospital Infection</i> , 2020 , 106, 562-569	6.9	2
544	infections in Saudi Arabia: Where are we standing?. 2020 , 28, 1118-1121		2
543	Risk of complications and mortality following recurrent and non-recurrent <i>Clostridioides difficile</i> infection: a retrospective observational database study in England. <i>Journal of Hospital Infection</i> , 2020 , 106, 793-803	6.9	3
542	The (p)ppGpp Synthetase RSH Mediates Stationary-Phase Onset and Antibiotic Stress Survival in <i>Clostridioides difficile</i> . 2020 , 202,		7
541	Clinical characteristics and prognostic factors of extraintestinal infection caused by <i>Clostridioides difficile</i> : analysis of 60 consecutive cases. 2020 , 39, 2133-2141		2
540	Faecal microbiota transplantation in <i>Clostridioides difficile</i> infection: real-life experience from an academic Italian hospital. 2020 , 13, 1756284820934315		5
539	Baseline Gut Microbiota Composition Is Associated with Major Infections Early after Hematopoietic Cell Transplantation. 2020 , 26, 2001-2010		6

538	Patient Outcomes With Prevented vs Negative Tests Using a Computerized Clinical Decision Support Tool. 2020 , 7, ofaa094	3
537	Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent <i>Clostridioides difficile</i> Infection. 2020 , 159, 1982-1984	15
536	Quantifying bacterial spore germination by single-cell impedance cytometry for assessment of host microbiota susceptibility to <i>Clostridioides difficile</i> infection. 2020 , 166, 112440	14
535	Review of high dose vancomycin in the treatment of infection. 2020 , 52, 847-857	0
534	Systems biology analysis of the <i>Clostridioides difficile</i> core-genome contextualizes microenvironmental evolutionary pressures leading to genotypic and phenotypic divergence. 2020 , 6, 31	9
533	Quantitative characterization of <i>Clostridioides difficile</i> population in the gut microbiome of patients with <i>C. difficile</i> infection and their association with clinical factors. 2020 , 10, 17608	2
532	Changes in blood biomarkers in Arabian horses with <i>Clostridium difficile</i> -induced enterocolitis. 2020 , 73, 101525	2
531	[Non-severe <i>Clostridioides difficile</i> Infection: Are the data adequate to give up metronidazole?]. 2020 , 58, 778-784	1
530	An Analysis of Environmental Contamination During and After Treatment for Infection. 2020 , 7, ofaa362	4
529	Changes in the Association Between Diagnostic Testing Method, Polymerase Chain Reaction Ribotype, and Clinical Outcomes From <i>Clostridioides difficile</i> Infection: One Institution's Experience. 2021 , 73, e2883-e2889	6
528	Molecular Epidemiology and Risk Factors of ST81 Infection in a Teaching Hospital in Eastern China. 2020 , 10, 578098	5
527	Are Antimotility Agents Safe for Use in Infections? Results From an Observational Study in Malignant Hematology Patients. 2020 , 4, 792-800	0
526	Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent <i>C. difficile</i> Infection. 2021 , 27, 1371-1378	14
525	Randomized Trial Evaluating Clinical Impact of RAPid IDentification and Susceptibility Testing for Gram-negative Bacteremia: RAPIDS-GN. 2021 , 73, e39-e46	18
524	Molecular characteristics of <i>Clostridium difficile</i> in children with acute gastroenteritis from Zhejiang. 2020 , 20, 343	4
523	The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI. 2020 , 1,	10
522	One Health approach to <i>Clostridioides difficile</i> in Japan. 2020 , 26, 643-650	0
521	Immune Profiling To Predict Outcome of <i>Clostridioides difficile</i> Infection. 2020 , 11,	10

520	Antibiotic Treatment Pipeline for <i>Clostridioides difficile</i> Infection (CDI): A Wide Array of Narrow-Spectrum Agents. 2020 , 22, 1	3
519	Hospital acquired <i>Clostridioides difficile</i> infection and risk factors for severity in a university hospital: A prospective study. 2020 , 48, 1426-1430	
518	Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of () Infection. 2020 , 7, ofaa157	4
517	ribotype distribution in a large teaching hospital in Serbia. 2020 , 12, 26	4
516	<i>Clostridium difficile</i> Infection Epidemiology over a Period of 8 YearsâA Single Centre Study. 2020 , 12, 4439	4
515	A Single-Center Experience and Literature Review of Management Strategies for Infection in Hematopoietic Stem Cell Transplant Patients. 2020 , 28, 10-15	2
514	Investigation of Intestinal Microbiota and Fecal Calprotectin in Non-Toxigenic and Toxigenic Colonization and Infection. <i>Microorganisms</i> , 2020 , 8,	4-9 2
513	Infection Prevention Quality Metrics. 2020 , 47-61	
512	Biological characteristics associated with virulence in ribotype 002 in Hong Kong. 2020 , 9, 631-638	2
511	Make Sure You Have a Safety Net: Updates in the Prevention and Management of Infectious Complications in Stem Cell Transplant Recipients. 2020 , 9,	4
510	Rapid Assessment of Inhibition by Probiotics Using Dielectrophoresis to Quantify Cell Structure Alterations. 2020 , 6, 1000-1007	10
509	Cost-effectiveness analysis of fidaxomicin for the treatment of <i>Clostridioides (Clostridium) difficile</i> infection in Japan. 2020 , 26, 611-618	1
508	<i>Clostridioides difficile</i> associated peritonitis in peritoneal dialysis patients - a case series based review of an under-recognized entity with therapeutic challenges. 2020 , 21, 76	1
507	Modeling inpatient and outpatient antibiotic stewardship interventions to reduce the burden of <i>Clostridioides difficile</i> infection in a regional healthcare network. 2020 , 15, e0234031	7
506	Ribotype Classification of Isolates Is Not Predictive of the Amino Acid Sequence Diversity of the Toxin Virulence Factors TcdA and TcdB. 2020 , 11, 1310	6
505	Microbiota-associated Risk Factors for <i>Clostridioides difficile</i> Acquisition in Hospitalized Patients: A Prospective, Multicentric Study. 2021 , 73, e2625-e2634	1
504	<i>Clostridioides difficile</i> infection evaluation and management in the emergency department. 2020 , 38, 2203-2208	0
503	High-Level Resistance of Toxigenic Genotype to Macrolide-Lincosamide- Streptogramin B in Community Acquired Patients in Eastern China. 2020 , 13, 171-181	3

502	Role of Surgery in Infection. 2020 , 33, 87-91	2
501	Heart Failure Is a Risk Factor for Suffering and Dying of Infection. Results of a 15-Year Nationwide Study in Spain. 2020 , 9,	4
500	Evaluating Adherence to Guideline-Directed Infection Management Pre- and Postimplementation of an Electronic Order Set. 2021 , 34, 721-726	3
499	Comparative Study of Clinical Detection Methods in Patients with Diarrhoea. 2020 , 2020, 8753284	4
498	Strategies to prevent adverse outcomes following infection in the elderly. 2020 , 18, 203-217	0
497	Infection: An Epidemiology Update. 2020 , 33, 49-57	20
496	The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases. 2020 , 12,	52
495	Detection of <i>C. difficile</i> toxin as a model assay for performing fully automated high-throughput RT-PCR on clinical stool samples. 2020 , 172, 105882	4
494	Excess length of hospital stay, mortality and cost attributable to () infection and recurrence: a nationwide analysis in Japan. 2020 , 148, e65	3
493	Postoperative Infection after Colorectal Surgery: Subanalysis of Data from the 2015 Japan Postoperative Infectious Complications Survey. 2020 , 87, 204-210	2
492	Recommendations and guidelines for the treatment of <i>Clostridioides difficile</i> infection in Taiwan. 2020 , 53, 191-208	4
491	Washer disinfectant and alkaline detergent efficacy against <i>C. difficile</i> on plastic bedpans. 2020 , 48, 761-764	
490	Environmental shedding of toxigenic <i>Clostridioides difficile</i> by asymptomatic carriers: A prospective observational study. 2020 , 26, 1052-1057	9
489	Economic impact of antimicrobial-resistant bacteria outbreaks on Japanese hospitals. 2020 , 48, 1195-1199	0
488	Recurrent community-acquired <i>Clostridium</i> (<i>Clostridioides</i>) <i>difficile</i> infection in Serbian children. 2020 , 39, 509-516	3
487	Proton Pump Inhibitors in the Elderly Hospitalized Patient: Evaluating Appropriate Use and Deprescribing. 2020 , 36, 54-60	1
486	Persistent Systemic Microbial Translocation, Inflammation, and Intestinal Damage During Infection. 2020 , 7, ofz507	6
485	A systematic review of economic evaluation in fecal microbiota transplantation. <i>Infection Control and Hospital Epidemiology</i> , 2020 , 41, 458-466	2 4

484	Structure of the cell-binding component of the binary toxin reveals a di-heptamer macromolecular assembly. 2020 , 117, 1049-1058	12
483	Pet Ownership Protects Against Recurrence of Infection. 2020 , 7, ofz541	4
482	Impact of the stress ulcer prophylactic protocol on reducing the unnecessary administration of stress ulcer medications and gastrointestinal bleeding: a single-center, retrospective pre-post study. 2020 , 8, 10	2
481	Evaluation of Addition of Intravenous Metronidazole to Oral Vancomycin Therapy in Critically Ill Patients with Non-Fulminant Severe <i>Clostridioides difficile</i> Infection. 2020 , 40, 398-407	4
480	Introduction of Group Electronic Monitoring of Hand Hygiene on Inpatient Units: A Multicenter Cluster Randomized Quality Improvement Study. 2020 , 71, e680-e685	9
479	Occurrence of in Patients with Infection. 2020 , 9,	6
478	Management of hospital-acquired infections among patients hospitalized at Zewditu memorial hospital, Addis Ababa, Ethiopia: A prospective cross-sectional study. 2020 , 15, e0231949	3
477	Incidence of <i>Clostridioides difficile</i> infection at a Saudi Tertiary Academic Medical Center and compliance with IDSA/SHEA, ACG, and ESCMID guidelines for treatment over a 10-year period. 2020 , 13, 1156-1160	4
476	Impact of Revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Clinical Practice Guidelines on the Treatment of <i>Clostridium difficile</i> Infections in the United States. 2021 , 72, 1944-1949	11
475	Impact of a <i>Clostridioides Difficile</i> Testing Computerized Clinical Decision Support Tool on an Adult Stem Cell Transplantation and Hematologic Malignancies Unit. 2021 , 27, 94.e1-94.e5	1
474	Chlorhexidine gluconate bathing in children with cancer or those undergoing hematopoietic stem cell transplantation: A double-blinded randomized controlled trial from the Children's Oncology Group. 2020 , 127, 56-66	7
473	A 2-step algorithm combining glutamate dehydrogenase and nucleic acid amplification tests for the detection of <i>Clostridioides difficile</i> in stool specimens. 2021 , 40, 345-351	0
472	Evolution of clinical guidelines for antimicrobial management of infection. 2021 , 14, 17562848211011953	1
471	<i>Clostridioides-difficile</i> -Infektion. 2021 , 179-183	
470	The Role of Vaccines in Combating Antimicrobial Resistance. 2021 , 347-430	3
469	Neurogenic Bowel: Dysfunction and Rehabilitation. 2021 , 407-430.e4	2
468	Clinical complications in patients with primary and recurrent infection: A real-world data analysis. 2021 , 9, 2050312120986733	5
467	Uncovering the Harms of Treating <i>Clostridioides difficile</i> Colonization. 2021 , 6,	

466	Economic burden of recurrent <i>Clostridioides difficile</i> infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study. 2021 , 34, 126-135		2
465	Proton-Pump Inhibitor Use and the Risk of Community-Associated <i>Clostridium difficile</i> Infection. 2021 , 72, e1084-e1089		7
464	Long term outcomes of Hospital-Identified <i>Clostridium Difficile</i> Infection (HICDI): A retrospective cohort analysis of adult patients in a teaching hospital. 2021 , 008-015		
463	<i>Clostridioides difficile</i> Infection in a Rural New Zealand Secondary Care Centre: An Incidence Case-Control Study. 2021 ,		
462	Real-time polymerase chain reaction (PCR) cycle threshold and infection outcomes. <i>Infection Control and Hospital Epidemiology</i> , 2021 , 42, 1228-1234	2	1
461	High Prevalence of Multidrug-Resistant Following Extensive Use of Antimicrobials in Hospitalized Patients in Kenya. 2020 , 10, 604986		5
460	Prevalence and phylogenetic relationship of <i>Clostridioides difficile</i> strains in fresh poultry meat samples processed in different cutting plants. 2021 , 339, 109032		6
459	Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against. <i>Microorganisms</i> , 2021 , 9,	4.9	3
458	Treatment of <i>Clostridium difficile</i> infection in community teaching hospital: a retrospective study. 2021 , 14, 19		0
457	Clinical characteristics associated with the severity of <i>Clostridium</i> [<i>Clostridioides</i>] <i>difficile</i> infection in a tertiary teaching hospital from Mexico.. 2021 ,		0
456	Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. 2021 , 9,		7
455	Assessment of the Effect of Multidrug Resistance <i>Clostridium difficile</i> Clinical Strains on the Dynamics of <i>Clostridium difficile</i> Infection Rate at Pediatric Oncological Hospital. 2021 , 20, 25-31		1
454	ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. 2021 , 15, 879-913		22
453	Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe <i>Clostridioides difficile</i> infection: a retrospective, observational, nationwide cohort study. 2021 , 57, 106282		4
452	Changes in Metronidazole and Vancomycin Utilization for Nonsevere <i>Clostridioides difficile</i> Infection Among Institutions Caring for Children. 2021 , 40, 634-636		1
451	Effect of oral vancomycin dose on outcomes in patients with <i>Clostridioides difficile</i> infection. 2021 , 57, 106311		
450	The Golden Hour: Sustainability and Clinical Outcomes of Adequate Time to Antibiotic Administration in Children with Cancer and Febrile Neutropenia in Northwestern Mexico. 2021 , 7, 659-670		2
449	Gut microbiota composition in health-care facility-and community-onset diarrheic patients with <i>Clostridioides difficile</i> infection. 2021 , 11, 10849		1

448	Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination with <i>Clostridioides difficile</i> . 2021 ,	4
447	ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of <i>Clostridioides difficile</i> Infections. 2021 , 116, 1124-1147	40
446	Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases. 2021 , 167-174	
445	Proton pump inhibitor use and risk for recurrent <i>Clostridioides difficile</i> infection: a systematic review and meta-analysis. 2021 ,	6
444	IL-16 and BCA-1 Serum Levels Are Associated with Disease Severity of Infection. 2021 , 10,	2
443	Class-specific relationship between use of immunosuppressants and risk for community-acquired <i>Clostridioides difficile</i> infection. 2021 ,	0
442	The Extremophilic Actinobacteria: From Microbes to Medicine. 2021 , 10,	9
441	Risk factors for development of initial <i>Clostridioides difficile</i> infection. 2021 , 25, 18-22	0
440	A prospective, observational study of fidaxomicin use for infection in France. 2021 , 49, 3000605211021278	2
439	Laboratory markers predictive of fulminant infection refractory to fluid resuscitation. 2021 , 3, 100127	
438	Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of <i>Clostridioides difficile</i> Infection in Adults. 2021 , 73, e1029-e1044	39
437	Genomic evolution and virulence association of sequence type 37 (ribotype 017) in China. 2021 , 10, 1331-1345	4
436	Prevalence and impact of antimicrobial resistance in gastrointestinal infections: A review. 2021 , 86, 265-275	2
435	Decreasing ICU-associated infection through fluoroquinolone restriction, the FIRST trial: a study protocol. 2021 , 11, e046480	1
434	An evaluation of toxigenic positivity as a patient outcome metric of antimicrobial stewardship in Saudi Arabia. 2021 , 22, 231-236	
433	Prevalencia e impacto de resistencias a antimicrobianos en infecciones gastrointestinales: una revisión. 2021 ,	0
432	Microbiological features, epidemiology, and clinical presentation of <i>Clostridioides difficile</i> strains from MLST Clade 2: A narrative review. 2021 , 69, 102355	4
431	Factors Associated with <i>Clostridioides</i> (<i>Clostridium</i>) <i>Difficile</i> Infection and Colonization: Ongoing Prospective Cohort Study in a French University Hospital. 2021 , 18,	2

430	Clostridioides difficile Diarrhea: An Emerging Problem in a South Indian Tertiary Care Hospital.. 2021 , 13, 346-352	0
429	Clostridioides difficile. 2021 , Publish Ahead of Print,	
428	Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Infection. 2021 , 8, ofab365	5
427	Protective Effect of Baicalin against Infection in Mice. 2021 , 10,	0
426	Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States. 2021 , 1	2
425	Prospective Multicenter Study of Chemotherapy-Induced (Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204. 2021 , 11, 685320	2
424	Management of Clostridioides difficile infection in patients with inflammatory bowel disease. 2021 , 19, 265-274	8
423	Changes in treatment of community-onset Clostridioides difficile infection after release of updated guidelines, Atlanta, Georgia, 2018. 2021 , 70, 102364	2
422	Antibiotic-associated diarrhea in hospital: frequency and prophylaxis. 2021 , 35-37	
421	Blockade of T helper 17 cell function ameliorates recurrent Clostridioides difficile infection in mice. 2021 , 53, 1290-1299	1
420	Pragmatic Strategy for Fecal Specimen Storage and the Corresponding Test Methods for Diagnosis. 2021 , 10,	
419	Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. 2021 , 73, 755-757	15
418	Effect of gastric acid suppression on Clostridioides difficile-induced diarrhea and appropriateness of gastric acid suppressors in hospitalized patients: A matched case-control study. 2021 ,	
417	The Risk of Infection in Cirrhotic Patients Receiving Norfloxacin for Secondary Prophylaxis of Spontaneous Bacterial Peritonitis-A Real Life Cohort. 2021 , 57,	0
416	Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial. 2021 , 326, 1024-1033	19
415	Ultrasensitive and quantitative toxin measurement correlates with baseline severity, severe outcomes, and recurrence among hospitalized patients with Clostridioides difficile infection. 2021 ,	1
414	Retrospective study of the efficacy and safety of metronidazole and vancomycin for Clostridioides difficile infection. 2021 , 27, 1407-1412	
413	Fecal host biomarkers predicting severity of Clostridioides difficile infection. 2021 , 6,	2





412	IL-27 induces LL-37/CRAMP expression from intestinal epithelial cells: implications for immunotherapy of infection. 2021 , 13, 1968258		1
411	Laboratory Tests in Older Adults: Indications, Interpretation, Issues. 2012 , 261-269		2
410	Glycopeptides, Lipopeptides, and Lipoglycopeptides. 2011 , 333-353		1
409	Infection Prevention and Control Issues After Solid Organ Transplantation. 2016 , 843-867		1
408	Specific GI Microbial Infections. 2016 , 75-109		1
407	Impact of superimposed <i>Clostridium difficile</i> infection in Crohn's or ulcerative colitis flares in the outpatient setting. 2018 , 33, 1285-1294		5
406	Adherence to clinical practice guidelines for the management of <i>Clostridium difficile</i> infection in Japan: a multicenter retrospective study. 2017 , 36, 1947-1953		14
405	Clostridial Infections. 2012 , e137-e143		1
404	Antimicrobial Agents. 2012 , 1453-1484.e5		7
403	Update on Treatment of <i>Clostridioides difficile</i> Infection. 2020 , 95, 758-769		17
402	Catheter-Associated Urinary Tract Infection, <i>Clostridioides difficile</i> Colitis, Central Line-Associated Bloodstream Infection, and Methicillin-Resistant <i>Staphylococcus aureus</i> . 2020 , 104, 663-679		6
401	Effect of testing methods on incidence of infection rates in Veterans' Affairs medical centers. <i>Infection Control and Hospital Epidemiology</i> , 2021 , 42, 461-463	2	2
400	Validation of the SHEA/IDSA severity criteria to predict poor outcomes among inpatients and outpatients with infection. <i>Infection Control and Hospital Epidemiology</i> , 2020 , 41, 510-516	2	3
399	Effects of defined gut microbial ecosystem components on virulence determinants of <i>Clostridioides difficile</i> . 2019 , 9, 885		12
398	Functional analysis of sortase B reveals key residues for catalytic activity and substrate specificity. 2020 , 295, 3734-3745		3
397	Assessment of Kidney Injury as a Severity Criteria for Infection. 2020 , 7, ofaa476		4
396	Cost-Effectiveness Analysis of Probiotic Use to Prevent Infection in Hospitalized Adults Receiving Antibiotics. 2017 , 4, ofx148		9
395	<i>Clostridium difficile</i> in paediatric populations. 2014 , 19, 43-48		4

394	Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. 2021 , 55, 43-51	4
393	Norovirus and Clostridium difficile outbreaks: squelching the wildfire. 2017 , 30, 440-447	3
392	Non-inferiority of pulsed xenon UV light versus bleach for reducing environmental Clostridium difficile contamination on high-touch surfaces in Clostridium difficile infection isolation rooms. 2015 , 64, 191-194	38
391	Non-inferiority of pulsed xenon UV light versus bleach for reducing environmental Clostridium difficile contamination on high-touch surfaces in Clostridium difficile infection isolation rooms. 2015 , 64, 191-4	16
390	A comparison of diagnostic methods for identification of local strains in a South African centre. 2016 , 65, 320-327	16
389	Clostridium difficile infections in a university hospital in Greece are mainly associated with PCR ribotypes 017 and 126. 2017 , 66, 1774-1781	5
388	Clostridium difficile shows no trade-off between toxin and spore production within the human host. 2018 , 67, 631-640	5
387	Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters. 2013 , 62, 1394-1404	25
386	Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses. 2013 , 62, 1453-1460	49
385	Designing fecal microbiota transplant trials that account for differences in donor stool efficacy.	0
384	Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium difficile Patients With and Without IBD.	2
383	Acute kidney injury impact on inpatient mortality in Clostridium difficile infection: A national propensity-matched study. 2018 , 33, 1227-1233	10
382	Antibacterial Agents. 1169-1211	2
381	Selected Topics in Anaerobic Bacteriology. 493-535	1
380	Enteral vancomycin and probiotic use for methicillin-resistant Staphylococcus aureus antibiotic-associated diarrhoea. 2012 , 2012,	8
379	Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection. 2011 , 2011,	4
378	Clinical impact of a pharmacist-led antimicrobial stewardship initiative evaluating patients with colitis. 2020 , 68, 888-892	4
377	Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey. 2020 , 4, 14	9

376	Reduced <i>Clostridioides difficile</i> Tests Among Solid Organ Transplant Recipients Through a Diagnostic Stewardship Bundled Intervention. 2019 , 24, 304-311	12
375	Recent Advances in the Diagnosis and Treatment of <i>Clostridium Difficile</i> Infection. 2016 , 5,	8
374	Rendered Speechless. 2017 , 12, 352-355	0
373	Days of Therapy Avoided: A Novel Method for Measuring the Impact of an Antimicrobial Stewardship Program to Stop Antibiotics. 2018 , 13, 326-327	2
372	Next Steps in Improving Healthcare Value: AHRQ Evidence-based Practice Center Program-Applying the Knowledge to Practice to Data Cycle to Strengthen the Value of Patient Care. 2019 , 14, 311-314	2
371	Analysis of Clinical Characteristics and Risk Factors to Neurosurgical Patients with <i>Clostridium Difficile</i> -Associated Diarrhea. 2011 , 7, 92	2
370	Quantitative Fecal Lactoferrin as a Biomarker for Severe Infection in Hospitalized Patients. 2014 , 2, 3	6
369	Characterisation of <i>Clostridium difficile</i> hospital ward-based transmission using extensive epidemiological data and molecular typing. 2012 , 9, e1001172	172
368	Surveillance for <i>Clostridium difficile</i> infection: ICD-9 coding has poor sensitivity compared to laboratory diagnosis in hospital patients, Singapore. 2011 , 6, e15603	29
367	Reconsidering the sporulation characteristics of hypervirulent <i>Clostridium difficile</i> BI/NAP1/027. 2011 , 6, e24894	73
366	Prediction tools for unfavourable outcomes in <i>Clostridium difficile</i> infection: a systematic review. 2012 , 7, e30258	59
365	Characterization of a stable, metronidazole-resistant <i>Clostridium difficile</i> clinical isolate. 2013 , 8, e53757	57
364	Procalcitonin levels associate with severity of <i>Clostridium difficile</i> infection. 2013 , 8, e58265	32
363	Novel strategies for enhanced removal of persistent <i>Bacillus anthracis</i> surrogates and <i>Clostridium difficile</i> spores from skin. 2013 , 8, e68706	14
362	Outpatient healthcare settings and transmission of <i>Clostridium difficile</i> . 2013 , 8, e70175	32
361	Fate of ingested <i>Clostridium difficile</i> spores in mice. 2013 , 8, e72620	14
360	Molecular epidemiology of <i>Clostridium difficile</i> at a medical center in Taiwan: persistence of genetically clustering of A?B+ isolates and increase of A+B+ isolates. 2013 , 8, e75471	21
359	Asymptomatic <i>Clostridium difficile</i> colonisation and onward transmission. 2013 , 8, e78445	90

358	A simulation-based assessment of strategies to control Clostridium difficile transmission and infection. 2013 , 8, e80671	33
357	Early Clostridium difficile infection during allogeneic hematopoietic stem cell transplantation. 2014 , 9, e90158	60
356	The systemic inflammatory response to Clostridium difficile infection. 2014 , 9, e92578	36
355	Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. 2014 , 9, e98400	199
354	A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection. 2015 , 10, e0123405	38
353	Identification of toxemia in patients with Clostridium difficile infection. 2015 , 10, e0124235	24
352	Efficacy and Safety of Metronidazole Monotherapy versus Vancomycin Monotherapy or Combination Therapy in Patients with Clostridium difficile Infection: A Systematic Review and Meta-Analysis. 2015 , 10, e0137252	20
351	Identification of Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population Attributable Risk Analysis. 2016 , 11, e0146822	21
350	Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection. 2016 , 11, e0149521	45
349	Impact of a Prospective Audit and Feedback Antimicrobial Stewardship Program at a Veterans Affairs Medical Center: A Six-Point Assessment. 2016 , 11, e0150795	26
348	Isolation of C. difficile Carriers Alone and as Part of a Bundle Approach for the Prevention of Clostridium difficile Infection (CDI): A Mathematical Model Based on Clinical Study Data. 2016 , 11, e0156577	27
347	Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model. 2016 , 11, e0157970	13
346	Comparison of Diagnostic Algorithms for Detecting Toxigenic Clostridium difficile in Routine Practice at a Tertiary Referral Hospital in Korea. 2016 , 11, e0161139	14
345	Surveillance of Antibiotic Resistance among Hospital- and Community-Acquired Toxigenic Clostridium difficile Isolates over 5-Year Period in Kuwait. 2016 , 11, e0161411	14
344	The Association between GABA-Modulators and Clostridium difficile Infection - A Matched Retrospective Case-Control Study. 2017 , 12, e0169386	2
343	A mathematical model of Clostridium difficile transmission in medical wards and a cost-effectiveness analysis comparing different strategies for laboratory diagnosis and patient isolation. 2017 , 12, e0171327	4
342	Microbicidal effects of weakly acidified chlorous acid water against feline calicivirus and Clostridium difficile spores under protein-rich conditions. 2017 , 12, e0176718	11
341	National epidemiology of initial and recurrent Clostridium difficile infection in the Veterans Health Administration from 2003 to 2014. 2017 , 12, e0189227	27

- 340 Serum-Derived Bovine Immunoglobulin as Novel Adjunct in Complicated Colitis Treatment. **2017**, 4, e64 1
- 339 Early Colectomy Saves Lives in Toxic Megacolon Due to Infection. **2020**, 113, 345-349 6
- 338 Lack of Association Between the Clinical Outcome of Infection and Current Steroids Use. **2017**, 10, 116-119 2
- 337 Clostridium Difficile Infection Complicated By Toxic Megacolon In Immunocompetent Patient. **2017**, 23, 39-46 1
- 336 Experiences with fecal microbiota transplantation in infections via upper gastrointestinal tract. **2019**, 66, 179-188 4
- 335 [Clostridium difficile infection: epidemiology, disease burden and therapy]. **2013**, 154, 1188-93 1
- 334 Clostridium difficile and cytomegalovirus colitis coinfection after bariatric surgery: case report. **2013**, 26 Suppl 1, 85-7 1
- 333 Recent changes in Clostridium difficile infection. **2012**, 10, 105-9 16
- 332 [Place of probiotics in the prevention and treatment of antibiotic-associated diarrhea]. **2015**, 87, 127-131 2
- 331 Initial experience with fecal microbiota transplantation in Clostridium difficile infection - transplant protocol and preliminary results. **2015**, 107, 402-7 13
- 330 Characteristics of Clostridium difficile infection in patients with discordant diagnostic test results. **2016**, 108, 304-8 5
- 329 Clostridium difficile colonization in preoperative colorectal cancer patients. **2017**, 8, 11877-11886 17
- 328 Clostridium Difficile Infection in Inflammatory Bowel Disease Patients. **2019**, 19, 929-935 2
- 327 A High Throughput Assay for Discovery of Bacterial β Glucuronidase Inhibitors. **2011**, 5, 13-20 15
- 326 Optimizing Telehealth Experience Design Through Usability Testing in Hispanic American and African American Patient Populations: Observational Study. **2020**, 7, e16004 4
- 325 Characterization of Strains Isolated from Patients with -associated Disease in Korea. **2017**, 8, 325-331 1
- 324 Appearance of Clostridium difficile infections in health care institutions in Slovakia and in the district of martin. **2018**, 18, 5-12 1
- 323 Interaction between gut microbiota and host immune cells. **2015**, 35, 140-147 1

322	Survey of Clostridium difficile infection surveillance systems in Europe, 2011. 2016 , 21,		12
321	Emergence and spread of predominantly community-onset Clostridium difficile PCR ribotype 244 infection in Australia, 2010 to 2012. 2015 , 20, 21059		51
320	The COVID-19 Lockdown Trap, How do we get out?. 2020 , 11, em00752		1
319	Application of an objective structured clinical examination to evaluate and monitor intern's proficiency of hand hygiene and personal protective equipment use in the United States. 2019 , 16, 31		4
318	 -  -  -  - CLOSTRIDIUM DIFFICILE (CDI). 2018 , 7-23		8
317	Clostridium difficile—a moving target. 2011 , 3, 6		10
316	Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland. 2014 , 2, 192-206		2
315	Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR). 2020 , 33, 151-175		7
314	Clostridium difficile infection in the community: are proton pump inhibitors to blame?. <i>World Journal of Gastroenterology</i> , 2013 , 19, 6710-3	5.6	7
313	Predictors of Clostridium difficile infection severity in patients hospitalised in medical intensive care. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8034-41	5.6	23
312	Clostridium difficile-associated disease: adherence with current guidelines at a tertiary medical center. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8647-51	5.6	14
311	Hematologic diseases: high risk of Clostridium difficile associated diarrhea. <i>World Journal of Gastroenterology</i> , 2014 , 20, 6602-7	5.6	10
310	Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe. <i>World Journal of Gastroenterology</i> , 2015 , 21, 6728-35	5.6	27
309	Use of rifaximin in gastrointestinal and liver diseases. <i>World Journal of Gastroenterology</i> , 2016 , 22, 6638-51	5.6	28
308	Management of inflammatory bowel disease with infection. <i>World Journal of Gastroenterology</i> , 2017 , 23, 4986-5003	5.6	33
307	Current knowledge on the laboratory diagnosis of infection. <i>World Journal of Gastroenterology</i> , 2017 , 23, 1552-1567	5.6	40
306	Risk Factors for Relapse and Mortality of Clostridium Difficile-Associated Diarrhea. 2014 , 2, 249-252		0
305	Advanced chronic kidney disease: a strong risk factor for Clostridium difficile infection. 2016 , 31, 125-33		22

304	Two Cases of Refractory Pseudomembranous Colitis that Healed Following Fecal Microbiota Transplantation. 2013 , 84, 395		7
303	A case of fulminant <i>Clostridium difficile</i> infection complicated with toxic megacolon. 2012 , 19, 638-643		4
302	Clinical Guideline for the Diagnosis and Treatment of Gastrointestinal Infections. <i>Infection and Chemotherapy</i> , 2010 , 42, 323	3.9	12
301	Current epidemiology and treatment of <i>Clostridium difficile</i> infection. <i>Infection and Chemotherapy</i> , 2010 , 42, 362	3.9	5
300	Cadazolid: A new hope in the treatment of <i>Clostridium difficile</i> infection. 2015 , 8, 253-62		20
299	Fidaxomicin--the new drug for <i>Clostridium difficile</i> infection. 2015 , 141, 398-407		14
298	<i>Clostridium Difficile</i> Infection and Takotsubo Cardiomyopathy: Is There a Relation?. 2016 , 8, 316-9		3
297	Toxigenic isolates from clinically significant diarrhoea in patients from a tertiary care centre. 2017 , 145, 840-846		10
296	Early Results of Fecal Microbial Transplantation Protocol Implementation at a Community-based University Hospital. 2018 , 10, 47-57		12
295	Use of culture- and ELISA-based toxin assay for detecting , a neglected pathogen: A single-center study from a tertiary care setting. 2017 , 9, 254-259		3
294	Detection of antigen and toxin in stool specimens: Comparison of the quik chek complete enzyme immunoassay and GeneXpert polymerase chain reaction assay. 2017 , 23, 259-262		14
293	Reducing hospital inpatient complications: A four year experience. 2013 , 04, 118-125		1
292	Surveillance for Antibiotic Resistance in <i>Clostridium difficile</i> Strains Isolated from Patients in a Tertiary Care Center. 2015 , 05, 336-345		4
291	Current status of surgical treatment for fulminant <i>clostridium difficile</i> colitis. 2013 , 5, 167-72		13
290	The Recent Emergence of Infection in Romanian Hospitals is Associated with a High Prevalence of Polymerase Chain Reaction Ribotype 027. 2018 , 35, 191-195		5
289	What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?. 2016 , 7, 387-96		6
288	Video Surveillance of Hand Hygiene: A Better Tool for Monitoring and Ensuring Hand Hygiene Adherence. 2019 , 23, 224-226		3
287	Recurrent Infection: Risk Factors, Treatment, and Prevention. 2019 , 13, 16-24		38

286	Diagnostic accuracy of loop-mediated isothermal amplification in detection of Clostridium difficile in stool samples: a meta-analysis. 2015 , 11, 927-36	8
285	Antimicrobial stewardship program implementation in a medical intensive care unit at a tertiary care hospital in Saudi Arabia. 2013 , 33, 547-54	28
284	A Diagnostic Algorithm for the Detection of Clostridium difficile-Associated Diarrhea. 2016 , 33, 80-6	20
283	Clostridium difficile Infection: What's New?. 2013 , 11, 1	8
282	Long-Term Clinical Outcome of Clostridium difficile Infection in Hospitalized Patients: A Single Center Study. 2014 , 12, 299-305	17
281	Refractory pseudomembranous colitis that was treated successfully with colonoscopic fecal microbial transplantation. 2016 , 14, 83-8	6
280	Management of inflammatory bowel disease in older persons: evolving paradigms. 2018 , 16, 194-208	15
279	Characteristics of infection in patients hospitalized with myelodysplastic syndrome or acute myelogenous leukemia. 2017 , 8, 398-404	8
278	Clostridium difficile infection outbreak in a male rehabilitation ward, Hong Kong Special Administrative Region (China), 2011. 2012 , 3, 59-60	5
277	A Prospective Pilot Study on the Systemic Absorption of Oral Vancomycin in Children With Colitis. 2016 , 21, 426-431	6
276	An Updated Review of Clostridium difficile Treatment in Pediatrics. 2019 , 24, 90-98	2
275	A Tiered Approach for Preventing Clostridioides difficile Infection. 2019 , 171, S45-S51	6
274	Applying fecal microbiota transplantation (FMT) to treat recurrent infections (rCDI) in children. 2018 , 6, e4663	15
273	infection after cardiac surgery: Assessment of prevalence, risk factors and clinical outcomes-retrospective study. 2020 , 8, e9972	2
272	Evaluation of Antibiotic Prophylaxis and Discharge Prescriptions in the General Surgery Department. 2019 , 11, e4793	4
271	Predicting the Risk of Clostridium difficile Infection upon Admission: A Score to Identify Patients for Antimicrobial Stewardship Efforts. 2016 , 20, 20-5	16
270	Nagging Presence of Associated Diarrhoea in North India. 2017 , 11, DC06-DC09	5
269	A superior test for diagnosis of Clostridium difficile-associated diarrhea in resource-limited settings. 2012 , 65, 326-9	11

- 268 Faecal transplantation and Clostridioides difficile infection. **2021**, 52, 215-223
- 267 Defining the black box: a narrative review of factors associated with adverse outcomes from severe infection. **2021**, 14, 17562848211048127 1
- 266 Bowel Dysfunction and Gastrointestinal Complications. **2021**, 429-449
- 265 Medicare Prescription Plans Limit Access to Recommended Drugs for Clostridioides difficile Infection. **2021**, 0
- 264 European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. **2021**, 32
- 263 Infliximab Rescue in Acute Severe Ulcerative Colitis Complicated by Clostridium Difficile Infection: A Case Series. **2021**, 13, e19019
- 262 Contribution of Medical Wards Contamination to Wound Infection among Patients Attending Ruhengeri Referral Hospital. **2021**, 2021, 7838763 0
- 261 Ontogeny and function of the circadian clock in intestinal organoids. **2021**, e106973 5
- 260 Clostridium difficile?????????????????????. **2010**, 25, 272-276
- 259 Clostridium difficile Colitis. **2011**, 1105-1107
- 258 Clostridium difficile ?????????? Vancomycin ??????????????????????????????. **2011**, 26, 149-153
- 257 Therapie mit Antiinfektiva. **2011**, 371-389
- 256 Metronidazole and Other Antibiotics for Anaerobic Infections. **2011**, 961-965
- 255 Neutropenic Enterocolitis and Clostridium difficile Infections. **2011**, 181-188
- 254 Clostridium difficile Infection. **2011**, 994-995.e1
- 253 Spezielle nosokomiale Infektionen auf der Intensivstation. **2012**, 141-297 1
- 252 On the occasion of the 4th congress of infectiologists of bosnia and herzegovina with international participation. **2012**, 24, 20-31
- 251 Approach to the Diagnosis and Management of Gastrointestinal Tract Infections. **2012**, 372-377.e4

- 250 A case of fulminant clostridium difficile infection following colectomy for descending colon cancer. **2012**, 73, 1465-1471 1
- 249 Clostridium difficile-Associated Diseases. **2012**, 519-526
- 248 Infections in Children with Cancer. **2012**, 573-579.e3
- 247 Clostridium difficile. **2012**, 977-979.e2
- 246 Rifaximin: Clostridium difficile Infection (Recurrent). **2012**, 47, 106-109
- 245 Classification of Inflammatory Bowel Disease in Children. **2013**, 147-157 0
- 244 H. **2013**, 447-566
- 243 Allergy. **2013**, 304-319
- 242 Surgery in the Immunocompromised Patient. **2013**, 2262-2272
- 241 Gastrointestinal Disease. **2013**, 169-184
- 240 Recent new drug approvals, part 2: drugs undergoing active clinical studies in children. **2013**, 18, 14-38 6
- 239 Overview of Clostridium difficile Infection as an Emerging Health Care Facility-Acquired Infection. **2013**, 48, S1-S6
- 238 Update on Management of Clostridium difficile Infection. **2013**, 48, S7-S13
- 237 [Antimicrobial therapy of Clostridium difficile infection. Systematic review and meta-analysis of the scientific evidence]. **2013**, 154, 890-9 0
- 236 Conventional therapeutics for Clostridium difficile infection. **2013**, 94-108
- 235 Successful Fecal Transplantation by Enema for Recurrent and Refractory Clostridium difficile Infection. **2013**, 17, 152-156 3
- 234 Care and Prevention of Infection. **2014**, 73-90
- 233 Probiotics for Gastrointestinal Diseases. **2013**, 308-324

- 232 Le Clostridium difficile dans les populations d'âge pédiatrique. **2014**, 19, 49-54
- 231 Gastrointestinal Complications. **2014**, 105-134
- 230 Infection in the Patient with Cancer. **2014**, 562-580.e5
- 229 Interpretation of Quick Test Results in Clostridium difficile Infection. **2014**, 29, 203-206 1
- 228 Severe Clostridium difficile infection. **2014**, 217-226
- 227 Fever in Acute and Critical Care. **2014**, 25, 237-248 1
- 226 Hospital Acquired Infections and Their Prevention. **2015**, 213-257
- 225 Nosokomiale Infektionen – Epidemiologie, Diagnostik, Therapie und Prävention. **2015**, 949-970
- 224 Clostridium-difficile-assoziierte Diarrhöe **2015**, 1-3
- 223 Infectious Complications. **2015**, 201-222
- 222 Appendix C. Case Study Answer Keys. **2015**,
- 221 State of Perineal Cleansing Assessed as Infection Control – National Wide Survey Regarding Perineal Cleansing and Diaper Change in Health Care Settings and Nursing Care Homes – **2015**, 30, 117-126 1
- 220 Chapter 33. Infectious Disease. **2015**,
- 219 Clostridium difficile Infection. **2015**, 2744-2756.e3 2
- 218 Nosokomiale Infektionen auf der Intensivstation. **2015**, 1-38
- 217 A Case of Successful Partial Colectomy for Severe C. Difficile-associated Disease. **2015**, 76, 2740-2744 1
- 216 Bacterial Inflammatory Enteritides. **2015**, 1263-1269.e3 0
- 215 Is Clostridium difficile-associated enterocolitis in pediatric hematology/oncology a solved problem? A review of literature and the authors' experience. **2015**, 25-31 1

214 GUT in FOCUS Symposium NOBEL FORUM, Karolinska Institutet, February 2nd 2015. **2015**, 26, 28480

213 Feces transplantation for recurrent Clostridium difficile infection: US experience and recommendations. **2015**, 26, 27657 5

212 Bacterial, Viral, and Toxic Causes of Diarrhea, Gastroenteritis, and Anorectal Infections. 1196-1248

211 Erregerbezogene Epidemiologie und Prävention nosokomialer Infektionen. **2016**, 163-284

210 Role of Clostridium difficile Toxins in Antibiotic-Associated Diarrhea and Pseudomembranous Colitis. **2016**, 1-18 0

209 Clostridium difficile as a Pathogen Involved in Antimicrobial Agent-Associated Diarrhea, Colitis, and Pseudomembranous Colitis. 4.15.1-4.15.7

208 JAID/JSC ??????????2015 ??????2016, 90, 31-65 5

207 A case of community-acquired fulminant Clostridium difficile colitis in a patient with end-stage renal disease. **2016**, 49, 539-546

206 Clostridium difficile Infection. 265-294 1

205 Pseudomembranous Colitis following Cesarean Delivery with Adjunctive Intracolonic Vancomycin. **2016**, 2, 055-060

204 There is a trend favoring vancomycin vs. metronidazole in treating severe C. difficile infection. **2016**, 2,

203 The Immunosuppressed Patient. **2017**, 267-303

202 CREST - Risk Prediction for Clostridium Difficile Infection Using Multimodal Data Mining. **2017**, 52-63 4

201 Infliximab use in ulcerative colitis flare with clostridium difficile infection: A report of two cases and literature review. **2018**, 5, 256-260

200 Healthcare-Associated Infections in Surgical Practice. **2017**, 449-460 0

199 Infectious Diarrhoeas in the Elderly. **2017**, 1-8

198 Fulminant Clostridium difficile Colitis Successfully Treated by Left Hemicolectomy. **2017**, 50, 401-408 2

197 Nutrition, Antibiotics, and Post-traumatic Seizure Prophylaxis. **2017**, 239-246

- 196 Infectious Complications of Pediatric Inflammatory Bowel Disease. **2017**, 605-614
- 195 Healthcare-Associated Infections in Pediatric Hematology-Oncology. **2017**, 183-204
- 194 Diagnosis and Management of Clostridium Difficile Infection (CDI). **2017**, 569-573
- 193 The First Evidence of Epidemic Strain Clostridium Difficile (027/NAP1/BI) in Eastern Croatia. 014-016
- 192 RISK FACTORS FOR DIARRHEA ASSOCIATED WITH CLOSTRIDIUM DIFFICILE, IN COLOPROCTOLOGICAL PATIENTS (review). **2017**, 59-67 4
- 191 A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-associated Diarrhea (CDAD) in Medical Intensive Care Unit (MICU). **2017**, 27, 77-82 0
- 190 CLOSTRIDIUM DIFFICILE INFECTION: CLINIC, DIAGNOSTICS AND TREATMENT (review). **2017**, 80-88
- 189 An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection. **2017**, 12, e0182815
- 188 Clostridium difficile Infection: Considerations in the Geriatric Population. **2018**, 291-297
- 187 Clostridium difficile in the ICU.
- 186 Removal of metronidazole from aqueous solution using activated carbon. **2017**, 8, 310-313 0
- 185 Prosthetic Joint Infection: Prevention Update. **2018**, 193-246
- 184 The Importance of C. difficile Colonization in Infection Prevention. **2018**, 251-256
- 183 Chapter 33: Infectious Diseases. **2017**,
- 182 Antibiotic and Antifungal Therapy in the ICU. **2018**, 373-389 1
- 181 Clostridium-difficile-Infektion. **2018**, 392-395
- 180 The role of probiotics and synbiotics in diarrhea associated to antibiotic treatment. **2018**, 3, 27
- 179 Medication-Related Problems in Surgical Patients. **2018**, 1-29

- 178 Review of updated clinical practice guidelines of the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) for Clostridium difficile infection in adults and children (2017). **2018**, 20, 76-124 1
- 177 Duration and Recurrence Rate of Vancomycin Powder, Metronidazole Tablets and Injections in the Treatment of Clostridium Difficile Associated Diarrhea. **2018**, 44, 90-93
- 176 Management of Recurrent Clostridium difficile Infection During Intensive Chemotherapy and Stem Cell Transplantation for Leukemia: Case with Literature Review. **2018**, 10, e2413
- 175 Diarreia causada por Clostridium difficile: recentes avanços. **2018**, 43, 155-161
- 174 A Study on the Prevention of Healthcare Associated Infection in Chest PA Projection of Contact Infected Patients. **2018**, 41, 297-304
- 173 Drug Use Evaluation of Clostridium difficile Infection in Elderly Patients and Risk Factors of Non-improving Group. **2018**, 28, 174-180
- 172 Rapid Assays for Detection of Clostridium difficile and Its Toxins in Hospitalized Patients. **2018**, 12, 1247-1254
- 171 Clostridium difficile in ulcerative colitis; a retrospective study. **2018**, 46, 474-481
- 170 infection: Is there a change in the underlying factors? Inflammatory bowel disease and. **2019**, 25, 384-389 1
- 169 Neurogenic Bowel Dysfunction and Gastrointestinal Problems. **2019**, 337-355
- 168 Clostridioides difficile: An Overview of Current Diagnostic and Infection Prevention Modalities. **2019**, 2, 61-64
- 167 Infection with Clostridium difficile from the family doctor perspective. **2019**, 1, 40
- 166 Clostridium-difficile-Infektion. **2019**, 224-227
- 165 Nanofibers and Biofilm in Materials Science. **2019**, 389-408
- 164 Cerebrospinal Fluid Presepsin as a Marker of Nosocomial Infections of Central Nervous System. **2019**, 8, 18-29
- 163 Optimizing Telehealth Experience Design Through Usability Testing in Hispanic American and African American Patient Populations: Observational Study (Preprint).
- 162 The clinical drug candidate ebselen attenuates inflammation and promotes microbiome recovery after antibiotic treatment for Clostridium difficile infection.
- 161 Structure of the cell-binding component of the Clostridium difficile binary toxin reveals a novel macromolecular assembly.

- 160 A case report of successful management of fulminant *Clostridium difficile* colitis post-ileostomy reversal with administration of vancomycin through a transverse colostomy. **2019**, 5, 181
- 159 Introduction. **2020**, 1-6
- 158 The protocol of empirical antimicrobial therapy of the inpatient hospital of the National Medical and Surgical Center n. a. N. I. Pirogov (fourth edition, 2018). **2019**, 1, 58-71 1
- 157 Prevalence, Characterization and Inhibition by Probiotics of Multidrug Resistant Bacteria Isolated from Renal Failure Patients Undergoing Hemodialysis. **2019**, 20, 1-12
- 156 Infection Prevention in Radiology. **2020**, 129-139
- 155 Healthcare facility associated *Clostridium difficile* infection. **2019**, 153, e61
- 154 Medication-Related Problems in Surgical Patients. **2020**, 159-187
- 153 Molecular Characterization and Diagnosis of Nosocomial *Clostridium difficile* Infection in Hospitalized Patients. **2020**, 15,
- 152 Assessment of the Management of Diarrhoea Among Children Under Five in Addis Ababa, Ethiopia. **2020**, 11, 135-143 2
- 151 Integrating Gut Microbiota and Host Immune Markers for Highly Accurate Diagnosis of *Clostridioides difficile* Infection.
- 150 The Face of Infections in the Outpatient Setting. **2020**, 5, 12883
- 149 Hematolojik Malignansili Hastalarda Geliġn Diyare Olgularında *Clostridium difficile* Toksinlerinin Araġtırılması. **2020**,
- 148 Fecal Microbiota Transplantation in Recurrent *Clostridium Difficile* Infection: Is it Superior to Other Conventional Methods?. **2020**, 12, e9653 1
- 147 Inhibition of *Clostridium difficile* TcdA and TcdB toxins with transition state analogues. **2021**, 12, 6285 2
- 146 Environmental shedding of toxigenic *Clostridioides difficile* by asymptomatic carriers: A prospective observational study.
- 145 A preliminary study of bowel rest strategy in the management of *Clostridioides difficile* infection. **2020**, 10, 22061 1
- 144 Uncommon Case of Oral Vancomycin Neurotoxicity With Sexual Dysfunction. **2020**, 12, e12396
- 143 ERKRANKUNGEN DER VERDAUUNGSORGANE. **2020**, pA-1-pA7.8-14

142 Clostridium Difficile Infectionâ€”Diagnosis, Treatment and Prevention. **2020**, 267-273

141 INFEKTIONSKRANKHEITEN. **2020**, pL1-pL16.2-10

140 Postoperative Complications and Management. **2020**, 913-940

139 Clostridium difficile. **2020**, 1115-1120

138 Utilization of Faecal Microbiota in Humans and Animals. **2020**, 54, 1-18

137 Fulminant Clostridium difficile Colitis Successfully Treated by Loop Ileostomy with Colonic Lavage Following Transverse Colectomy and Distal Gastrectomy. **2020**, 53, 246-256

136 Ontogeny and function of the circadian clock in intestinal organoids.

135 Efficacy of Photodynamic Inactivation against the Major Human Antibiotic-Resistant Uropathogens. **2021**, 8, 495

1

134 Gastrointestinal Issues in the Cardiothoracic ICU. 481-516

133 Diagnostic Algorithm for the Rapid and Cost- Effective Detection of Clostridioides difficile Infection: Comparison between C. DIFF QUIK CHEK COMPLETE and VIDAS GDH & Toxin Assay. **2020**, 42, 130-139

132 Trasplante de microbiota fecal: una revisi3n. **2020**, 35, 229-337

131 South African Society of Clinical Microbiology infection diagnosis, management and infection prevention and control guideline. **2020**, 35, 219

0

130 Performance Comparison of a Novel Rapid Stand-alone Molecular Test and a 2-Step Diagnostic Algorithm for Clostridioides difficile Detection in Children. **2021**, 40, 169-172

129 Fidaxomicin (Dificid), a Novel Oral Macrocyclic Antibacterial Agent For the Treatment of Clostridium difficile-Associated Diarrhea in Adults. **2012**, 37, 278-81

10

128 PURLs: prescribing an antibiotic? Pair it with probiotics. **2013**, 62, 148-50

9

127 The complex dynamics of antimicrobial activity in the human gastrointestinal tract. **2013**, 124, 123-32

11

126 Clostridium difficile in paediatric populations. **2014**, 19, 43-54

2

125 infection in patients with inflammatory bowel disease. **2011**, 24, 263-270

12

124	Intestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal disease. 2014 , 10, 230-7	19
123	Fecal Microbiota Transplantation for Clostridium difficile Infection: The Ochsner Experience. 2014 , 14, 538-44	17
122	Adherence to and Outcomes Associated with a Clostridium difficile Guideline at a Large Teaching Institution. 2015 , 50, 42-50	5
121	Management of Infection. 2016 , 12, 609-616	8
120	The Daniel K. Inouye College of Pharmacy Scripts: Updates on Infection: Advances in Laboratory Testing to Aid Diagnosis and Treatment. 2017 , 76, 59-64	1
119	Conventional and alternative treatment approaches for infection. 2017 , 11, 1-10	1
118	Clostridium Difficile Associated Disease: Burden of and Predictors for in Hospital Fatal Outcome. Results of a Hospital-Based Study, Bucharest, Romania. 2015 , 10, 97-100	
117	Evidence-Based Approach to Infection. 2017 , 13, 238-241	1
116	Bezlotoxumab (Zinplava) for Infection: The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection. 2017 , 42, 735-738	10
115	A prospective cross sectional study of detection of toxin in patients with antibiotic associated diarrhoea. 2018 , 10, 1-6	5
114	A outbreak in an Italian hospital: the efficacy of the multi-disciplinary and multifaceted approach. 2018 , 59, E132-E138	4
113	Healthcare-associated Clostridium difficile infection: role of correct hand hygiene in cross-infection control. 2018 , 59, E145-E152	14
112	HIV-Related Opportunistic Infections Are Still Relevant in 2015. 2015 , 23, 116-9	6
111	Fecal microbiota transplantation for recurrent Clostridium difficile infection: Experience, protocol, and results. 2018 , 31, 411-418	5
110	A Primary Hospital Antimicrobial Stewardship Intervention on Pneumonia Treatment Duration. 2017 , 34, 14-18	
109	Patient Knowledge and Attitudes About Fecal Microbiota Therapy for Infection. 2017 , 34, 15-19	
108	PURL: Do probiotics reduce C diff risk in hospitalized patients?. 2019 , 68, 351;352;354	1
107	[Efficacy of real-time PCR for detecting Clostridium difficile infection: comparison with enzyme-linked fluorescent spectroscopy-based approaches]. 2017 , 37, 1648-1653	

106	Frequency of toxin genes and antibiotic resistance pattern of isolates in diarrheal samples among hospitalized patients in Hamadan, Iran. 2021 , 14, 165-173	
105	A systematic review and meta-analysis of decontamination methods to prevent hospital environmental contamination and transmission of <i>Clostridioides difficile</i> . 2021 , 73, 102478	2
104	Patients with infection and prior appendectomy may be prone to worse outcomes.. 2021 , 13, 1436-1447	0
103	Safety Concerns, Regulatory Guidelines, Current Market Trends, and Future Directions toward the Use of Probiotics in Gut-Brain-Skin Axis. 2022 , 245-268	1
102	Trends in Incidence and Clinical Outcomes of <i>Clostridioides difficile</i> Infection, Hong Kong. 2021 , 27,	0
101	A Rare Case of Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Enterocolitis Treated With Oral Vancomycin.. 2021 , 13, e20143	
100	The knowledge of nurses about prevention of infections caused by the bacteria <i>Clostridium difficile</i> . 2021 , 12, 61-68	
99	Inactivation of <i>Clostridioides Difficile</i> Spores in Carpeting and Upholstery to Reduce Disease Recurrence in Households and Nursing Care Facilities. 2021 , 5,	
98	Machine learning approaches to investigate <i>Clostridioides difficile</i> infection and outcomes: A systematic review.. 2022 , 160, 104706	1
97	Association between prevalence of laboratory-identified infection (CDI) and antibiotic treatment for CDI in US acute-care hospitals, 2019.. <i>Infection Control and Hospital Epidemiology</i> , 2022 , 1-6	2
96	Nationwide Survey for Current Status of Laboratory Diagnosis of Infection in Korea.. 2022 , 37, e38	1
95	The intended purpose and regional patterns of use of antibiotics for managing <i>Clostridioides</i> (<i>Clostridium</i>) <i>difficile</i> infections: An analysis of the National Database of Health Insurance Claims and Specific Health Checkups data of Japan.. 2021 ,	
94	Efficacy and safety of proton pump inhibitors versus histamine-2 receptor blockers in the cardiac surgical population: insights from the PEPTIC trial.. 2022 ,	0
93	Risk factors and clinical outcomes for <i>Clostridioides difficile</i> infections in a case control study at a large cancer referral center in Mexico.. 2022 ,	
92	<i>Clostridioides difficile</i> : Current overview and future perspectives.. 2022 , 129, 215-245	0
91	Outcomes of Continuous Enteral Vancomycin Infusion in Intensive Care Unit Patients: A Novel Treatment Modality for Severe <i>Clostridium Difficile</i> Colitis.. 2022 , 14, e22872	
90	<i>Clostridioides difficile</i> in Latin America: A comprehensive review of literature (1984-2021).. 2022 , 102547	2
89	Molecular characterization of <i>Clostridioides difficile</i> by multi-locus sequence typing (MLST): A study from tertiary care center in India.. 2022 , 102545	0

- 88 Characterization of a outbreak caused by PCR ribotype 046, associated with increased mortality.. **2022**, 1-31
- 87 Defining optimal treatment for recurrent *Clostridioides difficile* infection (OpTION study): A randomized, double-blind comparison of three antibiotic regimens for patients with a first or second recurrence.. **2022**, 106756 0
- 86 A Rare Case of Pseudomembranous Colitis Presenting with Pleural Effusion and Ascites with Literature Review.. **2021**, 2021, 6019068
- 85 Comparison of Bacterial Community in Paddy Soil after Short-Term Application of Pig Manure and the Corresponding Organic Fertilizer. **2022**, 11, 9 2
- 84 Antibiotic-associated colitis in patients with COVID-19 â€”from imaging to diagnosis. **2021**, 13, 25-34 1
- 83 Chapter 33: Infectious Diseases. **2022**,
- 82 DataSheet_1.docx. **2020**,
- 81 Table_1.XLSX. **2018**,
- 80 Image1.PDF. **2017**,
- 79 Image2.PDF. **2017**,
- 78 Image_1.TIFF. **2018**,
- 77 Table1.XLSX. **2018**,
- 76 Table10.XLSX. **2018**,
- 75 Table11.XLSX. **2018**,
- 74 Table12.XLSX. **2018**,
- 73 Table13.pdf. **2018**,
- 72 Table2.XLSX. **2018**,
- 71 Table3.XLSX. **2018**,

70 Table4.XLSX. 2018,

69 Table5.XLSX. 2018,

68 Table6.XLSX. 2018,

67 Table7.XLSX. 2018,

66 Table8.XLSX. 2018,

65 Table9.XLSX. 2018,

64 Image_1.JPEG. 2020,

63 Table_1.docx. 2020,

62 Table_2.doc. 2020,

61 Clostridoides difficile Infection Severity Assessment by Fecal Calprotectin: A Pilot Study. *Current Health Sciences Journal*, 2021, 47, 204-208 0.3 0

60 <i>Clostridium difficile</i> Toxin B: Insights into Its Target Genes. *Open Journal of Applied Sciences*, 2022, 12, 368-386 0.3

59 Comparative Evaluation of Three Immunoassays for the Simultaneous Detection of Clostridoides difficile Glutamate Dehydrogenase and Toxin A/B. *Microorganisms*, 2022, 10, 947 4.9 0

58 Neurogenic Bowel Dysfunction and Gastrointestinal Complications. 2022, 595-616

57 Carbohydrate-based drugs launched during 2000â2021. *Acta Pharmaceutica Sinica B*, 2022, 15.5 4

56 Clinical Usefulness of the "MN Criteria" - the <i>Clostridoides difficile</i> Infection Severity Scoring System - in the Japanese Setting. *Internal Medicine*, 2022, 1.1

55 Which is the Preferred Regimen for Non-Severe Clostridoides difficile Infection in Korea, Vancomycin or Metronidazole?. *Infection and Chemotherapy*, 54, 3.9 0

54 One-day prevalence of asymptomatic carriage of toxigenic and non-toxigenic Clostridoides difficile in 10 French hospitals. *Journal of Hospital Infection*, 2022, 6.9 0

53 Towards Development of a Non-Toxigenic Clostridoides difficile Oral Spore Vaccine against Toxigenic C. difficile. *Pharmaceutics*, 2022, 14, 1086 6.4 1

52	Bacterial Infections and Antibiotic Utilization Varies by Coronavirus Disease 19 (COVID-19) Severity in Hospitalized Cancer Patients: Analysis from the First Phase of the Pandemic. <i>Infection Control and Hospital Epidemiology</i> , 1-25	2	0
51	Association between Nutrition Protocol with <i>Clostridium butyricum</i> MIYAIRI 588 and Reduced Incidence of <i>Clostridioides difficile</i> Infection in Critically Ill Patients: A Single-Center, Before-and-After Study. <i>Surgical Infections</i> , 2022 , 23, 483-488	2	0
50	Validation of Clinical Risk Models for <i>Clostridioides difficile</i> - Attributable Outcomes. <i>Antimicrobial Agents and Chemotherapy</i> ,	5.9	2
49	The Importance of <i>C. difficile</i> Colonization in Infection Prevention. 2022 , 301-308		
48	Risk Factors, Diagnosis, and Management of <i>Clostridioides difficile</i> Infection in Patients with Inflammatory Bowel Disease. <i>Microorganisms</i> , 2022 , 10, 1315	4.9	1
47	Histological features of <i>Clostridioides difficile</i> colitis in patients with inflammatory bowel disease. <i>Histopathology</i> ,	7.3	0
46	A Case of Diarrhoea. <i>Annals of the Academy of Medicine, Singapore</i> , 2014 , 43, 386-387	2.8	
45	Global research on <i>Clostridium difficile</i> -associated diarrhoea: A visualized study. <i>World Journal of Gastroenterology</i> , 2022 , 28, 3720-3731	5.6	0
44	Molecular typing of <i>Clostridioides difficile</i> from frozen stool samples to investigate cross-transmissions: A proof of concept. 2022 ,		
43	The value of fecal calprotectin in <i>Clostridioides difficile</i> infection: A systematic review. 13,		0
42	Toxic megacolon after irrational antibiotic treatment of pregnant patient with Covid 19: Case report. 2022 , 9, 1189-1195		0
41	Peculiarities of <i>Clostridioides Difficile</i> Infection in Children Seen at a Tertiary Pediatric Hospital in Fortaleza.		0
40	<i>Saccharomyces cerevisiae</i> strain Boulard. 2022 ,		0
39	Systematic Review and Meta-Analysis on the Frequency of Antibiotic-Resistant <i>Clostridium</i> Species in Saudi Arabia. 2022 , 11, 1165		0
38	Trends in the incidence of <i>Clostridioides difficile</i> infection in adults and the elderly insured by Medicaid compared to commercial insurance or Medicare only. 1-9		0
37	Microbial Interdomain Interactions Delineate the Disruptive Intestinal Homeostasis in <i>Clostridioides difficile</i> Infection.		0
36	Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant <i>Clostridioides difficile</i> .		1
35	Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for <i>Clostridioides difficile</i> Infection and Associated Clinical Outcomes.		0

- 34 Features of diet therapy for Clostridium difficile-associated disease. **2022**, 229-239 ○
- 33 Airborne spores dissemination of a swine associated Clostridioides difficile clone. **2022**, 78, 102651 ○
- 32 Infections in Patients with Cancer. 1-13 ○
- 31 Clostridioides difficile infection recurrence in the VINC at hospitals: a prospective observational cohort study. ○
- 30 Metronidazole and Peripheral Neuropathy: A Report of Two Cases of (Unusual) Side Effects. **2022**, ○
- 29 Isolation, molecular typing and antimicrobial resistance of Clostridium difficile in dogs and cats in Lanzhou city of Northwest China. 9, ○
- 28 Clostridioides difficile. **2023**, 1024-1027.e2 ○
- 27 European survey on the current surveillance practices, management guidelines, treatment pathways and heterogeneity of testing of Clostridioides difficile, 2018-2019: results from The Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI). **2023**, 131, 213-220 ○
- 26 Evaluation of Two Rapid Diagnostic Clostridioides difficile Infection Tests in a Chinese Hospital: A Real-world Analysis. **2022**, 15, ○
- 25 Pseudomembranous colitis in patients with COVID-19 (review). **2022**, 21, 111-119 ○
- 24 Application of Procalcitonin for the Rapid Diagnosis of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease. **2022**, 12, 3108 ○
- 23 A superoxide reductase contributes to Clostridioides difficile resistance to oxygen. ○
- 22 Vaccination strategies to combat nosocomial infections. **2023**, ○
- 21 Emerging Options for the Prevention and Management of Clostridioides difficile Infection. ○
- 20 Time to Place Clostridium difficile Infections in Major Healthcare-associated Infections List. **2023**, 27, 152-153 ○
- 19 Clostridioides difficile infection in mechanically ventilated critically ill patients: A nested cohort study. **2023**, 154254 ○
- 18 A Review on Clostridioides Difficile Testing and How to Approach Patients With Multiple Negative Tests: A Case Report. **2023**, ○
- 17 Previously Unreported Pseudomembranous Duodenitis: A Case Report With Histopathology. **2022**, 3, e260 ○

- 16 A Case of Severe Stenosis of the Colon due to Fulminant &i&t;Clostridioides Difficile&/i&t; Colitis Treated by Subtotal Colectomy. **2022**, 83, 1325-1330 ○
- 15 Controversies in the Prevention and Treatment of Clostridioides difficile Infection in Adults: A Narrative Review. **2023**, 11, 387 ○
- 14 Retrospective Cohort Analysis of Outpatient Antibiotic Use for Clostridioides difficile-Indicated Agents in British Columbia, from 2000 to 2018. **2023**, 2023, 1-8 ○
- 13 Research Progress of Fecal Microbiota Transplantation in Liver Diseases. **2023**, 12, 1683 1
- 12 Impact of Nucleic Acid Amplification Test on Clinical Outcomes in Patients with Clostridioides difficile Infection. **2023**, 12, 428 ○
- 11 Vaccination strategies to combat nosocomial infections. **2023**, 24, 60-67 ○
- 10 Infectious Complications of Pediatric Inflammatory Bowel Disease. **2023**, 687-697 ○
- 9 Research Progress on the Synthesis of Nitrogen-Containing Compounds with Cyanamide as a Building Block. **2023**, 43, 436 ○
- 8 Diarrhea donâ&tEs: Reducing inappropriate stool cultures and ova and parasite testing for nosocomial diarrhea. **2023**, ○
- 7 Laboratory diagnosis of Clostridioides difficile infection in symptomatic patients: what can we do better?. ○
- 6 Nosokomiale Infektionen auf der Intensivstation. **2023**, 1-30 ○
- 5 The Role of Vaccines in Combating Antimicrobial Resistance. **2023**, 1-35 ○
- 4 Evaluation of risk factors, causative pathogens, and treatment in recurrent percutaneous nephrostomy catheter-related urinary tract infections in cancer patients. **2023**, 102, e33002 ○
- 3 Multicenter Evaluation of an MIC-Based Aztreonam and Ceftazidime-Avibactam Broth Disk Elution Test. ○
- 2 Validating agent-based simulation model of hospital-associated Clostridioides difficile infection using primary hospital data. **2023**, 18, e0284611 ○
- 1 Characterization of Food Chain Clostridioides difficile Isolates in Terms of Ribotype and Antimicrobial Resistance. **2023**, 11, 1296 ○